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1.1 Genera/ Introduction 
Cellular proliferation and differentiation in the living organism are regulated at least in 
part by a complex network of interacting peptides, or polypeptide growth factors. The 
biology of these factors differs somewhat from classical hormones as neither their 
site(s) of synthesis nor site(s) of action is restricted to defined tissues. During the past 
decades, a considerable number of growth factors has been identified and isolated, 
such as epidermal growth factor (EGF), transforming growth factor alpha (TGFa) and -
3 (TGF-S), platelet-derived growth factor (PDGF), insulin and insulin-like growth factor 
I (IGF-I) and -II (IGF-II), and others (for reviews e.g. James and Bradshaw 1984, 
Carpenter 1987, Carpenter and Cohen 1990). As a result, it is now generally accepted 
that polypeptide growth factors represent a large family of regulatory agents, which 
interact on their target cells by high-affinity binding to specific cell surface receptors. 
The members of one group of growth factor receptors have in common that they 
contain intrinsic protein tyrosine kinase activity, by which the action of growth factors 
is mediated: upon binding of a growth factor to its receptor, a number of intracellular 
biochemical events is started that ultimately leads to the initiation of DNA replication 
and cell division (Hunter and Cooper 1985, Yarden and Ullrich 1988, Gill et al. 1988, 
Ullrich and Schlessinger 1990). Some growth factors can also have an inhibitory 
function, e.g. TGFB (Dickson and Lippman 1987, Dickson 1990). 
Some growth factor receptors show a striking homology with particular oncogene 
products (Doolittle et al. 1983, Downward et al. 1984, Heldin and Westermark 1984, 
Hanks ( al. 1988), which may interfere in receptor-mediated cellular responses. 
Constitutive or improper expression either of growth factors or of their receptors may 
result in loss of regulated growth and neoplastic transformation. 
The results of an expanding number of investigations suggest that growth factors and 
their receptors are involved in the control of breast tumor growth (Barker and Vinson 
1990, Dickson 1990). In this respect, a striking inverse relationship has been reported 
between the level of EGFR and the level of estrogen receptors (ER) in human primary 
breast tumors (Fitzpatrick et ai. 1984, Pérez et al. 1984, Sainsbury et al. 1985, Skoog 
et al. 1986, Spitzer et al. 1987, Cappelletti et al. 1988, Delarue et al. 1988, Battaglia et 
al. 1988, Nicholson 1988, Pekonen et al. 1988, Foekens et al. 1989a, Fekete et al. 
1989). High levels of EGFR in those tumors have been related to an early recurrence 
and a poor prognosis (Sainsbury et al. 1987, Rios et al. 1988, Grimaux et al. 1989, 
Foekens et al. 1989a, Nicholson et al. 1989). Increased expression of EGFR in 
neoplastic tissue might be an indicator of greater aggressiveness of the disease. 
1.2 Epidermal growth factor 
EGF was first identified and isolated from the mouse submaxillary gland in 1962 
(Cohen 1962). The peptide was recognized by its ability to accelerate the eruption of 
teeth and the opening of eyelids of new born mice. The abundance of EGF in mouse 
salivary glands facilitated its purification and by 1972 the full amino add sequence of 
mouse EGF had been determined (Savage et al. 1972). A few years later, a human 
urinary protein responsible for the inhibition of gastric acid secretion known as B-
urogastrone, was identified as the human EGF (Gregory 1975). The primary sites of 
EGF synthesis in mice are the salivary gland and the kidney, but the observation that 
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EGF can be found in milk and urine suggests that other sites may be important 
(Starkey and Orth 1977, Connolly and Rose 1988). In humans EGF has been found 
in most tissues (Kajikawa 1991). 
Both mouse and human EGF are small polypeptides of 53 amino acid residues with 
a molecular mass of approximately 6000 daltons (Carpenter and Cohen 1979,1990, 
Campbell et el. 1990). The three disulfide bonds in EGF between cysteine residues 6 
and 20,14 and 31, and 33 and 42, produce three disulfide loops in the secondary 
structure of the molecule (Savage et al. 1972,1973) (Figure 1.1a). 
5 10 15 20 25 30 
hEGF N S Y P G C P S S Y D Q Y C L N G G V C M Y I E A L D K Y A 
mEGF N S D S E C P L S H D G Y C L H D G V C M H I E S L D S Y T 
hTGFo V V S F H N D C P D S H T Q F C F H - G T C R F L V Q E D K P A 
rTGFa V V S H F N K C P D S H T Q Y C F H - G T C R F L V Q E E K P A 
VGF D I P A I R L C Q P E G D G Y C L H - G D C I H A R D I D G M Y 
AR N P C N A E F Q N F C I H - G E C K Y I E H L E A V T 
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hEGF C N C V V G Y I G E R C Q Y R D L K W W E L R 
mEGF C N C V I G Y S G D R C Q Y R D L K W W E L R 
hTGFo C V C H S G Y V G A R C E H A D L L A 
rTGF« C V C H S G Y V G V R C E H A D L L A 
VGF C R C S H G Y T G I R C Q H V V L V D Y Q 
AR С К С Q Q E Y F G E R С G Ε К 
Flg. 1.1 a. The mouse EGF molecule; b, Alignment of the sequences of some members of the EGF-
family (h= human; m - mouse; r= rat); VGF" Vaccinia growth factor; AR= Amphiregulin. Amino acids 
are represented by standard one-letter symbols (A=Ala; C=Cys; D=Asp; E=Glu; F=Phe; G=Gly; 
H=His; l-lle; K=Lys;L=Leu; M=Met; N=Asn; P=Pro; Q-GIn; R=Arg; S=Ser; T=Thr; V=Val; W-Trp; 
Y= Tyr). Conserved amino acid residues are marked with an asterisk. Hyphen indicate gap introduced 
to maximize homology. 
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These disulfide bonds in EGF are the most conserved structural characteristic among 
EGF-like peptides (Carpenter and Wahl 1990) (Figure 1.1b) and are required for 
biological activity (Taylor et al. 1972). In addition, further studies have demonstrated 
a nearly absolute requirement for Arg-41 (Engler et al. 1990), and the importance of 
the hydrophobic Leu-47 (Engler et al. 1988) in receptor binding. Furthermore, other 
amino acid residues, such as Val-19, Met-21, lle-23, Leu-26, and Tyr-29, have been 
proposed to play an important role in ligand-receptor interactions (Engler ef al. 1990, 
1991, Campion et al. 1990). 
From analysis of the cDNA sequence, the precursor (preproEGF) for mouse EGF is 
predicted to be a 1217 amino acid transmembrane protein with an extracellular 
domain that contains at least seven EGF-like sequences (Gray et al. 1983, Scott et al. 
1983, Doolittle eta/. 1984). The human EGF precursor is a 1207 amino acid molecule 
with 66% homology with the mouse protein (Bell et al. 1986). The EGF precursor may 
be proteolytically cleaved to biologically active lower molecular weight fragments 
(Breyer and Cohen 1990). 
EGF has been demonstrated to elicit significant biological responses in intact animals, 
organ cultures, and cell culture systems (Carpenter and Cohen 1990, Burgess 1989). 
The in vivo functions of EGF are assumed to be stimulation of fetal growth and 
development, regulation of growth and differentiation of continuously regenerating 
tissues, and stimulation of wound healing processes (Fisher and Lakshmanan 1990). 
1.3 Epidermal growth factor-like peptides 
Based on their structural homologies, polypeptide growth factors can be grouped into 
different families. Each family has probably arisen from common ancestor genes by 
duplications and evolutionary divergence (Yarden and Ullrich 1988). One growth factor 
family is constituted by the EGF-family (Carpenter and Wahl 1990) that includes EGF, 
TGFa (Massague 1983, Derynck eta/. 1984), vaccinia growth factor (VGF) (Stroobant 
et al. 1985), amphiregulin (Shoyab et al. 1989, Plowman et al. 1990), cripto 
(Ciccodicola et al. 1989), and a heparin-binding factor from macrophages 
" (Higashiyama ef al. 1991). The EGF-like peptide growth factors are all encoded by 
separate genes, but each one is structurally analogous to the EGF sequence, 
compete with 125I-EGF in radioreceptor assays, and produce EGF-like biological 
responses in sensitive cells (Donaldson et al. 1989, Burgess 1989, Carpenter and 
Wahl 1990, Campbell et al. 1990). 
TGFa, originally isolated from retrovirus-transformed cells (Delarco and Todaro 1978) 
is an important member of the EGF-family, since it has been proposed to play an 
important role in carcinogenesis (Dickson and Lippman 1987). A large variety of tumor 
cells indeed do synthesize TGFa (Derynck et al. 1987, Dickson 1990). Comparative 
studies of the effects of both EGF and TGFa have established that both growth factors 
evoke similar actions, but that TGFa is more potent than EGF in a variety of biological 
systems (Stern et al. 1985, Ibbotson ef al. 1986, Gan ef al. 1987). This observation is 
not explained by differences in affinities of the ligands for the receptor, because the 
affinity constants of both factors are similar (Todaro et al. 1980, Massague et al. 1983, 
Winkler et al. 1986, Lax etal. 1988a). Differences in binding (Lax eta/. 1988a, Winkler 
et al. 1989) or differences in processing of ligand-receptor complexes (Ebner and 
Derynck 1991) may explain why TGFa exerts quantitatively higher activities than EGF. 
10 
1.4 The epidermal growth factor receptor 
The first step in the action of EGF is specific binding in a 1:1 stoichiometry (Weber et 
al. 1984) to a surface glycoprotein known as the EGF receptor, a single chain 
membrane-bound glycoprotein composed of 1186 amino aad residues (Mr = 
170,000), and a substantial amount of N-linked oligosaccharide (Carpenter 1987, 
Schlessinger 1988a,b, Donaldson et al. 1989, Velu 1990). The receptor is, like other 
growth factor receptors, composed of an extracellular ligand-bmding domain 
connected by a single hydrophobic region to the cytoplasmic protein tyrosine kinase 
domain (Fig. 1.2) (Carpenter 1987, Schlessinger 1988a,b, Hsuan et al. 1989a, 
INSULIN IGF-1 
EGF/TGI 
η 
Ϊ 
PDGF 
Fig. 1.2. Schematic representation of the EGF/TGFa receptor and other ligand activated tyrosine protein 
kinases. The hatched boxed and black dots indicate cysteine neh homologous regions The black 
boxes represent the tyrosine kinase region IGF-1, insulin-like growth factor-1; PDGF, platelet derived 
growth tactor, (adapted from Waterfield, 1989). 
Waterfield 1989). The cytoplasmic domain of the EGF receptor bears a striking 
similarity to the transforming v-erbB protein of the Avian Erythroblastosis Virus 
(Downward et al. 1984). This virus transforms cells by introducing a truncated EGF 
receptor into the cells. This truncated EGFR lacks most of the external EGF-binding 
domain and provides a mrtogenic signal in the absence of exogenous EGF. 
The extracellular domain of the EGF receptor (621 amino acids), which contains 10-11 
N-linked oligosaccharide chains (Cummings et al. 1985), can be subdivided into four 
subdomains (Lax et al. 1988b, 1989, 1990). According to this assignment, domain I 
is the amino-terminal domain, domains II and IV are two cysteme-nch domains, and 
domain III is located between these latter cysteine-rich domains and possesses 
significant homology with domain I (Lax ef al. 1988b). Domain III has been shown to 
be a major ligand-bmding domain (Wu et al. 1989,1990, Lax. et al. 1988b). The added 
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contributions of both domain I and III to the binding energy generate the high-affinity 
binding site typical of human EGFR (Lax et el. 1991a). Electron microscopic studies 
suggested the ligand binding domain to be located in the cleft between domän I and 
III, while the two cysteine-rich domains are in contact with each other and dose to the 
plasma membrane (Lax ef al. 1991b). 
The ligand-binding domain of the EGF receptor is separated from the cytoplasmic 
domain by a single transmembrane segment of 23 uncharged, hydrophobic amino 
add residues (622-644) (Ullrich et al. 1984), which is anchored intracellularly by a 
highly basic, stoptransfer sequence (645-657). The functional role of this domain in 
transmission of the mitogenic signal has not been established. Mutations within the 
transmembrane domain do not affect receptor function (Kashles et al. 1988, Carpenter 
et al. 1991). In contrast, mutations within the equivalent domain of the EGFR-related 
rat neu or c-erbB2 putative receptors stimulate the kinase activity and can lead to 
cellular transformation (Bargmann et al. 1986, Bargmann and Weinberg 1988). The 
Observation that an alteration of the lipid environment in cell lysates can modify both 
ligand affinity and kinase activity provides further evidence for a possible functional 
role of the transmembrane domain (Downward et al. 1985). 
The cytoplasmic domain of the receptor (542 amino adds) contains a tyrosine kinase 
domain, which is the most highly conserved portion of all receptor tyrosine kinase 
molecules (Hanks ef al. 1988, Ullrich and Schlessinger 1990, Yarden and Ullrich 1988). 
Lysine residue 721 within this region binds ATP, generating the phosphate for the 
tyrosine phosphorylation reaction. Replacement of this lysine residue in EGFR 
abolishes the tyrosine kinase activity both in vitro and in vivo (Honegger ef al. 1987a, 
Chen et al. 1987). Various mutant EGFFts devoid of kinase activity have normal ligand 
binding characteristics, but are unable to stimulate various responses of EGF (Uvneh 
et al. 1986,1987, Chen et al. 1989, Honegger et al. 1987a,b, Moolenaar et al. 1988). 
This suggests that tyrosine phosphorylation of cellular substrates by the receptor 
tyrosine kinase is essential for transduction of the mitogenic signal. This suggestion 
is confirmed by the observation that mutation of the EGFR molecule which removes 
three C-terminal conserved tyrosine residues results in a receptor that is almost 
inactive biologically (Helin et al. 1991, Helin and Beguinot 1991, Magni et al. 1991). 
The tyrosine kinase activity of the EGF receptor has also been found to be necessary 
for normal receptor targeting to lysosomes (Honegger et al. 1987a, Glenney et al. 
1988, Chen et al. 1989, Felder eta/. 1990). Kinase-def active receptors are internalized, 
but are recycled to the cell surface for reutilization (Honegger et al. 1990). It is not 
known whether this means that lysosomal targeting requires phosphorylation of 
particular substrates. 
In cells expressing EGFR the major substrate of the intrinsic tyrosine kinase is the 
receptor itself: the main phosphorylation sites are four tyrosine residues located in the 
C-terminal region of the intracellular domain, which become phosphorylated after 
ligand binding (Downward et al. 1984, Yarden and Schlessinger 1987a, Yarden and 
Ullrich 1988, Hsuan et al. 1989b, Margolis et al. 1989a, Lai et al. 1989b). Point 
mutation analyses of these autophosphorylation sites have shown only minor 
differences in receptor activities of mutant versus wild type receptors. Recent studies 
suggest that autophosphorylation sites have a regulatory function for the kinase 
activity in that they compete with exogenous substrates for the substrate binding site 
of the tyrosine kinase domain (Honegger et al. 1988a,b, Bertics et al. 1988, Margolis 
et al. 1990). Autophosphorylation seems to be mediated by intermolecular cross-
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phosphorylation within a oligomeric receptor complex (Schlessinger 1988b). 
Another regulatory site is Thr-654, which is phosphorylated by protein kinase C-
mediated phosphorylation (Hunter et el. 1984, Davis and Czech 1985). Mitogens that 
activate protein kinase С reduce EGF binding affinity and inhibit EGF receptor tyrosine 
kinase activity (Shoyab et el. 1979, Cochet θί el. 1984). It has been proposed that the 
phosphorylation of Thr-654 allosterically regulates ligand binding affinity and tyrosine 
kinase activity of the EGF receptor (Hunter and Cooper 1985). Phosphorylation of 
EGFR at Thr-654 leads to downregulation of the tyrosine kinase activity and to rapid 
physiological attenuation of the mitogenic response to EGF (Davis 1988, Livneh et el. 
1988, Lund et el. 1990, Welsh et al. 1991), but does not lead to downregulation of 
high-affinity binding of the receptor (Livneh et el. 1988). The latter effect might be 
induced by phosphorylation of other residues on the receptor. 
7.5 Signal transducuon 
The binding of EGF to its receptor is the initial event in the stimulation of cell growth 
induced by this growth factor. In the absence of EGF, EGF receptors are randomly 
distributed on the cell surface (Schlessinger et el. 1978, Haigler et al. 1978, Haigler 
and Cohen 1979). After ligand binding, the receptors rapidly aggregate in clathrin-
coated pits and are internalized via endosomes (Carpenter and Cohen 1979, Lai et al. 
1989a). The ligand then dissociates from its receptor in the acidic environment of the 
endosomes. Following fusion with lysosomes, EGF and EGFR are rapidly degraded 
(Carpenter and Cohen 1979). 
Binding of EGF to the extracellular receptor domain is proposed to result in receptor 
oligomerization (Schlessinger 1988a,b, Cochet et al. 1988), followed by intermolecular 
activation of the intrinsic protein tyrosine kinase domain (Schlessinger et el. 1983, 
Schlessinger 1986, Yarden and Schlessinger 1987a,b, Lammers et el. 1990). The 
ligand-induced dimerization seems to induce higher ligand binding affinity. It has been 
hypothesized that oligomeric receptors show high affinity binding, while single 
receptors have low affinity (Böni-Schnetzler et el. 1987, Schlessinger 1988a), and 
therefore, the binding of EGF will stabilize the oligomeric state, which leads to the 
activation of the kinase domain. 
Several proteins are phosphorylated by the EGF receptor, e.g. phospholipase C-r 
(PLC-r) (Margolis 1989b, Wahl 1989). After ligand binding, EGFR becomes associated 
with PLC-r (Kim et al. 1990, Margolis et al. 1990). The phosphorylation of PLC-r 
apparently activates the enzyme and triggers hydrolysis of phosphatidylinositol 4,5-
bisphosphate (PIP2), which generates two intracellular second messengers: 
diacylglycerol (DAG) and inositol 1,4,5,-triphosphate (IP3) (Heplereta/. 1987, Nishibe 
et a/. 1990, Payrastre et al. 1991). DAG stimulates protein kinase С (PKC) which in 
turn phosphorylates the EGF receptor at Thr654 and at other residues and activates 
the Na+-H+ exchange (Nishizuka 1988). IP3 binds to its receptor (IP3-R) at the surface 
of an intracellular Ca2+ storage organelle and induces release of stored Ca2+ to the 
cytoplasm and Ca2* Influx, increasing [Ca2+] l (Chen eta/. 1987, Pandiella et al. 1989, 
Hepler et al. 1987). Ultimately, the EGF initiated signal leads to increased nuclear 
activity, which includes induction of synthesis of specific mRNA (c-fos, c-myc, and c-
jun proto-oncogenes) and DNA (Müller et al. 1984, Bravo et al. 1985, Quantin et al. 
1988). 
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1.6 Epidermal growth factor receptors In breast cancer 
Estrogens play an important role in the development and progression of human breast 
cancer. In the normal breast it acts as a mitogen and induces the progesterone 
receptor (PgR) which is responsible for the development and differentiation of the 
breast (Horwitz et al. 1985). It has generally been accepted that ER levels in breast 
tumors define the hormone dependency of the tumor and predict those patients who 
have a good prognosis and who are likely to benefit from endocrine therapy (King 
1990, Barker and Vinson 1990). However, an enigma of the human breast cancer work 
is that many ER-positive tumors do not respond to endocrine therapy, i.e. there 
remains a large percentage (50%) of ER positive tumors who fail to respond (King 
1990). A great deal of evidence has arisen to suggest that the mitogenic effects of 
oestrogens are mediated in some part via peptide growth factors and their receptors 
(Lippman and Dickson 1989). 
The majority of information on the mechanism of action of growth factors and their 
receptors has been obtained in studies with human breast cancer cells in vitro. The 
proliferative response to estrogen is accompanied by increased expression of a 
number of growth factor genes (EGF, TGFa and -β, IGF-I and -II, PDGF) that are 
thought to control proliferation via autocrine and paracrine mechanisms (Mori ef al. 
1986, Dickson and Lippman 1987, Bates ef al. 1988). Information regarding possible 
interactions between ER and EGFR through the action of their respective ligands has 
so far been contradictory. Studies using MCF-7 human breast cancer cells indicate 
that estrogen can cause an increase in EGFR levels with a concomitant decrease in 
ER, and that the anti-estrogen hydroxytamoxifen causes a decrease in EGFR (Berthois 
et al. 1989). Treatment of these cells with EGF was shown to increase ER and PgR, 
with a corresponding decrease in EGFR levels, inferring a parallel inverse relationship 
to that found in breast tumor biopsies. However, since binding of ligand to EGFR 
causes receptor downregulation and TGFa production is stimulated by estrogen and 
inhibited by anti-estrogen treatment (Lippman and Dickson 1989), it is not clear how 
far such a parallel extends (Barker and Vinson 1990). 
Apart from their effects on cell proliferation in vitro, various effects of growth factors 
and their receptors have been observed to be mediated by progestins. Incubation of 
human breast cancer cells with progestins increased in a time and dose-dependent 
manner the amount of EGFR, both at the protein and the mRNA level (Murphy et al. 
1985, Murphy ef al. 1988a, Ewing ef al. 1989), and of its ligands EGF and TGFa 
(Murphy ef al. 1988b, Murphy and Dotzlaw 1989). Under these in vitro conditions EGF 
plays a dominant role (Sarup ef al. 1988), capable of reversing any growth inhibitory 
effects of progestins. In vivo, EGF as well as TGFa are probably produced locally in 
many tissues as local growth factors rather than as systemic hormones (Dickson and 
Lippman 1987). There is evidence that EGF plays a role in carcinogenesis and that the 
EGF-stimulated growth regulatory system is also involved in proliferation of malignant 
cells (Stoscheck and King 1986), but the majority of evidence indicates that TGFa, via 
the EGF receptor, and IGF-I promote cell proliferation, while TGF-B is thought to be 
a growth inhibitor (Dickson and Lippman 1987). 
In the search for prognostic factors in human breast cancer in addition to ER, EGF 
receptors have been demonstrated on breast cancer cells, especially on ER-negative 
tumor cells, and in human primary breast tumors and their metastases (Davidson ef 
al. 1987). An increase in EGFR has been proposed as a mechanism by which 
14 
unopposed estrogen might play a role in the etiology of breast cancer and as an 
additional prognostic factor in human breast cancer. In human primary breast tumors, 
based on 40 separate studies comprising more than 5,000 patients, the mean 
percentage of EGFR-positivity was ±45% (Klijn et el. 1992). Gene amplification and 
mRNA overexpression of EGFR or the closely related erbB2 oncogene have also been 
found in mammary carcinomas (Klijn et al. 1992). Moreover, EGFR has been identified 
in a wide variety of tissues (O'Keefe et al. 1974), including all histological types of 
breast tissue (Barker et al. 1989, Möller et al. 1989). At present there is no agreement 
on the clinical relationships and prognostic value of EGFR in human breast cancer. 
The levels of EGFR and its incidence as described in the literature vary widely (P.G. 
Koenders, doctoral thesis University of Nijmegen, 1992). Nearly all reported studies 
indicate a negative relationship between EGFR and ER status, and PgR status 
(Fitzpatrick et al. 1984, Pérez et al. 1984, Sainsbury et al. 1985, Skoog et al. 1986, 
Spitzer et al. 1987, Cappelletti et al. 1968, Delarue et al. 1988. Battaglia et al. 1988, 
Pekonen et al. 1988, Foekens et al. 1989a, Fekete et al. 1989). Interestingly, it has 
been reported that the tumor's EGFR status could predict an early recurrence and 
death, and EGFR positivity of the tumor was associated with a lack of response to 
endocrine therapy (Sainsbury et al. 1987), but the results correlating EGFR status and 
relapse-free survival are very controversial and the prognostic value of EGFR for 
length of (relapse-free) survival in breast cancer is currently a matter of debate. 
1.7 Scope of the thesis 
As was stated above, the levels of EGFR and its incidence in human primary breast 
tumors in various studies vary widely. This may have contributed essentially to the 
highly controversial reports regarding the prognostic value of EGFR. Methodological 
differences provide plausible explanations for this disturbing variation. Assay 
conditions differ widely with respect to tissue processing, the procedure for the 
radioiodination of EGF, the incubation conditions, the ligand concentrations used in 
multiple point and single saturation dose analysis, and the method of separation of 
receptor-bound from unbound ligand. For application in clinical studies, strict assay 
conditions should be defined and the availability of a reproducible and reliable assay 
is imperative. The European Organization for Research and Treatment of Cancer 
(EORTC) Receptor Study Group urged our department to develop an EGFR assay 
which stands under rigorous conditions. This thesis concerns the development of such 
an assay and its evaluation in all its aspects. These aspects involve the establishment 
of strict assay conditions, such as time and temperature of the assay, ligand 
concentrations, and the preparation of the radioactive ligand. For separation of 
receptor-bound from free ligand, hydroxylapatite (HAP) was used. The use of HAP 
circumvents the employment of high-speed centrifugation for the separation step 
(Benraad and Foekens 1990). 
EGF receptor function depends on its ligands EGF and TGFo. Therefore, besides 
measurement of EGFR, it is of major interest to assess the concentration of its 
ligand(s). This thesis describes a radioreceptor assay (RRA) to measure the levels of 
EGFR ligand(s) in tumor cytosols. The RRA procedure was also based on the HAP 
bound-free separation. Furthermore, employing a specific rabbit anti-mouse EGF 
antibody, a radioimmunoassay to measure mEGF could be developed. 
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The analytical methods described were applied to investigate the role of the EGF/ 
TGFo - EGFR pathway in breast cancer using two different approaches. Firstly, human 
primary breast tumors were analyzed for EGFR and EGFR ligand(s) in addition to 
steroid hormone receptors, which is described in the doctoral thesis by P.G. Koenders 
("Epidermal growth factor receptor and its ligand(s): associations with prognosis of 
patients with breast cancer", University of Nijmegen, 1992). The data obtained were 
examined in relation to tumor and patient characteristics and in relation to prognosis 
of patients with breast cancer. Secondly, in the present thesis the analytical methods 
described were used to investigate the relationship of the levels of EGFR and EGFR 
ligand(s) with the levels of steroid hormone receptors in a mouse mammary tumor 
model. In this model progression of tumors to hormone independence is observed in 
serial transplants of tumors that are induced in ovariectomized female GR strain mice 
by continuous administration of estrone and progesterone (Sluyser and Van Nie 1974, 
Sluyser et al. 1976). The induced tumors are initially hormone dependent, but during 
transplantation they become hormone responsive and finally hormone independent. 
References are listed on pages 99-110. 
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CHAPTER 2 
DEVELOPMENT OF A RADIOUGAND BINDING ASSAY FOR THE MEASUREMENT 
OF THE EPIDERMAL GROWTH FACTOR RECEPTOR 
2.1 Introduction 
2.2 Materials and methods 
2.3 Results 
2.4 Discussion 
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2.1 Introduction 
Many studies have been reported analyzing EGFR levels in primary human breast 
tumors and/or whether this level can serve as a prognostic factor in human breast 
cancer (for reviews: Klijn ef el. 1992, P.G. Koenders, doctoral thesis, University of 
Nijmegen, 1992). It is highly disturbing however, that the percentages of EGFR 
positivity as reported in these vast number of publications vary from 15% to 91% This 
large variation can partly be ascribed to differences in methodology (Dittadi ef al. 
1990b). Assay conditions differ widely with respect to the preparation of the membrane 
fraction, the radioiodination procedure of EGF, the ligand concentrations used in 
multiple point and single point saturation dose analysis, the Incubation conditions such 
as time and temperature, and the method of separation of receptor-bound from 
unbound ligand (Table 2.1). To restrict the variation in EGFR assay results between 
laboratories, it was decided to establish an efficient analytical method which under 
rigid assay conditions gives reproducible results with high comparability between 
laboratories. As many routine laboratories do not have the facilities to employ a 
method dependent on high speed centrifugation to separate receptor-bound from free 
ligand on a large scale, an assay was introduced using hydroxylapatite (HAP) to 
achieve this separation in a more convenient way. An outline of this HAP procedure 
was reported earlier (Benraad and Foekens 1990). 
HAP, a form of calcium phosphate, is widely used in preparative biochemistry for the 
fractionation and purification of monoclonal antibodies (Stanker ef al. 1985, Smith ef 
al. 1984) and other proteins (Engel ef al. 1980) and nucleic adds (Kantler and 
Schwartz 1979, Johnson and Han 1983). Binding of proteins to HAP occurs by 
attraction between the positive charges of the protein and HAP, and by complexing 
of protein carboxyls with calcium loci on the mineral (Gorbunoff 1984a,b, Gorbunoff 
and Timasheff 1984). Low molecular weight substances, such as amino acids, are 
poorly or not at all bound to HAP. 
HAP has already been used in steroid hormone receptor assays (Erdos ef al. 1970, 
Smith et al. 1979, Garola and McGuire 1978). In the case of the EGFR assay, HAP 
adsorps the ligand-EGFR complex which is present in the membrane fraction leaving 
the nonbound ligand In solution. One obtains this membrane fraction when tumor 
tissue is processed for routine steroid hormone receptor determinations in the 
cytosolic fraction (Benraad and Foekens, 1990). 
In this chapter, a rigorous analyse of the assay conditions of the radioligand binding 
assay of EGFR using HAP is described. These include for example time and 
temperature required for reaching equilibrium in the ligand-receptor reaction, time and 
temperature to be used during the HAP separation step, measures adopted to reduce 
nonspecific binding and thereby to increase assay sensitivity, and choice of the range 
of ligand concentrations used in the multiple point tracer analysis. 
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Table 2.1. Variance in EGFR ligand binding assay methodology in breast cancer 
Author Membrane lodination [EGF1 Incubation Separation 
fraction method1 (nM) conditions bound-free3 
Fitzpatrick (1984) 
Pérez (1984) 
8коод(19в6) 
Sainsbury (1985) 
Weisman (1987) 
Wyss(1987) 
Battaglia (1988) 
СарреН Ш (1988) 
Delarue (1988) 
Nicholson (1988) 
Pekonen (1988) 
Rios(1988) 
Barker (1989) 
Bauknecht (1989) 
Fekete (1989) 
Foekens (1989a) 
Qrimaux (1989) 
Hams (1989) 
Dorens (1989) 
Lyonnais (1989) 
Boda (1990) 
Bolufer (1990) 
Costa (1990) 
Dlttadl (1990a) 
105,000 χ g 
-2,000 χ g 
100,000 χ g 
-12,000 χ g 
100,000 χ g 
-12,000 χ g 
100,000 χ g 
-1,000 χ g 
100,000 χ g 
-7,000 x g 
100,000 χ g 
-1,000 χ g 
105,000 x g 
-7,000 x g 
40.000 x g 
-800 x g 
100.000 x g 
-вООхд 
100,000 x g 
-вООхд 
30,000 x g 
-вООхд 
100,000 x g 
-12,000 x g 
100,000 X g 
-800 x g 
5,000 x g 
-100 x g 
105,000 x g 
-500 x g 
50,000 x g 
-8,000 x g 
105,000 x g 
-7,000 x g 
100,000 x g 
-800 x g 
100,000 x g 
-800 x g 
100,000 x g 
-800 x g 
25,000 x g 
-1,500 x g 
25,000 x g 
-1.000 x g 
100,000 x g 
-1,000 x g 
100,000 x g 
-800 x g 
cm τ 
Chi Τ 
Chi Τ 
lodogen 
CIU Τ 
Chi Τ· 
unknown 
ewT 
lodogen 
lodogen 
Chi Τ 
unknown 
unknown 
Chi Τ 
Chi Τ 
Chi Τ 
Chi Τ 
lodogen 
lodogen 
LP 
Chi Τ 
Chi Τ* 
unknown 
LP 
1.0 
0.1-10 
comp. 
K^cpm 
comp. 
0.6 
comp. 
0.2 
3.6 
2.6 
0.4-Ζβ 
5.0 
0.3-1.2 
1.0 
0.15-10 
0.1 
0.6 
comp. 
1.0 
0.4 
0.4 
comp. 
0.8 
0.1-0.8 
3.0 
1.0 
0.03-0.5 
0.2-1.6 
1.0 
0.5 
0.015-0.15 
3.8 
0.03-3.0 
1 h 2 5 4 ; 
1 h20°C 
1 h20°C 
2h26°C 
16 h 254; 
2h2S°C 
і б і і г с г с 
1 h25°C 
2h25°C 
1 ьге-с 
1 h37°C 
1 іігоос 
гьгегс 
45min37°C 
3h21°C 
16h20°C 
гьгв-с 
ι ьге-с 
2h25»C 
45 min 25°C 
1 h25°C 
2h20°C 
2h4°C 
QelmanGA-8 
3,000 x g 
3,000 x g 
14,000 x g 
2,300 x g 
MiUipore HVLP 
2,000 x g 
Whatman QF/B 
15,000 x g 
14,000 x g 
30,000 x g 
3,000 x g 
10,000 x g 
Cellulose-
acetaat 
3,000 x g 
30,000 x g 
3,000 x g 
14,000 x g 
5,000 x g 
10,000 x g 
Whatman GF/C 
20,000 x g 
Millipore 
20 h 2645 тАЬП1/4,000 x g 
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Formerto (1990) 
Spyratos (1990) 
Toi (1990) 
Falene (1992) 
105,000 χ g 
-aooxg 
100,000 χ g 
-800 χ g 
105,000 χ g 
-2,000 χ g 
48,000 x g 
-BOOxg 
LP 
lodogen 
Chi Τ 
lodogen 
1.0 
0.3-1.2 
0.05-5.0 
0.5 
10 
1.5h22°C 
2h25°C 
1 h25°C 
1 h20°C 
11,000 χ g 
15,000 χ g 
GeliTianGA-8 
3,000 χ g 
' Chi Τ: Chloremine Τ; Chi Τ*: probably Chloramine Τ; LP: Lactoperoxidase. 
2
 In those cases one concentration is mentioned here, a single saturation dose is used; a range ot 
concentrations denotes a multiple point titration method; comp: competition between one concentration 
of 12il-EGF and varying concentrations of unlabeled EOF. 
3
 g-force (centrifugation) or type of filter (ultraliltraiion) used. 
2.2 Material» and methods 
2.2.1 Materials 
Receptor grade mouse EGF was obtained from Bioproducts for Science, Inc. 
(Indianapolis, IN, U.S.A.). Carrier-free Na125l was obtained from Amersham International 
pic. (Amersham, Buckinghamshire, U.K.). Iodine monochloride (ICI) was obtained from 
Merck (Darmstadt, Germany). Enzymobeads and hydroxylapatite (HAP; DNA grade 
Biogel HTP) were obtained from Bio-Rad Labs. (Richmond, CA, U.S.A.). 0-D-Glucose 
was supplied by Sigma Chemical Co. (St. Louis, MO, U.S.A.). Bacitracin was obtained 
from Serva (Heidelberg, Germany). Bovine serum albumin (BSA) was purchased from 
Behringwerke AG (Marburg/Lahn, Germany). Protag-125 and disposable 3-mL C l e 
solid-phase extraction (SPE) columns (200 mg of C,^ were obtained from J.T. Baker, 
Inc. (Phillipsburg, NJ, USA). 
2.2.2 Preparation of membranes 
2.2.2.1 Human placental membranes (HPM) 
Placental tissue was dissected free of total membranes and fleeces and homogenized 
in 1 ml of ice-cold Tris buffer (20 mM Tris-HCI, 250 mM sucrose, 2 mM MgCI2, 2 m M 
KCl, pH 7.6) per gram of tissue for 10 seconds, three times, in a Waring Blendor (high 
setting). After centrifugation for 20 min at 800 χ g, the pellet was rehomogenized in an 
equal volume of Tris buffer with the Waring Blendor and centrifuged for 20 min at 800 
χ g. The pellet obtained after this centrifugation step was discarded. The supernatant 
fractions from both centrifugation steps were pooled and centrifuged for 30 min at 
10,000 χ g, and the resulting pellet was also discarded. The membrane fraction was 
obtained by centrifugation of the supemate for 40 min at 45,000 χ g. The pellet was 
resuspended in 1 ml of PBB-buffer (20 mM phosphate, 150 mM NaCI, 50 μΜ 
bacitracin, pH 7.4) per gram of placenta tissue (initial weight). All procedures were 
performed at 0-4 "C. The membrane preparation was stored at -80 °C in 1 ml-aliquots. 
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2.2.2.2 Human breast tumor membranes 
Human breast tumor membranes were obtained during routine processing of tumor 
biopsy samples for steroid hormone receptor assays (EORTC 1980). Breast tumor 
biopsies were pulverized in the frozen state in a microdismembrator (Braun, 
Melsungen, Germany) and homogenized in 5 ml of steroid hormone receptor assay 
buffer (10 mM K2HP04/KH2P04, 1.5 mM dipotassium EDTA, 3 mM NaNj, 10 mM 
monothioglycerol, 10%, v/v, glycerol, pH 7.4) per gram of tumor powder. The crude 
homogenate was centrifugea for 10 min at 800 χ g (4 "С). The supemate was 
centrifugea for 1 h at 105,000 χ g (4 °C). The pellet was rinsed with 1 ml of ice-cold 
PPB-buffer and stored at -80 °C under an aliquot of PBB-buffer. The membrane pellet 
was resuspended in 1100 μΙ of PBB-buffer by sonication (3x5 sec, Soniprep 150 MSE, 
Scientific Instruments, Crawley, U.K.). Prior to the binding studies a 100 μΙ aliquot of 
the membrane fraction was taken out for protein determination (Bradford 1976), after 
which a solution of 10% of BSA in PBB-buffer was added to the membrane 
preparation to a final concentration of 0.1% of BSA. 
2.2.3 Radioiodination of EGF 
EGF was radioiodinated by using either Protag-125, iodine monochloride (ICI), or 
Enzymobeads to a specific radioactivity of about 500 Ci/mmol (100 цС\/цд). The 
details of these iodination procedures are described in chapter 4. 
2.2.4 Preparaüon of HAP suspension 
The HAP suspension was prepared according to the manufacturer's instructions. 
Approximately 40 ml of PBB-buffer without BSA was added to about 5 g of HAP 
powder. Course HAP particles were eliminated by repeatedly settling the HAP 
suspension for 15 sec at gravity and decanting the suspension into another tube, 
leaving the course particles in the first one. The remaining HAP slurry was washed 
several times with PBB-buffer until the pH of the supernate was 7.4. Finally, PBB-buffer 
was added to the HAP pellet in a HAP:buffer ratio of 2:1 (v/v). 
2.3 Results 
2.3.1 Nonspecific adsorption of 12il-EGF to HAP (Blank HAP binding) 
The reliability of the HAP assay strongly depends on the efficiency of the separation 
of bound and free 1г^ЕОР. Any amount of 125I-EGF remaining adsorbed to HAP 
contributes to the nonspecific binding and therefore should be avoided as much as 
possible, thereby increasing assay sensitivity. Therefore, the capability of various 
substances in reducing the blank HAP binding was investigated. Table 2.1 shows that 
a large amount (almost 65%) of the ,25I-EGF was adsorbed to HAP when the buffer 
only contains phosphate and sodium chloride (phosphate buffered saline, PBS), even 
after washing of the HAP twice with PBS. In the presence of 0.1% of BSA, the blank 
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Tab/e ZI Effect of BSA and bacitracin on blank HAP binding of 1ial-EGF 
Addition to Addition Blank HAP 
assay buffer to HAP binding (%) 
-BSA/-bac -bac 649 ± 19 
+BSA/-bac -bac 5.1 ± 0 7 
+BSA/+bac +bac 06 ± 0 02 
About ISxH? cpm of 125I-EGF in 140 μΙ of PBS or PBS containing BSA (0 1%) and/or bacitracin (50 
μΜ) was incubated with 100 μΐ of HAP suspension for 30 mm at 20 °C The HAP suspension was 
prepared in PBS with or without 50 μΜ bacitracin Blank HAP binding is represented asthe%otthe 
total radioactivity added (mean ±SD, n=5) The 1Z5I-EGF preparation was premcubated with 200 μΙ 
of HAP suspension for 30 mm at 20 °C with HAP After centrifugaoon for 2 mm at 800 xg.the resulting 
tracer preparation was recovered in the supernale This HAP purification reduced the blank HAP 
binding of the 12St-EGF (See also chapter 4) BSA= bovine serum albumin, bac= bacitracin 
HAP binding decreased to about 5% of total 12SI-EGF added When in addition 
bacitracin (50 μΜ) was present in the buffer, the blank HAP binding reduced further 
to about 0 6% under the conditions of this experiment, which included two HAP 
washing steps with buffer Additional washing steps did not further reduce the blank 
HAP binding Increasing the concentration of bacrtraan to 75 and 100 μΜ did not 
further decrease the blank HAP binding 
Insulin (50 μΜ) was equally effective as bacitracin in reducing the blank HAP binding, 
but other proteins tested, ι e vancomyane, colimycine, streptomycine, cystabne, and 
Vasopressine, were less effective in reducing blank HAP binding (data not shown) 
As expected, the blank HAP binding increased with increasing volumes of HAP 
suspension added The amount of nonspecific binding detected was directly 
proportional to the volume of HAP suspension used In the EGFR assay ultimately 
developed, 100 μΙ of HAP suspension was employed, adding it to the 140 μΙ 
incubation mixture 0 1 % of BSA and 50 μΜ bacitracin were included in the assay 
buffer, and 50 μΜ bacitracin was included in the HAP suspension buffer 
2 3 2 Temperature and time of the HAP separation procedure 
The first step in the HAP separation procedure consisted of incubation of HAP with the 
already equilibrated receptor-ligand reaction mixture Simultaneous incubation of HAP 
with the other constituents to equilibrium proved less appropriate, since the amount 
of specifically bound ,25I-EGF in those incubations was lower than if the HAP 
suspension was added after equilibration of the receptor preparation with the ligand 
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This was probably due to shielding of a number of ligand binding sites when HAP was 
added before equilibrium was reached 
After incubation with HAP, the mixture is centrifugad and, after decanting of the 
supernate, the HAP pellet is washed with assay buffer to eliminate free EGF 
Interestingly, kinetic dissociation experiments revealed that the net dissociation (ι e the 
overall effect of both dissociation and reassociation) upon the addition of an amount 
of buffer was faster at 4 °C than at 20 "C (Fig 21) The incubation with HAP and the 
subsequent washing steps were therefore performed at 20 °C 
In Fig 2 1 it is shown that a new equilibrium situation was achieved within incubation 
for 1 h at 20 °C It was of importance to know whether calculation of the binding data 
had to be performed using the incubation volume before the one hour of incubation 
with HAP, or using the final volume Therefore, an expenment was performed in which 
different volumes of HAP suspension, containing the same amounts of HAP, were 
added to different volumes of incubation reaction mixtures, such that the final volumes 
were identical (conditions I, II, and III, Table 2 2) The binding data obtained were 
subsequently analyzed by Scatchard analysis (Scatchard 1949) Using the incubation 
volume for calculation, the apparent Kd-values obtained in the various incubation 
conditions decreased obviously with increasing incubation volumes (1 65, 1 28, and 
0 61 nM, respectively) 
В/Во(%) 
100 «a 
120 
Time (min) 
Flg. 2.1 Dissociation kinetics of i,al-EGF 
(x), 4 °C, (a), 20 °C HPM was incubated with 35 nM '^LEGF m 140 μΙ of EGFR assay butter After 
incubation for 16 hat 20 °C, 100 μΙ ot HAP suspension was added and incubation was proceeded for 
another hour at 20 °C The suspension was centrifugea and washed twice with PBB-buffter Then, 
dissociation was inibated by the addition of 1 ml of PBB-bufter After vanous periods of urne, the bound 
fraction was determined by centnfugabon of the tube for 2 min at 800 x g, decanting the supernate and 
counting of the pellet Every point represents the mean of tnplicate Incubations 
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Using the final (including HAP) volume for calculation of the results, however, similar 
Kd's were obtained Irrespective of the incubation volume (0.52, 0.70, and 0.47 nM), 
confirming the establishment of new equilibrium after 1 h of incubation at 20 "C. 
Therefore, in the ultimate assay procedure the incubation with HAP was performed for 
1 h at 20 "C to ensure new equilibrium, and the final volume (incubation volume of 
membranes with 12SI-EGF, and the volume of the added HAP suspension) was used 
for calculation. 
2.3.3 Effecf ol тиШрІ washing steps on 12il-EGF binding 
The HAP incubation was followed by centrifugation and decanting of the supemate 
containing the nonbound EGF. For optimal elimination of the nonbound EGF it was 
necessary to perform additional washing steps. 
Table 2.2 Effect of incubation with HAP on ligand-receptor equilibrium. 
,2SI-EGF (μΙ) 
PBB-buffer (μΙ) 
HPM (μΙ) 
- > Incubation volume (μΙ) 
HAP volume (μΙ) 
Buffer (μΙ) 
- > Final volume (μΙ) 
Scatchard analysis: 
N (fmol/ml) 
K d ^ ^ i n M ) 
1 
10 
30 
100 
140 
100 
200 
440 
292 
1.65 
0.52 
II 
10 
130 
100 
240 
100 
100 
440 
299 
1.28 
0.70 
III 
10 
230 
100 
340 
100 
0 
440 
294 
0.61 
0.47 
HPM was incubated with 12SI-EGF (01-2 0 nM) in 140, 240 or 340 μΙ of assay buffer respectively. After 
incubation for 16 h at 20 °C, identical amounts of HAP in different volumes of assay buffer were added 
such that the final incubation volumes were identical for all incubations Incubation was proceeded for 
another hour at 20 °C. Then the tubes were centnfuged for 2 mm at 800 χ g and the HAP pellets were 
washed twice with PBB-buffer (20 Ό) and subsequently counted for radioactivity Results were 
calculated using the incubation volume (before the addition of HAP) or using the final volume (after the 
addition of HAP) N= apparent number of receptors, Kd= apparent dissociation constant 
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Bt (%) Bns (%) 
100 
2 3 4 
Washing steps 
Flg. 2.2 effecf of washing steps on EGF binding. 
(x), Bs (=specific binding); (tj), Sns (=nonspecilic binding). Breast tumor membrane preparations were 
incubated with 12SI-EGF. Alter incubation with HAP for 1 h а 20 °C, the incubation mixtures were 
centrifugad for 2 min at 800 χ д. The HAP pellets were counted for radioactivity and subsequently 
washed several (1-5) times with 1 ml of assay buffer without BSA. After every washing step the HAP 
pellets were counted for radioactivity. 
The blank HAP binding experiments indicated that two washing steps were necessary 
to minimize blank HAP binding as much as possible. In Fig. 2.2 it is shown that 
nonspecific binding profoundly decreased after the first two washing steps. 
Subsequent washing steps only marginally decreased nonspecific binding. In Fig. 2.2 
it is further shown that the total binding of 125I-EGF decreased slightly after each 
washing step. Specific binding, the difference between total and nonspecific binding, 
also decreased slightly after each washing step, leaving approximately 85% of the 
specifically bound EGF after two washing steps. As a compromise, because of the 
relatively low nonspecific binding and the relatively high specific binding, it was 
decided to perform two washing steps with 1 ml of PBB-buffer. 
The observed decrease in specific binding by the dissociating washing steps was not 
due to a release of receptor protein from the HAP, but was exclusively due to 
dissociation of ,25I-EGF from the receptor, which was concluded from the data shown 
in Fig. 2.3. In this experiment, the reaction mixture after incubation with HAP was 
centrifuged for 2 min at 800 χ g or for 1 h at 105,000 χ g. In both cases the 
radioactivity in the supemates or assodated with the HAP pellet were similar (Fig. 2.3). 
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Radioactivity (cpm χ IO' 3 ) 
-
I гт 
г- -
f 
i 
1 
Bs F Bs F 
0.1 nM 1.0 nM 
Fig. 2.3 Effect of washing steps: dissociation of radioactivity from HAP after the addition of buffer. 
HPM was incubated with 0.1 nMorl.O nM '2SI-EGF fori h at 20'C and 100 μΙof HAP suspension was 
added. Alter an additional Incubation for 1 h at 20 °C, the reaction mixture was centrifuged for 2 min 
at 800 χ д. The HAP pellet was washed once with 1 ml of PBB-buffer and resuspended in 1 mlotPBB-
buffer (20 °C). Alter incubation for 3.5 h at 20 °C, the suspension was centrifuged either for 2 min at 
800 χ g (empty bars) or for 1 hat 105,000 χ g (hatched bars). The pellet and 100 μΙ ol the superna» 
were counted for radioactivity in a gamma counter. 
Moreover, the supernate remaining after the first centrifugation step was again 
centrifuged for 1 h at 105,000 χ g to pellet non-HAP-bound membranes containing 
EGFR, but no radioactivity could be precipitated. 
2.3.4 Binding capacity of HAP 
To study the capacity of HAP to bind EGFR-containing membranes, a representative 
mammary tumor membrane preparation containing 1.0 mg of membrane protein per 
ml was incubated with 1 nM 125I-EGF. 140 μΙ aliquots of this incubation mixture 
(correspondinging to 100 μΙ of pure membrane preparation, i.e. 100 ßQ of membrane 
protein) were added to increasing volumes of HAP suspension. As is shown in Fig. 
2.4a, the amount of 125I-EGF specifically bound increased at increasing HAP volumes. 
A plateau was reached at about 60 μΙ of HAP, Indicating that 60 μΙ of HAP was 
sufficient to bind quantitatively the membranes in this experiment. 100 μΙ of HAP 
suspension was used for further experiments. 
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Bound (cpm χ IO ' 3 ) Bound (cpm χ 10" 3 ) 
50 100 
HAP volume (μΙ) 
zoo 400 eoo 
Membrane protein (μς) 
Flg. 2.4 Capacity of HAP 
a. Effect ol increasing volumes of HAP on the amount of specifically bound 12SI-EGF b, Capacity of100 
μΙ HAP to bind EGFR-contaimng membranes 5 ml of a tumor membrane preparation (10 mg 
membrane protein/ml) was incubated with 10 nM 12SI-EGF tor 16 h ai 20 °C In a final volume of 7 ml 
Nonspecific binding was assessed in a parallel incubation with 250-fold excess of unlabeled EGF After 
incubation with HAP, the radioactivity bound was determined after two washing steps with PBB-buffer 
Subsequently, increasing amounts of the incubation mixture were added to 100 μΙ of 
HAP suspension A linear relationship was observed between the amount of incubation 
mixture added and the amount of specifically bound 125I-EGF Up to 250 дд of 
membrane protein could be bound quantitatively to 100 μΙ of HAP suspension In the 
ultimate EGFR assay 100 μΙ aliquots of the samples were intended to be used, so 
membrane preparations containing protein levels up to 2 5 mg/ml could be assayed 
using 100 μΙ of HAP suspension without overflowing the HAP capacity. The ultimate 
assay was therefore performed with 100 μΙ of HAP suspension. 
2.3.5 Effect of time and temperature on 125I-EGF binding to HPM 
Kinetic experiments were performed at 4 °C, 20 "C, 30 "C and 37 °C to investigate the 
time and temperature required to reach maximum EGF binding to its receptor Fig 2.5 
shows that maximum binding was achieved at 20 °C and remained constant for at 
least up to two days At 30 0C and 37 "C, specific 1Z5I-EGF binding was maximal within 
2 h of incubation, but decreased after extended Incubation tmes Experiments in 
which incubation was performed in the presence of protease inhibitors (tosyl-
phenylalanine chloromethylketone, TPCK, 1 mM, and tosyllysyl chloromethylketone, 
TLCK, 1 mM, Urban ef al. 1979) showed that the binding of 125I-EGF remained 
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maximal for at least one day, even at 30 °C and 37 "C (data not shown) This suggests 
that endogenous proteases were present in the HPM preparation 
At 4 °C, the resulting specific binding of 129I-EGF was substantially lower than at the 
other temperatures examined, even after two days of incubation In the final assay 
procedure, an incubation penod of 16-20 h at 20 "C was used for the measurement 
of EGFR. 
Bound (cpm χ 10 
Fig. 2.5 Association kineacs of EGF binding to HPM at different temperatures 
(·), 4 °C, (n), 20 °C, (ж), 30 °C, (o), 37 'C HPM was diluted 5-fold with assay buffer from a stock HPM 
(100 μΙ) and HAP (100 μΙ) were mixed and pre-incubated fori h at 20 °C to be able to study the initial 
binding kinetics 25l EGF (1 nM) was added at time-point zero and incubated for vanous periods of 
time The incubation mixtures were centnfuged for 2 mm at BOO χ g, the supemates were decanted, 
and the HAP pellets were rapidly washed twice with 1 ml of assay buffer The resulting HAP pellets 
were counted for radioactivity to determine bound EGF Nonspecific binding was determined by the 
addition of 12SI-EGF and 250 nM unlabeled EGF simultaneously The data points are taken from one 
experiment performed in duplicate 
2.3.6 ügand concentration range 
In the ligand binding assay of EGFR described In the present thesis the so-called 
saturation technique is used (the binding of increasing amount of radioactive ligand). 
It is assumed that saturation is achieved at the highest concentration of ligand used 
Analysis^ of the pattern of binding upon incubation of an HPM preparation with 
increasing concentrations of 125I-EGF (0 02-7 7 nM) revealed that saturation occurred 
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at about 2 nM of tracer (Fig. 2.6a). Similarly, analyzing membrane preparations 
obtained from human breast tumors, saturation of specific EGF binding sites was 
reached at about 2 nM 125I-EGF (Fig. 2.7a). Accordingly, for routine analysis of EGFR 
in breast tumor membranes we decided to employ ligand concentrations up to 2.0 nM. 
The lowest concentration of ligand used in the routine assay of breast tumor samples 
was 0.1 nM. Ideally, the lowest ligand concentration would be about 0.1 χ Kd 
(Kermode 1989). Assuming a Kd of about 0.5 nM for the high affinity EGFR, this 
concentration would be 0.05 nM. Practically, at this very low concentration of 1ZSI-EGF 
specific binding turned out to be too low to be measured significantly, since often bw 
amounts of receptors are present in breast tumor membranes. However, HPM 
preparations containing high levels of EGFR could be analyzed using 125I-EGF 
concentrations down to as low as 0.02 nM (vide infra). Due to the low number of 
EGFR present in the majority of human breast tumor samples, generally a low amount 
of specific 125I-EGF binding occurs at the lower concentrations of tracer. Therefore, we 
used a saturation assay (labeled ligand only) in stead of a competitive assay (fixed 
concentration of labeled ligand and increasing amounts of unlabeled ligand). 
2.3.7 Scatchard analysis of the binding data 
Scatchard analysis (Scatchard 1949) of the binding data was performed using a 
nonlinear weighted regression analysis employing Marquardt's algorithm (Marquardt 
1963), which fits the experimental binding data into either a one binding site model or 
a two binding site model (see addendum). Chi-square analysis gives the opportunity 
to discriminate between the two possible models. Scatchard plot analysis performed 
on the binding data obtained with the HPM showed a curvilinear pattern as is shown 
in Fig. 2.6b. Analysis of these binding data according to the two binding site model 
revealed the presence of a binding moiety with an extremely high affinity, Kd 0.01 nM, 
and one with a Kd of 0.32 nM, which is generally regarded as the high affinity EGFR. 
If such binding data were evaluated according to the one binding site model, the 
apparent ligand binding parameters obtained depended on the concentration range 
of EGF used. The higher the concentration range, the higher EGFR values and 
apparent Kd's assessed (Table 2.3). 
Scatchard plots derived from the binding data obtained with breast tumor membranes 
(Fig. 2.7b), however, showed the best fit according to the one binding site model, 
even in those cases in which slightly curvilinear Scatchard plots were observed. 
So far, in the handling of the receptor binding data an experimentally estimated 
nonspecific binding was used (250-fold excess of unlabeled EGF) and the residual 
binding of 1ZSI-EGF was then subtracted from the experimental data (Rosenthal, 1967). 
In the one binding site model, used for the calculation of the binding data, it was also 
possible to use a computer estimated value of the nonspecific binding, assuming 
nonsaturable behaviour only within the range of ligand concentrations tested. 
However, for the individual tumors analyzed the use of this computer estimated 
nonspecific binding did not result in a significant improvement of the binding data, as 
derived from chi-square analysis. It was therefore decided to use the one binding site 
model employing the experimental estimate for nonspecific binding. 
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Bound (nM) Bound/Free 
02 04 
Bound (nM) 
Fig. 2.6 a. Binding of 125I-EGF following Incubation of Increasing concentrations of 125I-EGF (0 02-7 7 
nM) to HPM, (x), total binding, (·), nonspecific binding obtained with a 250-fold excess ol unlabeled 
EGF, (a), specific binding b, Scatchard plot of the specific binding data from Fig 2 6a. 
Bound (nM) Bouid/Fre· 
001 002 
Bound (nM) 
fig. 2.7 a, Specific binding of 12il-EGF following incubation of increasing concentrations of 125I-EGF 
with three human breast tumor membrane preparations b, Scatchard plots of the binding data from Fig 
2 7a. 
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Table 2.3 Effect of the ligand concentration range on the apparent binding parameters 
Range EGFR Kd 
(nM) (pM) (nM) 
0.01-0.5 707 0.12 
0.01-1.0 823 0.16 
0.02-2.0 901 0.20 
0.04-3.9 930 0.22 
0.07-7.7 939 0.23 
The l-EGF binding data obtained with HPM were analyzed with the one binding site model, 
employing an experimental estimate for nonspecific binding (measured by using a 250-fold excess of 
unlabeled EGF). 
2.3.7 Ultimate EGFR assay procedure 
The data presented in the previous paragraphs have led to the ultimate EGFR assay 
procedure. A flowchart of this procedure for the assessment of EGFR in membrane 
preparations is shown in Table 2.4. 
Eight 100 μΙ aliquots of membrane fraction were incubated in polystyrene assay tubes 
with increasing concentrations of 1:!5I-EGF in a final volume of 140 μΙ of EGFR assay 
buffer (20 mM phosphate, 150 mM NaCI, 50 дМ bacitracin. 0.1% BSA, pH 7.4) for 16-
20 h at 20 "C. 
The concentrations of 125I-EGF in the incubation mixtures ranged from 0.15 nM to 3.3 
nM. Nonspecific binding was assessed in parallel incubations (in duplicate) in the 
presence of 1.0 nM 12SI-EGF and 250 nM unlabeled EGF. 
For separation of receptor-bound from free EGF, 100 μΙ of HAP suspension was 
added to each tube. The final concentrations of 125I-EGF ranged from 0.1 nM to 2.0 
nM. 
The tubes were incubated for another hour at 20 "C to ensure binding of EGFR to 
HAP and to reach a new equilibrium. During this incubation the tubes were vortex-
mixed 3-4 times. 
After centrifugation for 2 min at 800 χ g (20 eC) the supernates, containing the 
unbound ligand, were decanted. 
The pellets were washed twice with 1 ml of PBB-buffer (20 °C) and then centrifuged 
for 2 min at 800 χ g (20 "С). 
Finally the radioactivity associated with the HAP pellet was counted in a gamma 
counter. 
Calculation of the results by Scatchard analysis was performed using the nonlinear 
weighted regression curve fitting program according to the one binding site model, 
using 240 μΙ as incubation volume and with the experimentally estimated nonspecific 
binding. 
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Table 2.4 Flowchart for the measurement of EGFR in membrane preparations 
Tubes 1-8 Tubes 9-10 
t2!i-EGF (μΙ) 
Unlabeled EGF (μΙ) 
EGFR assay buffer (μΙ) 
Membrane preparation (μΙ) 
Incubate for 16-20 h at 20 "C 
HAP suspension (μΙ) 100 100 
Incubate for 1 h at 20 "C 
Centrifuge for 2 min at 800 χ g 
Decant supernate and add 1 ml of EGFR assay buffer without BSA 
Vortex and centrifuge for 2 min at 800 χ g 
Decant supernate and repeat washing step 
Count final HAP pellet in gamma counter 
Calculation of results using 240 μΙ incubation volume 
2.4 Discussion 
The assessment of EGFR in human breast cancer biopsies Is generally performed 
using a biochemical radioligand binding assay. As was shown in Table 2.1, research 
groups reporting the assessment of EGFR all employ different assay conditions. TTiis 
may provide an explanation for the large variation in EGFR positivity and EGFR levels 
and Kd's that have been reported. 
Different procedures for the isolation of the cell membranes have been shown to yield 
different EGFR levels (Dittadi ef al. 1990b). In view of standardization of the assay, we 
were restricted to use the crude membrane fraction that is obtained during preparation 
of tumor cytosols (100,000 χ g - 800 χ g) for routine steroid hormone receptor analysis 
according to EORTC guidelines (EORTC Breast Cancer Cooperative Group 1980). The 
majority of studies included in Table 2.1 obey to this guideline an therefore the 
membrane isolation procedure we used does not differ widely. 
In most of the studies, the preparation of radioiodinated EGF ( l-EGF) was performed 
by using Chloramine Τ or lodogen. It may be emphasized that these are relatively 
harsh reagents (Bolton 1985, chapter 4 of this thesis), resulting in oxidation and 
aggregation of iodinated peptide molecules. Moreover, EGF contains five tyrosine 
residues (Savage et al. 1972) sensitive to iodine incorporation, while some of these 
may be involved in receptor binding (Engler ef al. 1990,1991, Campion ef al. 1991). 
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Although receptor affinity and capacity estimates can be significantly affected when 
there is no equivalence in binding behavior between labeled and unlabeled ligand 
(Taylor 1975, Hollemans and Bertina 1975, Kermode 1988), investigators rarely test 
whether iodinated ligands behave the same as the natural ligand in receptor binding 
(Kermode 1988). In the case of 125I-EGF, no thorough attempts have been made to 
determine the binding behavior of this radioligand relative to that of unlabeled EGF. 
A study of Nicholson ef al. (Nicholson ef al. 1988) forms an exception. In that study 
It is reported that in their so-called displacement assay (using a fixed concentration 
of 125I-EGF and varying amounts of unlabeled EGF) the Kd's observed were 
significantly higher (the affinity lower) than in their so-called saturation technique (using 
increasing concentrations of 125I-EGF). 
In the various reports on the assessment of EGFR in breast tumor membranes, 
different concentration ranges of 125I-EGF have been used in multiple point titration 
assays as well as different concentrations in single dose analyses, as was shown in 
Table 2.1. These differences in ligand concentrations in single point assays certainly 
have led to substantial differences in EGFR results. As a matter of fact, the level of 
saturation of the receptor not only depends on the concentration of the ligand used, 
but also on the affinity of the receptor for the ligand. If in a tumor only one class of 
binding sites is present, e.g. with a Kd of 0.3 nM, a single point assay using a tracer 
concentration of 0.6 nM would saturate about 70% of the receptors. In another tumor 
with receptors with a Kd of 0.6 nM, the single point assay with the same tracer 
concentration would only result in a calculated receptor concentration of 50% of the 
receptors present. Results obtained in studies employing different concentrations of 
ligand therefore hardly can be compared with each other. 
In multipoint assays different ligand concentration ranges yield different EGFR values 
and apparent Kd's if curvilinear Scatchard plots are obtained. This phenomenon is 
represented by the results of the experiment collected in Table 2.3. In our ligand 
binding assay we used the saturation technique in stead of the competition technique. 
Ttie concentrations of 12SI-EGF used in the assay ranged from 0.1 nM to 2.0 nM. The 
upper concentration of 2.0 nM was employed since it appeared that saturation of 
specific binding sites occurred at that concentration. The lower concentration of 1 2 5 l -
EGF used ideally would have been about 0.1 χ Kd (Kermode 1989), which 
corresponds to about 0.05 nM assuming a Kd of about 0.5 nM. At this very low 
concentration of 125I-EGF the specific counts bound become too low. Accordingly, we 
used 0.1 nM 125I-EGF as the lowest concentration of tracer. Since the binding data 
obtained with breast tumor membranes showed the best fit according to the one 
binding site model, despite the slightly curvilinear Scatchard plots that were observed 
in some experiments, we used this one binding site model including the actual 
measured nonspecific binding for calculation of the binding data routinely. The slight 
curvilinearity of some of the Scatchard plots suggest a heterogeneous receptor 
population as will be discussed in more detail in chapter 7. 
As far as the estimate of nonspecific binding is concerned, it has been reported that 
nonspecific binding may in fact be saturable at very high ligand concentrations 
(Mendel and Mendel 1985). Therefore, the concentration of unlabeled EGF sufficient 
to eliminate all specific binding of labeled EGF is uncertain. Therefore, methods have 
been developed to determine ligand binding parameters without measuring 
nonspecific binding (Munson and Rodbard 1980, Van Zoelen 1989, see also 
addendum). For the individual tumors analyzed in our studies the binding data 
33 
obtáned using this computer-fitted value for nonspecific binding were not significantly 
improved as compared to those obtained by direct subtraction of experimentally 
measured nonspecific binding. While the excess of unlabeled EGF used (150 nM) is 
sufficient (250-350 χ Kd) to block >99% of the receptors, a larger excess may cause 
saturation of nonspecific sites or very low affinity binding sites yielding underestimated 
nonspecific binding values, and is therefore considered not appropriate (Chamness 
and McGuire 1975). 
According to the time and temperature of the equilibration step in EGFR assays, we 
found an incubation period of 16 h at 20 °C to be most favorable, although various 
investigators employ incubation conditions of one or two hours at room temperature. 
Such short incubation times may however be sufficient in case of employing a single 
point assay at a high concentration of ligand, but certainly not for the lower 
concentrations of ligand in the multiple point titration assays. 
Last but not least, different procedures for the separation of receptor-bound from free 
ligand have been reported. Achieving an optimal procedure for the separation of 
receptor-bound from free ligand is a serious challenge in receptor binding studies. 
Often, (ultra) centrifugation and (ultra) filtration are used (Table 2.1), methods which 
are probably adequate in the case of whole cell assays, or EGFR assays on other 
relatively large particles such as vesicles (Ensing et al. 1986, Berkers et al. 1990). In 
the case of small membrane fragments, quantitative pelletting of receptor-ligand 
complexes is only possible when the speed of centrifugation is very high (Oittadi et al. 
1990b). This is however a relatively time-consuming procedure, needs sophisticated 
equipment and cannot be performed on a large scale routine basis. Moreover, 
equilibrium conditions are easily perturbed using these separation methods (Ensing 
et al. 1986), which can lead to a substantial misinterpretation of the binding data 
(Munson 1983). We introduced HAP to overcome the difficulties in achieving 
quantitative pelletting of the membranes. HAP was found to quantitatively bind 
membranes containing EGFR, leaving the nonbound 12SI-EGF in solution (Benraad and 
Foekens, 1990). Only low-speed centrifugation is subsequently required for the 
separation step, which can therefore be performed rapidly with minimal dissociation 
of ligand-receptor complexes. The binding capacity of the routinely used HAP 
suspension was sufficient to analyze membrane fractions with a membrane protein 
content less than 2.5 mg/ml, which is the case in nearly all of the tumor membrane 
preparations. 
To optimize the HAP separation procedure several assay conditions were evaluated. 
Assay sensitivity increased markedly if BSA and bacitracin was included in the assay 
buffer, since the blank HAP binding of <ZSI-EGF, and therefore also nonspecific 
binding, was diminished. The bacitracin molecules likely preclude the binding of EGF 
to the HAP mineral. A very small amount of the 125I-EGF remained bound to HAP, even 
after multiple washing steps. As stated above, dissociation of receptor-ligand 
complexes has to be avoided as much as possible. Washing of the HAP pellet is 
however unavoidable since otherwise the bound fraction will be disturbingly 
contaminated with free ligand, which also affects the outcome of the receptor assay 
(Munson 1983). Actually, the most favorable assay conditions were chosen as a 
compromise between specific binding, nonspecific binding, and dissociation of ligand 
from the receptor. Regarding the latter, the HAP washing steps could be performed 
most conveniently at room temperature, since the net dissociation (i.e. the overall 
effect of both dissociation and reassociation) at 20 "С was less as compared to 4 °C. 
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It became evident that the reassociation of EGF at 20 "C was faster than at 4 eC (Fig. 
2.5). It is worth mentioning that this phenomenon has not been taken into account by 
the investigators that employ a high-speed centrifugation procedure for the bound-free 
separation step. In those studies, an aliquot of ice-cold buffer is added prior to the 
centrifugation step. 
In summary, an assay method involving HAP is described for the measurement of 
EGFR in cell membrane preparations. Separation of the receptor-ligand complexes 
from free ligand by HAP is rapid, such that dissociation of ligand-receptor complexes 
is relatively small. Moreover, only low-speed centrifugation is required for the 
separation step such that large series of samples can be analyzed simultaneously. The 
present assay procedure is easily applicable to the pellet fraction which remains after 
standard preparation of cytosols for routine assay of steroid hormone receptors 
according to EORTC guidelines. The methodology described will enable every 
laboratory which is currently involved in measurement of steroid hormone receptors 
to introduce an EGFR assay. 
References are listed on pages 99-110. 
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CHAPTER 3 
EVALUATION OF THE EPIDERMAL GROWTH FACTOR RECEPTOR 
HYDROXYLAPATITE ASSAY 
3.1 Introduction 
3.2 Methods 
3.3 Results 
3.4 Discussion 
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3.1 Introduction 
Hydroxylapatite (HAP) was introduced in the EGFR radioligand binding assay for the 
separation of epidermal growth factor receptor-bound from free 125I-EGF (chapter 2). 
Only low-speed centrifugation is subsequently required for separation of bound from 
free ligand. Experimental data on the actual performance of the HAP assay are 
presented in this chapter. The HAP assay was compared with the generally performed 
centrifugation- and filtration assays, using human placental membranes (HPM) and 
mammary tumor membranes. Moreover, in view of the potential importance of the 
EGFR status of primary breast tumors, the suitability of the HAP assay to act as a 
standard EGFR assay method was tested in a pilot interlaboratory quality control trial. 
3.2 Methods 
3.2.1 General 
Human placental membranes (HPM) and human breast tumor membranes were 
obtained as described in the previous chapter. EGF was radioiodinated by using either 
Protag-125, iodine monochloride (ICI), or Enzymobeads to a specific radioactivity of 
about 500 Ci/mmol (see chapter 4 for details). Human recombinant EGF (hEGF) was 
obtained from Bioproducts for Science Inc. (Indianapolis, IN, U.S.A.). Human 
recombinant transforming growth factor-o (hTGFa) was obtained from Peprotech Inc. 
(Rocky Hill, NJ, U.S.A.). 
3.2.2 EGFfl assays 
The HAP procedure for the measurement of EGFR was performed as described in the 
previous chapter. 
In the centrifugation assay, 1 ml of PBB-buffer (20 mM phosphate, 150 mM NaCI, 50 
μΜ bacitracin, pH 7.4) was added to the equilibrated reaction mixtures (20 °C) and 
centrifugation was performed for 15 min at 100,000 χ g. Subsequently, the supemates 
were aspirated and the pellets were counted for radioactivity. 
The ultrafiltration procedure was performed by pipetting 100 μΙ of the incubation 
mixture onto a Whatman GF-C filter (Whatman International Ltd., Maidstone, U.K.) that 
was placed in a microfiltration unit. The filters were washed twice with 5 ml of PBB-
buffer (20 °C), after which the filters were counted for radioactivity. 
Further details of the centrifugation and of the filtration assays were identical to those 
of the HAP assay. 
3.2.3 Preparation of quality control samples 
Membranes obtained from human placenta were diluted with appropriate volumes 
EGFR assay buffer to yield EGFR concentrations of about 40 and 80 fmol/ml 
respectively. Two-milliliter aliquots of the resulting preparations were lyophilized. The 
vials were sealed under vacuum and stored at 4 °C until shipment by regular mail. The 
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samples were shipped to ten EORTC laboratories. These laboratories received 4 vials 
(two of each concentration) of lyophilized control samples per trial, and also a 
lyophilized 12SI-EGF preparation. Samples were reconstituted with 2 ml of water and 
analyzed for EGFR. 
3.3 Results 
3.3.1 Reproducibility 
In several independent experiments performed in our laboratory, the reliability of the 
HAP assay was determined. The results of the examination of the within- and between-
assay variation of the HAP assay using HPM preparations that contained different 
amounts of EGFR are depicted in Table 3.1. The within-assay coefficient of variation 
of 8 individual experiments was found not to exceed 10%, even for EGFR levels down 
to as low as 4.1 fmol/ml. The between-assay variation, using different batches of 12S1-
EGF, was found to be about 13%, and the between-assay variation using one single 
batch of 125I-EGF was 8.6% (Table 3.1). 
Table 3.1 Reproducibility of the HAP assay assaying HPM 
Within-assay 
variation 
Between-assay3 
variation 
n' 
6 
6 
6 
7 
10 
12 
4 
15 
8 
42 
5 
EGFR 
mean ± S.D. 
(fmol/ml) 
4.1 ± 0.3 
6.4 ± 0.5 
11.6 ±0.7 
120 ± 4 
159 ± 15 
173 ± 9 
203 ± 12 
208 ± 15 
122 ± 15 
184 ± 25 
418 ±36 
C.V.2 
(%) 
6.6 
8.5 
5.8 
3.2 
9.5 
5.2 
5.8 
7.2 
12.6 
13.5 
8.6 
number of determinations 
'coefficient of variation. 
3The between-assay variation data in the upper two rows were obtained with several batches of '2>l-
EGF_(between-batch between-assay variation), whereas the lower row was obtained with a single batch 
of 12^I-EGF (within-batch between-assay variation). 
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3.3.2 Assay sensitivity 
The assay sensitivity was evaluated by experiments in which serial dilutions of HPM 
were prepared in EGFR assay buffer to yield membrane preparations containing 
various concentrations of EGFR. The results of one representative experiment are 
depicted in Fig. 3.1. It is shown that the EGFR concentration in the diluted HPM 
samples correlated well with the corresponding dilution factor. 
ТТте lower limit of sensitivity was defined as the lowest concentration of EGFR present 
in the membrane preparation that could be measured reliably. The lowest EGFR 
concentration that could be measured reliably was about 3 fmol/ml. Human breast 
tumor membranes generally show a somewhat higher nonspecific binding as 
compared to the HPM preparation used. If nonspecific binding accounts for a 
substantial amount of the total binding, the specific binding may be masked by the 
nonspecific counterpart, which can result in false negative EGFR concentrations. 
Actually, the lowest concentration of EGFR measured in a human breast tumor cell 
membrane preparation was 3 fmol/ml. 
EGFR (fmol/ml) 
0.2 
1/dilution 
Fig. 3.1 EGFR in serially diluted HPM. 
An HPM preparation was diluted with assay buffer. The membrane preparations obtained were analyzed 
tor EGFR by the HAP assay. 
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3.3.3 Recovery of EGFR 
An "EGFR recovery experiment' was performed to investigate the possible interference 
of nonspecific proteins present in tumor membranes on the outcome of the HAP 
assay. 10 μΙ aliquots of HPM, which contained 90 and 1136 fmol EGFR respectively, 
were added to human breast tumor biopsy membrane preparations with different 
concentrations of membrane protein (and EGFR). The apparent number of receptors 
subsequently measured by the HAP assay (recovery) was similar to that expected by 
calculation of the sum of the respective amounts of EGFR in the membrane fractions 
(Table 3.2). In this experiment the apparent Kd's measured after the addition of the 
tumor membranes did not differ from those measured before this addition (0.59 ± 
0.30 nM and 0.69 ± 0.18 nM respectively). 
Table 3.2 Recovery of EGFR 
Number of Tumor EGFR HPM EGFR Recovery 
membrane present added (%) 
preparations (fmol/ml) (fmol) (mean ± S.D.) 
0 
0 
9 
47 
19 
70 
8 
623 
5 
1136 
90 
90 
90 
90 
90 
90 
90 
90 
103 
98 
93 
98 
103 
110 
106 
98 
112 
10 μΙ of HPM preparation containing 90 and 1136 /motes of EGFR protein respectively were added to 
100 μΙ of human breast tumor membranes containing EGFRIml as indicated. The recovery was 
calculated as the percentage of EGFR relative to the expected value (the sum of the respective amounts 
of EGFR). 
3.3.4 Is occupied EGFR measured in the essay? 
Human breast tumors produce EGFR ligands (EGF, TGFa) (Dickson and Lippman 
1987). Furthermore, EGFR ligand(s) have been detected in the cytosols of human 
primary breast tumors (Macias ef al. 1989, Foekens ef al. 1989b). Membrane 
preparations derived from such tumors may also contain these ligands, either or not 
complexed to the receptor. Therefore, an experiment was performed to disclose 
whether also EGFR occupied by its ligands is measured under the conditions used. 
In other words, do endogenous ligands mask more or less the presence of EGFR. 
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Tab/β 3.3 Effect of the addition of EGF and TGFa to HPM 
membranes: not centrifugea centrifugea 
EGFR Kd EGFR Kd 
(fmol/ml) (fmol/ml) (fmol/ml) (fmol/mi) 
0.0 
0.1 
1.0 
2.0 
10.0 
0.0 
0.1 
1.0 
2.0 
10.0 
361 
368 
390 
391 
358 
361 
341 
369 
366 
376 
0.32 
0.31 
0.60 
0.90 
3.05 
0.30 
0.32 
0.51 
0.63 
2.18 
353 
334 
326 
330 
346 
353 
343 
358 
352 
358 
0.31 
0.33 
0.44 
0.63 
0.54 
0.31 
0.32 
0.37 
0.37 
0.37 
A HPM preparation was incubated with the indicated concentrations of hEGF or hTGFa In EGFR assay 
buffer for 2 h at 20 'C. EGFR was assessed in this suspension (not centrifuged) and, after centnfugaton 
fori hat 100,000 χ g, in the membrane pellet (centrifuged). Calculation of the results was performed 
using the specific radioactivity of the tracer. 
An HPM suspension was preincubated with different concentrations (up to 10 nM) of 
hEGF or hTGFa. EGFR was assessed in the suspension and also, after centrifugation, 
in the membrane pellet. In the latter procedure the presence of receptors occupied 
with endogenous ligands is mimicked. The data obtained in this experiment are 
collected in Table 3.3. 
Without centrifugation, irrespective of the addition of ligands, the multiple point HAP 
assay resulted in similar EGFR levels, even at 10 nM hEGF or hTGFa. These results 
demonstrate a reversible interaction between EGFR and the ligands added. 
Furthermore it appeared that the addition of 1 nM of ligands resulted in a nearly two­
fold increase of the apparent Kd, and the addition of 10 nM of ligands in a seven- to 
ten-fold increase of the apparent Kd. 
In the experiments in which the suspension was centrifuged all membrane 
preparations contained similar receptor values and nearly identical Kd's. These results 
imply that during the membrane isolation procedure at least most of the endogenously 
present EGFR ligands are eliminated from the membranes and that no interference will 
be encountered from ligands that are present in the membrane sample. 
It is noteworthy that recently a method has been described in which occupied and 
nonoccupied EGFR was measured in membranes from human breast tumor biopsies, 
involving acid (glycine pH 3) dissociation of endogenously bound ligand molecules to 
obviate the possibility of interference by endogenously bound ligands (Palette et al. 
hEGF (nM) 
hTGFa (nM) 
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EGFR (% Ol control) Membrane protein (mg/ml) EGFR Λ of control) 
Fig. 3.2 Mean EGFR and protein levels In tumors upon acid treatment and membrane washing, a, EGFR 
levels (expressed as fmol/ml), calculated as percentage of control; b, protein concentration (mg/ml); 
c, EGFR expressed as Imollmg Ы membrane protein, calculated as percentage of control. 
1992). In that study, a significant increase in EGFR levels In the tumors was found, as 
well as an increase in the number of EGFR positive tumors after the acid treatment. 
Unfortunately however, an essential control experiment was lacking. The addition of 
buffer (pH 7.4) in stead of acid should have been included In the experiment. Verifying 
those results, we analyzed mouse and human mammary tumors exactly according to 
the described method (Palette ef al. 1992). We included an additional control 
experiment in which the membrane preparations were washed with neutral EGFR 
assay buffer (membrane washing) in stead of glycine buffer (acid treatment) to 
investigate the effect of the membrane processing per se on the EGFR concentration. 
Mean EGFR concentrations (expressed as fmol/ml) slightly decreased (in stead of 
increased) upon both acid treatment and membrane washing (Fig. 3.2a) as compared 
to the untreated membrane preparations. No differences in apparent Kd's could be 
observed. However, both acid treatment and membrane washing resulted in a 
significant decrease of the protein concentration in the membrane preparations, when 
compared to the untreated membrane preparations (Fig. 3.2b, P=0.0001 for both acid 
treatment and membrane washing, paired t-test). Consequently, if EGFR in the 
membrane preparations was expressed as fmol/mg of protein, like reported by Palette 
et al. (1992), acid treatment and membrane washing resulted in an increase in EGFR 
levels (Fig. 3.2c). These results suggest that the add treatment in the radioligand 
binding assay results in an EGFR-enriched membrane preparation probably by 
elimination of contaminating cytosol proteins, which however also occurs by 
membrane washing. So we did not observe any increase in EGFR levels as a result 
of dissociation of ligands by acid treatment. 
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3 3 5 E/fecf of membrane protein on the level of EGFR 
Available primary breast tumors assessed for EGFR varied in size Therefore the 
relation between membrane protein and EGFR levels was studied. Statistical analysis, 
as described in the thesis by Ρ G Koenders, showed the number of EGFR positives 
of a total of 725 breast tumor membrane preparations to be positively related to 
membrane protein levels, with declining percentages of EGFR positives at the lower 
(<0 2 mg/ml) membrane protein level (Fig 3 3a) As a consequence, a negative 
relationship was observed between the EGFR levels and the membrane protein levels 
(Fig 3 3b) This result indicated that false negative assay results easily occur at the 
lower membrane protein levels When the EGFR estimations obtained with membrane 
protein levels up to 0 2 mg/ml were disregarded, EGFR levels and membrane protein 
levels were no longer associated A membrane protein level of 0 2 mg/ml was adopted 
as a threshold. 
3.3.6 Effect of storage of membrane preparations on EGFR 
Analysis of the 531 remaining sets of data (membrane preparations with protein levels 
>0 2 mg/ml) revealed that 57% (302 samples) of the tumor cell membrane 
preparations contained specific, saturable, high-affinity binding sites for EGF with a 
mean Kd of 0 5 nM (range 01-11 nM, 95% of the observations) Total EGFR levels 
ranged from 3 to 3600 fmol/mg of membrane protein, with a median value of 40 
fmol/mg of membrane protein Membrane preparations were stored under an aliquot 
of PBB-buffer at -80 °C for various periods of time No relationship was found between 
the percentage of EGFR positives and duration of storage at -80°C, ranging from 1 wk 
to 3 yr (Fig 3.4a). or between EGFR levels and duration of storage (Fig. 3 4b) 
EGFH positive (%) 
ι—1 
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Ì 
s 
Mean EGFR (tmol/mg) 
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Mebrane protein (mg/ml) 
• 
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I I I 
I 
I • 
h 
I 
'01 0.2 0.3 04 0.5 0.8 0 7 08 09 1 
Membrane protein (mg/ml) 
Fig. 3.3 a. Relation between membrane protein concentration and the percentages of EGFR positMty 
(bars representing percentage of numbers displayed in the bars) b. Relation between membrane 
protein concentration and EGFR levels Reproduced with permission 
44 
EGFR positives (%) EGFR (fmol/mg) 
ι I I ! i i 
30 60 180 360 eOO Ю О 30 60 180 360 900 1080 
Storage (days) Storage (days) 
Flg. 3.4 a, Relation between the duration of storage of the membrane preparations (days), and 
percentages of EGFR positivity (bars representing percentage of numbers displayed in the bars), b, 
Relation between duration of storage and mean EGFR concentration of positives (fmol/mg of membrane 
protein ± SEM). Reproduced with permission. 
3.3.7 Comparison of the HAP bound-free separation procedure with centrifugation and 
filtration procedures 
To study the performance of the HAP assay as compared to the generally used 
centrifugation and filtration assays, HPM was serially diluted with EGFR assay buffer 
to yield membrane preparations with six different concentrations of EGFR. Using the 
HAP assay, EGFR concentrations in the membrane preparations obtained were found 
to parallel the dilution factor, even if the EGFR concentration in membranes was 
diluted 32 times resulting in an EGFR concentration of 4 fmol/ml (Fig. 3.5). In both the 
centrifugation and filtration assay this parallellism was inferior. The larger error bars 
illustrate the higher variations observed in the centrifugation and filtration assays as 
compared to the HAP assay (Fig. 3.5b and c, compared to Fig. 3.5a). EGFR 
concentrations obtained in the centrifugation assay were generally lower than those 
obtained in the HAP assay (P<0.0001, paired t-test) or in the filtration assay 
(P=0.003). The centrifugation assay resulted in a significantly higher apparent Kd (0.29 
± 0.18 nM) as compared to the HAP assay (0.16 ± 0.06 nM) or the filtration assay 
(0.21 ± 0.12 nM) (P=0.0001 and P=0.03, respectively), indicating a greater extent of 
dissociation in the centrifugation assay. 
An additional experiment was performed to obtain information regarding the 
reproducibility of the three assays. A diluted HPM preparation was analyzed for EGFR 
in ten-fold. As shown in Table 3.5, the within-assay variation of filtration assay was 
remarkably higher as compared to either the HAP asssay or the centrifugation assay. 
Scatchard analysis of the receptor binding data obtained in the three respective 
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assays clearly illustrated the performance of the assays (Fig. 3.6). The data points 
obtained in the HAP assay were were much less scattering than those in other assays. 
Particularly at the most diluted HPM, the scattering of the data points in the 
centrifugation and filtration assays was considerable. Typical examples of the 
Scatchard plots obtained in the three different assays are shown in Fig. 3.6. 
Nonspecific binding in the HAP assay was 1.5-2.3% of the total 12SI-EGF added, 
whereas in the centrifugation and filtration assay 0.8-1.6% and 0.8-2.2% nonspecific 
binding was observed. 
EGFR (fmol/ml) 
200 
100 
1 2 4 8 16 32 1 2 4 8 16 32 
Di lu t ion fac to r 
1 2 4 8 16 32 
Fig. 3.5 EGFR concentrations in serially diluted HPM measured by using a, the HAP assay; b, the 
centrifugation assay; c, tfte filtration assay. EGFR levels were corrected for the respective dilution factor. 
Table 3.5 Within-assay variation of the HAP, centrifugation, and nitration assay. 
Assay EGFR (fmol/ml) 
HAP 
Centrifugation 
Filtration 
13.8 ± 1.9 (14.0%) 
10.6 ± 3.1 (29.3%) 
4.9 ± 6.2 (126.5%) 
A 1000-fold diluted HPM preparation was assessed for EGFR in ten-fold. Numbers represent mean 
EGFR values ± S.D, n=10. (%= coefficient of vanavon). 
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Fig. 3.6 Typical Scalchard plots, a, HAP assay; b, centrifugation assay; c, nitration assay. 
Membrane preparations obtained from human, mice and dog mammary tumors were 
analyzed for EGFR using the three different procedures. The results of these 
experiments are collected in Table 3.6. The EGFR levels obtained in the centrifugation 
or filtration assay were expressed relative to the EGFñ levels obtained in the HAP 
assay. Using a multiple point assay in this experiment no significant differences in the 
apparent numbers of receptors were observed between the HAP, the centrifugation 
and the filtration assay. However, the apparent Kd's obtained in the centrifugation 
assay were substantially higher than those obtained in the filtration assay and in the 
HAP assay. The Scatchard plots obtained in the different procedures were comparable 
to those shown in Fig. 3.6. 
In case EGFR levels were calculated by using a single concentration of 12SI-EGF (2 
nM), they were lower as compared to the multiple point assay (Table 3.6). The single 
point HAP assay resulted in higher receptor levels as compared to the centrifugation 
assay (P=0.02). No differences between the HAP assay and the filtration assay nor 
between the centrifugation assay and the filtration assay could be observed, due to 
the large variation in assay results in the filtration assay. 
Nonspecific binding in the HAP assay ranged from 1.4-3.0% of the total radioactivity 
added, whereas nonspecific binding in the centrifugation and filtration assays was 0.9-
2.9% and 1.4-4.4% respectively. 
47 
Table 3.6 Comparison of EGFR levels obtained by HAP-, centrifugation-, and filtration 
assays in human, mice, and dog mammary tumor membranes 
EGFR1 EGFR2 Kd 
Assay (nM) 
HAP 100 ± 6 78 ± 4 1.03 ± 0.29 
Centrifugation 98 ± 14 62 ± 4 3.24 ± 0.79 
Filtration 108 ± 60 76 ± 29 1.39 ± 0.56 
'EGFR measured by multiple point Scatchard analysis 
2EGFR measured by single point analysis with 2.0 nM 125I-EGF. 
EGFR levels obtained with the multiple point HAP assay were set at 100%. The standard deviation 
represents the mean standard deviation ot the experiments in duplicate. 
3.3.8 Interiaboratory quality control 
The between-laboratory variation of the HAP assay was evaluated in two pilot quality 
control trials. Hence, a reference membrane preparation had to be prepared which 
could be transported within Europe at ambient temperature, enabling evaluation of the 
performance of the HAP assay. Human placental membrane samples were found to 
contain sufficiently high EGFR levels. 
Lyophilized HPM was stored at 4 "C or at room temperature for various periods of 
time and analyzed for EGFR content. Approximately 60% of the original EGFR activity 
remained detectable after lyophilization of the samples in the presence of 0.1% BSA, 
the Kd's being unchanged (0.56 ± 0.16 nM before lyophilization and 0.59 ± 0.18 nM 
after lyophilization respectively). Omission of BSA resulted in an additional 10% loss 
(data not shown). Recently performed experiments revealed that lyophilization of HPM 
in the presence of 10% saccharose resulted in a loss of only 15% of EGFR and did 
not affect the apparent Kd. 
Storage of lyophilized HPM for up to 16 weeks at 4 °C did not result in a significant 
decrease in measurable EGFR levels, nor did storage for 3 weeks at ambient 
temperature (Table 3.7). TTierefore, it was concluded that lyophilized HPM could be 
used as reference material in quality control assessments. The results depicted in 
Table 3.7 were obtained with an HPM preparation that was prepared as described in 
the materials and methods section. Less pure HPM, obtained by the method that was 
used for preparation of human breast tumor membrane preparations, yielded less 
stable membrane fractions unsuitable for quality control purposes. The isolation 
procedure probably did not purify adequately the membranes from endogenous 
proteases. 
In the pilot quality control trials 10 laboratories received twice a set of 4 lyophilized 
samples in which the EGFR concentration was assayed using the HAP assay. 12SI-EGF 
was also lyophilized and dispatched. Results of this between-laboratory quality control 
are collected in Tables 3.8 and 3.9. The coefficient of variation ranged from 22-44%. 
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Table 3.7 Effect of storage of lyoptiilized HPM on EGFR 
Temperature of 
Sample A 
Sample В 
storage 
4 e C 
4 0 C 
20 "C 
Duration of 
storage (days) 
1 
35 
56 
84 
112 
18 
18 
EGFR 
(fmol/ml) 
391 
447 
465 
403 
384 
90 ± 7 
Θ0 + 10 
HPM preparations (lyophilaed and not lyoptiilized) were stored at4°C and at 20 °C (or various penods 
of time and assayed for EGFR content 
Table 3.8 Four HPM samples (Α-D) measured in 10 different laboratories (trial I) 
Lab. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
Mean 
S.D. 
C.V. (%) 
A 
108 
87 
93 
66 
86 
59 
54 
75 
51 
61 
74 
19 
26 
В 
41 
80 
40 
37 
43 
69 
52 
26 
20 
69 
48 
20 
41 
С 
120 
89 
90 
72 
100 
152 
92 
73 
65 
72 
93 
26 
29 
D 
43 
70 
44 
41 
43 
76 
25 
28 
25 
50 
45 
17 
39 
EGFR expressed In fmol/ml; A=C, B=D, A=2B 
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Table 3.9 Four HPM samples (Α-D) measured in 9 different laboratories (trial II) 
Lab. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
Mean 
S.D. 
C.V.(%) 
A 
63 
35 
43 
68 
58 
41 
46 
56 
45 
51 
11 
22 
В 
50 
41 
51 
62 
66 
32 
39 
37 
48 
47 
11 
24 
С 
26 
13 
22 
27 
20 
15 
23 
16 
14 
20 
5 
25 
D 
16 
12 
12 
10 
25 
10 
26 
13 
23 
16 
7 
44 
EGFR expressed in fmollml, A=B, C=D, A=2C 
3.4 Discussion 
Assaying EGFR in HPM, the HAP assay showed a good performance with a wrthin-
assay variation of 3.2-14% (Tables 3.1 and 3 5) and a between-assay variation of 8.6-
135% (Table 3.1). The lower limit of detection was about 3 fmol/ml. 
The impact of endogenously bound ligands on the outcome of the assay was 
suggested by Palette et al. (Palette et al. 1992) and therefore it was investigated 
whether the addition of hEGF to a HPM preparation affected the number of binding 
sites and the apparent Kd The results obtained indicate a reversible receptor binding 
interaction of hEGF. The effect of TGFa on the apparent Kd was somewhat less as 
compared to EGF. In the same experiment the occupation of EGFR by endogenous 
ligands was mimicked employing a centrifugation step. In all membrane preparations 
analyzed similar receptor values and nearly identical Kd's were observed These 
results demonstrated that the centrifugation step resulted in an almost complete 
elimination of the ligands. Those ligands occupying the receptors were still present in 
the centnfuged membrane preparation, but obviously did not affect measurable EGFR 
levels. The effect of the added ligands was in agreement with the competitive inhibition 
model Furthermore, acid treatment of tumor membranes did not increase measurable 
EGFR levels (Fig. 3 2a), as was claimed by Palette et al. (1992), who concluded that 
local production of EGF-like factors in breast tumors results in a masking of binding 
sites. However, Palette et al. expressed their results in fmol/mg of membrane protein. 
From our investigation it became clear that such an increase resulted from a selective 
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elimination of contaminating protein This could be concluded from the experiments 
in which both the acid treatment and membrane washing (neutral conditions) resulted 
in a significant decrease of the protein concentration in the membrane preparations, 
as a result of which the EGFR levels, if expressed as fmol/mg of membrane protein, 
increased The acid treatment therefore results merely in an enriched membrane 
preparation rather than in a detectable dissociation of endogenously bound ligands 
The question remains as to whether significant amounts of occupied receptors are 
present in a tumor membrane preparation While processing tumor tissue, a relatively 
large amount of buffer is normally used for homogenization purposes, thereby 
dissociating already a substantial amount of eventually present ligands from the 
receptors Moreover, in vivo the EGF receptor internalizes and degrades after 
occupation with ligand (downregulation) (Carpenter and Cohen 1990) If still small 
amounts of ligands are present in the membrane samples (in tumors containing very 
high levels of ligands), they do not interfere in a multiple point assay In a single point 
assay, however, the number of receptors will be underestimated due to the dilution 
of the specific radioactivity of the 12SI-EGF used by endogenous ligands 
The data presented demonstrate that EGFR remains stable for at least 3 yr in cell 
membrane preparatone stored at -80 °C, a finding which legitimizes the use of 
archived membrane preparations for the purpose of retrospective clinical studies on 
EGFR The stability of EGFR was also demonstrated in the experiments performed in 
order to obtain reference material for quality control purposes After lyophilization of 
membrane samples, which by itself resulted in a decrease of measurable specific 
binding sites in case lyophilization was performed in the absence of lyoprotectants, 
EGFR was stable for at least 16 weeks at 4 "C or for three weeks at ambient 
temperature. 
Measurement of EGFR by means of a ligand binding assay was found to easily result 
in a false-negative outcome in cases where the membrane protein level falls below a 
certain threshold Using the HAP assay, this threshold was 0 2 mg/ml Using other 
procedures to separate bound and free ligand such as centrifugation or filtration, this 
threshold may be higher or lower than in the HAP assay Nevertheless, the HAP assay 
showed a much better overall performance than the generally used centrifugation and 
filtration assays 
In the centrifugation assay, the higher apparent Kd's obtained suggest a more 
extended dissociation of EGF from the receptor as compared to the other two assays 
examined The dissociation in the centrifugation assay was initiated by the addition of 
1 ml of assay buffer pnor to the centrifugation step However, if the addition of buffer 
prior to the centrifugation step is omitted, this will lead to contamination of the bound 
fraction by free ligand, affecting the binding data (Munson 1983) The observation that 
similar receptor concentrations could be obtained in the tumor membranes using the 
centrifugation assay compared to the HAP assay, if both assays are performed using 
a multiple point titration procedure, indicates that quantitative pelleting of the 
membranes can be achieved with an ultracentrrfugation (100,000 χ g) step However. 
most investigators who perform centrifugation for separation of bound and free ligand, 
use much lower centrifugation forces, as was shown In Table 2 1 In those cases 
quantitative precipitation of all membranes present is not achieved (Dittadi ef al. 1990) 
yielding underestimated EGFR levels 
Membrane preparations containing relatively high levels of EGFR could be analyzed 
properly using the filtration assay Apparent Kd's were similar as compared to the HAP 
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assay, since in both assays rapid washing steps could be performed. However, using 
the filtration assay for membranes containing the lower EGFR levels, such as in the 
serial diluted HPM samples, no reliable filtration assays could be performed due to the 
huge scattering of the data points. As a consequence, false negative assay results 
easily occur by employing the filtration assay. Furthermore, the filtration assay was 
very time-consuming and is therefore unsuitable to perform large series of samples 
simultaneously. On the other hand, the HAP assay was the easiest to use in 
performing large series of measurements simultaneously. The use of HAP improves 
the performance of an EGFR radioligand binding assay. 
A relatively large variation was observed in the between-laboratory quality control trials 
as compared to the small variation observed in the within-assay examinations. The use 
of an internal standard preparation indicates that this variation can be improved 
significantly. In order to achieve more uniformity between laboratories, an effort to 
continue the between-laboratory quality control trials is undertaken. The 
standardization of EGFR assays is important for comparison of EGFR data, a 
prerequisite when trying to determine the significance of EGFR as a prognostic marker 
in human breast cancer and its role in tumor biology. The data presented in this 
chapter suggest that the HAP assay is acceptable as a standard technique for 
measurement of EGFR. 
References are listed on pages 99-110. 
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CHAPTER 4 
RADIOIODINATION OF EPIDERMAL GROWTH FACTOR 
4.1 Introduction 
4.2 Materials and methods 
4.3 Results 
4.4 Discussion 
53 
4.1 Introduction 
Radioiodinated epidermal growth factor (EGF) is generally used in EGF Receptor 
(EGFR)-binding studies (e.g. Carpenter ef al. 1975, Hock and Hollenberg 1980, Magun 
et al. 1982, Pérez et al. 1984, Fitzpatrick et al. 1984, Lin et al. 1987, Nicholson et al. 
1988, Marti et al. 1989). EGF contains five tyrosine residues (Savage et al. 1972) that 
allow formation of various labeled EGF species during iodination. Indeed, reversed-
phase HPLC studies by Matrislan et al. (1985) demonstrated that iodination of 
homogeneous EGF by Chloramine Τ results in a heterogeneous 12SI-EGF preparation. 
Moreover, some tyrosine residues in the EGF molecule may be involved in receptor 
binding (Engler et al. 1990,1991, Campion eta/. 1990), which implies that iodination 
might profoundly affect ligand-receptor interaction. Investigators rarely test whether the 
radioiodinated EGF preparation behaves the same as the natural ligand in receptor 
binding (Kermode 1988), although receptor affinity and capacity estimates can be 
seriously affected when there is no equivalence between the labeled and the native 
ligand (Kermode 1988, Taylor 1975, Hollemans and Bertina 1975). Therefore, if the 
receptor-binding data are to yield realistic information on the nature of the ligand-
receptor interaction, identical receptor-binding affinity of labeled and unlabeled EGF 
is necessary. This is particularly true for studies in which receptor-binding data are 
obtained by competition between labeled and unlabeled EGF (Kermode 1988). 
Various methods have been described for preparing radioiodinated EGF. Iodination 
of EGF has been established either directly, by oxidation of the radioiodide in the 
presence of the polypeptide (Carpenter et al. 1975, Hock and Hollenberg 1980, Kore 
and Finman 1989, Marti et al. 1989), or indirectly, for human EGF, by conjugating EGF 
with a radioiodine-containing acylating agent (Bolton-Hunter reagent) (Bolton and 
Hunter 1973, Kermode and Tritton 1990). The oxidation of the radioiodide can be 
performed either chemically or enzymatically. For chemical oxidation, various agents 
are available, of which Chloramine Τ has been used the most extensively (e.g. Hock 
and Hollenberg 1980, Magun eta/. 1982, Fitzpatrick efe/. 1984, Pekonen eta/. 1988). 
Despite its widespread acceptance, however, the Chloramine Τ method, in which the 
oxidizing agent is in solution, appears to damage the polypeptide to be iodinated 
(Sherman et al. 1974, Bolton et al. 1979, Lee and Griffiths 1984, Bolton 1985). In 
contrast, methods involving a sparingly soluble oxidizing agent (lodogen*) or agents 
coupled to a solid support (lodo-beads*, Protag-125*) have been claimed to be more 
gentle because direct contact between the oxidizing agent and the protein to be 
radiolabeled is minimized (Fraker and Speck 1978, Slacinski etaJ 1980, Markwell 1982, 
Guenther and Ramsden 1984, Nicholson et al. 1985, Kore and Finman 1989). 
Enzymatic oxidation of the radioiodide with lactoperoxidase can also be achieved both 
in the solubilized state (Marchalonis 1969, Thorell and Johansson 1971) and, more 
mildly, in the solid state (David and Reisfeld 1974, Marti et al. 1989). In the latter case, 
Sepharose-coupled lactoperoxidase (29) or lactoperoxidase and glucose oxidase 
immobilized on hydrophilic spheres (Enzymobeads*) are used. 
In the present study, we performed six different methods for direct iodination of mouse 
EGF. The binding behavior of the different radioligands to human placental 
membranes (HPM) containing EGFR was investigated by comparing the saturation 
binding curves (increasing concentrations of 125I-EGF) and the competitive binding 
curves (competition of 12*I-EGF with unlabeled EGF) of the various products in an 
attempt to establish whether receptor-binding equivalence could be achieved between 
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radioiodinated EGF and its unlabeled counterpart. Also the binding behavior of 
different 12SI-EGF column fractions, obtained after preparative separation by HPLC of 
Chloramine T- and Enzymobeads-labeled EGF, was evaluated to investigate whether 
a homogeneous radioligand exhibiting ligand equivalence could be obtained by HPLC 
purification. The effect of nonequivalence in binding behavior between labeled and 
unlabeled EGF was Investigated by performing Scatchard analysis of saturation and 
competitive binding data. We also assessed maximal binding capacity of each 125I-EGF 
preparation to HPM, i.e., the fraction of the tracer that would bind at infinite receptor 
concentrations, to observe whether nonequivalence in binding behavior between 
labeled and unlabeled EGF is associated with a decrease in binding capacity of the 
125I-EGF preparation. 
4.2 Materials and methods 
4.2.1 Materials 
Receptor grade mouse EGF was obtained from Bioproducts for Science, Inc. 
(Indianapolis, IN, U.S.A.). Carrier-free Na125l and commercially prepared 125l-labeled 
mouse EGF were obtained from Amersham International pic. (Amersham, 
Buckinghamshire, U.K.). lodogen and lodo-beads were purchased from Pierce 
Chemical Co. (Rockford, IL, U.S.A.). Chloramine T, sodium disuffite and iodine 
monochloride (ICI) were obtained from Merck (Darmstadt, Germany). Enzymobeads 
and hydroxylapatite (HAP; DMA grade Biogel HTP) were obtained from Bio-Rad Labs. 
(Richmond, CA, U.S.A.). ^-D-Glucose was supplied by Sigma Chemical Co. (St. Louis, 
MO, U.S.A.). Bacitracin was obtained from Serva (Heidelberg, Germany). Bovine 
serum albumin was purchased from Behringwerke AG (Marburg/Lahn, Germany). 
Protag-125 and disposable 3-ml C i e solid-phase extraction (SPE) columns (200 mg 
of Cie) were obtained from J.T. Baker, Inc. (Phillipsburg, NJ, U.SA). Protag-125 is not 
available anymore. 
4.2.2 lodination methods 
lodinations were carried out at room temperature with ±10 да of EGF in 10 μΙ of 50 
mM phosphate buffer, pH 7.4, and with 10 μΙ (1 mCi) of Na l S l (EGF/125I molar ratio 
= about 3). To remove unreacted iodine after the iodination reaction, the reaction 
mixture was loaded onto a C4e SPE column, pre-equilibrated sequentially with 4 ml 
each of methanol, water, and the respective dilution buffer (see the respective 
iodination reactions below). The SPE column was washed three times with 1 ml of an 
aqueous solution of 20% methanol and 0.1% trrfluoroacetic acid (TFA). 129I-EGF was 
eluted from the column with 1 ml of 80% methanol, 0.1% TFA. TTie efficiency of iodine 
incorporation was obtained by dividing the radioactivity eluted in the protein fraction 
by the total radioactivity added. The methanol was evaporated under a stream of dry 
nitrogen in a water bath at 37 °C. The 125I-EGF solution resulting was brought to a final 
volume of 1 ml with EGFR assay buffer (20 mM phosphate buffer, pH 7.4, containing 
150 mM NaCI, 50 μΜ bacitracin, and 0.1 mg/ml BSA). The recovery of EGF protein 
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was approximately 45%. 
To minimize adsorption of 1Z5I-EGF to hydroxylapatite (HAP) and to minimize 
nonspecific binding, the 125I-EGF preparations were pre-incubated with 200 μΙ of HAP 
suspension for 30 min at 20 °C. HAP was used to separate receptor-bound and free 
EGF In the binding experiments (see below). After centrifugation for 2 min at 800 χ g 
(20 °C), the tracer preparation was pipetted away from the HAP pellet. The amount of 
adsorption of the pretreated 12SI-EGF preparations to HAP (Blank HAP binding) was 
determined by incubating about 250,000 cpm of tracer with 100 μΙ of HAP suspension 
and counting the radioactivity of the HAP-bound 125I-EGF after two washes with 1 ml 
of EGFR assay buffer without BSA and subsequent centrifugation for 2 min at 800 χ 
g and decanting of the supernate. 
Approximately 5 χ 10e cpm of the 125I-EGF preparation was adjusted to a volume of 
200 μΙ with water; then 50 μΙ of acetonitrile was added, and the 125I-EGF preparation 
was subjected to HPLC analysis. For preparative separation of 125I-EGF, we performed 
two iodination reactions simultaneously. The 125I-EGF preparations obtained were then 
pooled before the HPLC step. 
4.2.2.1 Chlommine Τ method 
The Chloramine Τ method was performed by a modification of the method of Matrisian 
ef el. (1985). To 10 μΙ of EGF, 170 μΙ of 50 mM phosphate buffer (pH 7.4) and 10 μΙ 
(1 mCi) of Na125l were added. The reaction was started by the addition of 20 μΙ of 
Chloramine Τ (2 mg/ml). After 25 s of incubation 20 μΙ of sodium disulfite (4 mg/ml) 
was added to stop the reaction. Then 1 ml of 50 mM phosphate buffer (pH 7.4) was 
added to the reaction tube and unincorporated iodine was immediately removed by 
using SPE columns as described above. The efficiency of iodine incorporation was 45-
55%, which corresponds to about 0.3-0.4 iodine atomes incorporated per molecule of 
EGF. 
4.2.2.2 lodogen method 
According to the manufacturer's recommended procedure, to 10 μΙ of EGF, 20 μΙ of 
100 mM borate buffer (pH 8.0) and 10 μΙ (1 mCi) of Na125! were added. The reaction 
was started by pipetting the mixture into a 10 χ 75 mm borosilicate glass tube coated 
with 1 μg of lodogen. After 10 min of incubation, 1 ml of 100 mM borate buffer (pH 
8.0) was added, after which the mixture was pipetted out of the lodogen-coated tube 
to stop the reaction. Unreacted iodine was removed as described above. Radioiodine 
was incorporated with 45-50% efficiency. 
4.2.2.3 lodo-beads method 
According to the manufacturer's instructions, we mixed 10 μΙ of EGF with 180 μΙ of 100 
mM phosphate buffer (pH 7.0) and 10 μΙ (1 mCi) of Na12Sl. The reaction was initiated 
by the addition of one lodo-bead. After two min of incubation, 1 ml of 100 mM 
phosphate buffer (pH 7.0) was added and the reaction was stopped by loading the 
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reaction mixture without the lodo-bead onto a C,e SPE column. Free iodine was 
removed as described above. The efficiency of the lodo-bead iodination reaction was 
40-55%. 
4.2.2.4 Iodine monochloride method 
The iodine monochloride method was performed as described by Contreras et al. 
(1983). The molar ratio of ICI to EGF was 2:1 : approximately 3.4 nmol of ICI in 20 μΙ 
of 0.85 % NaCI solution was added to a mixture of 10 μΙ of EGF (10 дд = 1.7 nmol), 
100 μΙ of 200 mM borate buffer containing 160 mM of NaCI (pH 8.0), and 20 μΙ (2 mCi) 
of Na125l, while vortex-mixing. After vortex-mixing for 1 minute adding 1 ml of 200 mM 
borate buffer and 160 mM NaCI (pH 8.0), the mixture was loaded onto a C l e SPE 
column as described above to remove unincorporated iodine. The fraction of iodine 
incorporated into EGF ranged from 20% to 30%. 
4.2.2.5 Protag-125 method 
Iodination of EGF by using Protag-125, an insoluble glycouril agent (Guenther and 
Ramsden 1984), was performed by adding a mixture of 10 μΙ of EGF solution, 20 μΙ 
of 100 mM borate buffer (pH 8.4) and 10 μΙ (1 mCi) of Na , 2 Sl into a borosilicate glass 
tube containing 1.7 mg of Protag-125. After 6 min of incubation with intermittent mixing 
of the suspension for 5 s at 30-s intervals, 1 ml of 50 mM phosphate buffer (pH 7.4) 
was added. The Protag beads were sedimented at 1 χ g, after which the supernate 
was loaded onto an SPE column for removal of free iodine as described above. The 
efficiency of the Protag iodination reaction was 30-40%. 
4.2.2.6 Lactoperoxidase-glucose oxidase method (Enzymobeads) 
Iodination was performed according to the manufacturer's instructions. 10 μΙ of EGF, 
50 μΙ of 200 mM phosphate buffer (pH 7.4), 50 μΙ of Enzymobead reagent, and 10 μΙ 
(1 mCi) of Na125l were mixed and 25 μΙ of 1 % 0-D-glucose was added to start the 
reaction. After incubation for 10 min, 1 ml of 200 mM phosphate buffer (pH 7.4) was 
added. Unbound iodine was removed by SPE as described above. Iodine was be 
incorporated with 40-50% efficiency. 
4.2.3 Specific radioactivity and ligand equivalence 
The specific radioactivity of 125I-EGF preparations was determined by the "self-
displacement" method (Morris 1976, Calvo ef a/. 1983), plotting BoundfTotai (B/T) 
ratios versus radioactivity 12SI-EGF or mass of unlabeled EGF added to the receptor 
preparation. Separation of free and receptor-bound ligand was performed by using 
HAP. HAP adsorps EGFR protein, leaving nonbound EGF in solution. Only low-speed 
centrifugation is required subsequently for the separation step. 
Two sets of binding experiments, using EGFR-containing HPM prepared as described 
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in chapter 2, were performed. In one set, providing the saturation curve, 100 μΙ of 
HPM (30 дд of membrane protein) was equilibrated in duplicate incubations with 
increasing concentrations of 125I-EGF (ranging from 2 χ 10* to 3 χ 10е cpm) in a final 
volume of 140 μΙ of EGFR assay buffer at 20 °C for 16-20 h. In the second set of 
binding experiments, which provided the competitive binding curve, 100 μΙ of HPM 
was equilibrated in duplicate incubations with a fixed concentration of labeled EGF 
(about 2 χ 104 cpm) and increasing concentrations of unlabeled EGF (from 0 to 3500 
fmol/tube) at 20 °C for 16-20 h. To separate free and receptor-bound ligand, 100 μΙ 
of HAP suspension was added to each assay tube. The tubes were equilibrated for 
another hour at 20 °C with intermittent mixing to ensure new equilibrium. After 
incubation and centrifugation for 2 min at 800 χ g (20 °C), the supernate was 
decanted. The HAP pellets were washed twice with 1 ml of EGFR assay buffer without 
BSA and centrifuged for 2 min at 800 χ g (20 °C). The HAP pellets were counted for 
radioactivity in a Model 1261 multi gamma counter (LKB-Wallac, Turku, Finland) with 
82.5% efficiency. 
According to Van Zoelen (1992), in a system in which a homogeneous set of binding 
sites is equilibrated with either labeled ligand (L*) of unlabeled ligand (L"), which may 
differ in their receptor-binding affinity, the ratio of the corresponding dissociation 
constants K* and K" is related to the added concentrattons of L* and Lu, which lower 
the initial binding to the same B/T ratio, according to: 
Lu - L* K" - K* 
L*(1-B7T) K* 
In this equation B* is the experimentally obtained value for bound labeled ligand under 
such equivalent competition conditions, while in addition it is assumed that nonspecific 
binding components are negligible. Since L* is only known in cpm-values (C*), which 
are related by the specific radioactivity of the labeled ligand preparation {Ms),'A follows 
that 
Lu К" íB ' 
— = S — + - - (1-K7K*) 
С* Κ* Τ 
Thus, by plotting L7C* (fmol/cpm) for various values of В7Т, a linear plot is derived 
from which the values of both s and K7K* can be obtained from the intercept with 
ordinate at B*/T-values 0 and 1. This equation is analogous to the one derived for a 
homogeneous set of binding sites (Hollemans and Touber 1974, Hollemans and 
Bertina 1975). 
Therefore, in this study the binding data of the saturation curve were transformed into 
B/T ratios and plotted on a semilogarithmic scale against the radioactivity added to 
the receptor preparation, after subtraction of the initiai 2 χ 104 cpm added in the first 
tube. For the competitive binding curve, the binding data were transformed into ВД 
ratios and plotted against femtomoles of unlabeled EGF added, in the same 
semilogarithmic plot. At several B/T ratios in this plot, cpm of 125I-EGF and femtomoles 
of unlabeled EGF were read from the saturation curve and the competition curve, 
respectively-
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Then femtomoles obtained at several ВД ratios were divided by the cpm of labeled 
EGF which lowered the ВД to the same extent. Plotting the ratio of fmol/cpm at 
several B/T ratios vs the corresponding ВД ratio reveals the Ligand Equivalence (LE) 
plot. For a radioligand which has the same affinity as compared to that of the 
unlabeled ligand (K* = K"), the obtained line in the LE plot Is horizontal (Hollemans 
and Touber 1974, Hollemans and Bertina 1975, Van Zoelen 1992). There is 
nonequivalence in binding behavior between labeled and unlabeled ligand when the 
slope of this line differs significantly from zero. The specific radioactivity of the tracer 
preparation can then be obtained by extrapolation of the straight line to В Я = 1 , 
whereas the ratio of the intercepts at B/T=1 and ВАГ=0 represents the ratio of the 
Kd's of unlabeled and labeled ligand. 
In the case that multiple receptor classes are present, the LE plot is horizontal if there 
is equivalence in binding behavior between labeled and unlabeled ligand, i.e. that the 
dissociation constants of the labeled and unlabeled ligand for both high- (K*h and ICh) 
and low-affinity receptors (K*l and ICI) are identical. In the case in which there is 
nonequivalence but the ratios of the dissociation constants of the labeled and 
unlabeled ligand are similar for both the high- and low-affinity receptor class (K'h/lCh 
= K*l/Kul), a nonhorizontal but straight line is obtained. In cases in which K*h/Kuh not 
equals K*l/Kul, a complicated sigmoidal LE plot is obtained (Van Zoelen 1992). 
Another plot can be constructed from the obtained binding data. When cpm of 1 2 5 l -
EGF added, read from the saturation curve at several B/T ratios, are plotted versus 
fmoles of unlabeled EGF, read from the competitive binding curve at corresponding 
BIT ratios, a straight line is obtained when there is equivalence between labeled and 
unlabeled ligand, in which the slope represents the specific radioactivity of the tracer 
preparation in cpm/fmol (Calvo et al. 1983) 
4.2.4 Reversed-phase HPLC 
The HPLC apparatus included an SP8700 solvent delivery system and an SP8750 
organizer (Spectra-Physics, Santa Clara, CA), a Model 470 scanning fluorescence 
detector (Millipore, Waters Associates, Bedford, MA) and a Model 201-202 fraction 
collector (Gilson, Villiers-le-Bel, France). 12SI-EGF preparations were chromatographed 
using a 0.39 χ 30 cm /¿Bondapak C,e reversed-phase column (Millipore, Waters) 
connected to а дВопаарак С1 в guard column, with a linear gradient changing from 
20% to 31.7% acetonitrile (balance 0.1% trifluoroacetic acid) over 70 minutes at 20 °C. 
The solvent flow was maintained at 2 ml/min. Fractions (1 ml) were collected and 
counted for radioactivity. In those experiments where nonradioactive EGF was 
chromatographed, we used the fluorescence of endogenous tryptophan (excitation 
wavelength 215 nm, emission wavelength 340 nm) for detection. 
4.2.5 Maximal binding capacity 
About 2 χ 10* cpm of EGF was equilibrated in duplicate with increasing amounts of 
HPM (4-100 цд of membrane protein), containing about 6000 fmol of EGFR/mg of 
protein, in a total volume of 140 μΙ of EGFR assay buffer at 20 "C for 16-20 h. 
Separation of receptor-bound and free was performed under nondissodating 
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conditions: 100 μΙ of the incubate was added to an HAP pellet, which was obtained 
by centrifuging 100 μΙ of HAP suspension and subsequently aspirating the supemate. 
After incubation for 1 h at 20 "C with repeatedly mixing, the samples were centrifuged 
for 2 min at 800 χ g (20 "С). Then 50 μΙ of the supernate was counted for radioactivity 
(representing 50% of the free ligand) and the bound fraction was calculated by 
subtracting the nonbound 125I-EGF from the total radioactivity added to the HAP pellet. 
A pbt of 1 /radioactivity bound vs 1/volume of the membrane preparation was 
constructed, such that the ordinate intercept represented the fraction of 125I-EGF that 
would bind at infinite receptor concentrations (maximal binding capacity) (Kermode 
and Trrtton 1988, Calvo et al. 1983). 
4.3 Result* 
4.3.1 Specific radioactivity and ligand equivalence 
Mouse EGF was iodinated with Na12Sl by using six direct radioiodination methods. The 
binding behavior of the radioiodinated EGF preparations was assessed by binding 
studies with EGFR-containing HPM. 
For EGF labeled with Chloramine T, the competitive binding curve, in which unlabeled 
EGF increased, shows a steeper decline in binding than does the saturation curve, in 
which only labeled ligand was added (Fig. 4.1a). From the saturation curve in Fig. 
4.1a, cpm of 125I-EGF added were read at various B/T ratios. From the competitive 
binding curve, femtomoles of unlabeled EGF added were read at the same ВД ratios. 
The cpm of 125I-EGF obtained were plotted vs the corresponding fmoles of unlabeled 
EGF. This plot shows upward curvilinearity (Fig. 4.1b), which precludes a reliable 
estimation of the specific radioactivity. From the data shown in Fig. 4.1a, another plot 
was constructed (Fig. 4.1c) in which the ratio fmol/cpm at several B/T ratios was 
plotted vs the corresponding B/T ratio, providing the ligand equivalence (LE) plot. As 
shown in Fig. 4.1c, the slope of this line differs significantly from zero, which implies 
that the affinity of the Chloramine Τ labeled ,25I-EGF was lower as compared to that 
of the unlabeled EGF. Attempts to determine the specific radioactivity of Chloramine 
T-125I-EGF by extrapolation to ВД=1 failed, since these plots showed curvilinearity. 
Using commercially prepared 125I-EGF (Chloramine Τ method), the results of these 
binding experiments were essentially identical to those shown in Fig. 4.1 obtained with 
Chloramine T-12SI-EGF, prepared in our laboratory. 
In the literature iodinated ligands prepared with lodogen or lodo-beads have been 
described as undergoing a milder iodination procedure (Fraker and Speck 1978, 
Markwell 1982). In the present study it appeared that binding experiments performed 
with 125I-EGF labeled with lodogen (n=5) or lodo-beads (n=4) yielded essentially 
identical binding curves as were obtained with Chloramine Τ125I-EGF (Fig. 4.1a), i.e. 
diverging saturation and competition curves and nonhorizontal LE plots (data not 
shown). On the other hand, parallel binding curves were obtained when we used 1 2 S I -
EGF labeled by the ICI method (Fig. 4.2a). As a consequence of this parallelism, a 
perfectly straight line was obtained with cpm of 125I-EGF plotted vs femtomoles of 
unlabeled EGF (Fig. 4.2b), and a straight and horizontal LE plot could be constructed 
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(Fig. 4.2c), indicating equivalence in binding behavior between labeled and unlabeled 
EGF. The specific radioactivity of ICI-ial-EGF could be calculated accurately from the 
slope of the line in Fig. 4.2b. The specific radioactivity of ICI-1:SI-EGF preparations was 
415 ± 123 Ci/mmol (mean ± SD, n=5) 
Equivalence in binding behavior between labeled and unlabeled EGF could also be 
observed by using ,2SI-EGF, lodinated with Protag-125 and Enzymobeads. The specific 
radioactivities were 525 ± 146 Ci/mmol (n=9) and 570 ± 80 Ci/mmol (n=7) for 1 2 5 l -
EGF labeled with Protag and Enzymobeads respectively. 
Bound/Total cpm χ 10" 
0.2 
mmol/CI χ 10 
0 l / l I шин—I I I HUM—ι 11 ним—ι 11 ими—I I mill 
1 0 * 1 0 4 1 0 * cpm added 
10° i o ' 1 0 * f mol added 
Flg. 4.1. Binding experiments of a Chloramlne T-12SI-EGF preparation with an HPM preparation a, 
Binding curves obtained Irom experiments performed as described in matenals and methods (o, cpm 
of г l-EGF added, x, femtomoles of unlabeled EGF added), b, radioactivity added was plotted against 
the corresponding mass of unlabeled EGF at several points where the BIT ratio was the same for both 
curves in Fig 4 la, e, LE plot obtained by plotting the ratio Imollcpm at vanous BIT ratios against the 
corresponding BIT ratio 
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Bound/Total cpm χ 10 
0 l^i ι ι мчи—ι ι ι мни—ι 11 nini—ι ι ι nim—ι ι ι imi' 
1 0 a 10* 10° cpm added 
I O 1 IO 3 IO 9 f mol added 
mmol/Ci χ 10 
Flg. 4.2 Determination of the specific radioactivity and relative affinity of ICI-12,I-EGF. 
o, increasing овсег concenirations; x, increasing concentrations of cofd EOF. For a toe, see fegend 
Fig. 4.1, 
4.3.2 Reversed-phase HPLC 
As shown in the HPLC elution profiles (Fig. 4.3). all six iodination methods used 
resulted in a heterogeneous ,25I-EGF preparation. However, EGF that was iodinated 
using Chtoramine T, lodogen, or lodo-beads (Fig. 4.3a-c) showed the predominant 
peaks at shorter retention times on HPLC than unlabeled EGF. For EGF labeled with 
use of Enzymobeads, Protag-125, or ICI, the predominant peaks were shifted to 
longer retention times (Fig. 4.3d-f). The HPLC elution profile of commercially available 
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RtdloMtlvlly 
Elution t lm· (min) 
Flg. 4.3. Cia reversed-phase HPLC elubon profiles of val-EGF, prepared with sa different 
radioiodinaüon methods Approximately Sx Í0* cpm 125I-EGF were subjected to HPLC Fractions of 
1 ml were collected and counted for radioactivity a, Chloramine T, b, lodogen, c, lodo-beads, d, 
Enzymobeads, e, Protag-125, f. Iodine monochloride Unlabeled EGF eluted as indicated by arrows 
radioiodmated mouse EGF (Chloramine Τ method) was essentially identical to that 
shown in Fig 4 3a Neither the use of smaller amounts of Chloramine T, lodogen, or 
lodo-beads, nor lodmation for shorter incubation times changed the HPLC profiles for 
lodmated EGF significantly (data not shown) 
To study the effect of the nonradioactive reagents per se on the chromatographic 
properties of EGF, we performed the reactions under the conditions described for 
lodination, but with no radioiodide (Fig 4 4) The HPLC apparatus in this case was 
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Elution tlm· (min) 
Flg. 4.4. С,, reversed-phase HPLC elutìon profiles of EGF, treated with the various radloiodlnatlon 
reagents, In the absence of radioiodide. 10 yg EGF was treated and injected onto the HPLC column. 
EGF protein in the eluent was monitored by endogenous tryptophan fluorescence. Unlabeled EGF 
eluted as indicated by the dashed line and by arrows, a-f as in Fig. 4.Э. 
equipped with a fluorescence detector. Treating EGF with the Chloramine T, lodogen, 
or lodo-beads reagents resulted in shorter retention times (Fig. 4.4a-c). In contrast, 
treating EGF with the Enzymobeads or Protag-125 reagents (Fig. 4.4d, e) did not 
affect the elution position of the protein, except for a slight increase of the first peak 
in the elution profile of Protag-treated EGF. Treatment of EGF with nonradioactive ICI 
yielded several fluorescent peaks, one with the retention time of native EGF and others 
with longer retention times (Fig. 4.4f), probably from the incorporation of 
nonradioactive iodine from the ICI molecule into the EGF. 
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Oxidation of EGF with hydrogen peroxide also produced a shift to shorter retention 
times, comparable to the treatment of EGF with Chloramine T, lodogen, and kxdo-
beads Moreover, oxidation of ICI-12SI-EGF by hydrogen peroxide, also shifted the 
various peaks to shorter retention times (Fig. 4 5) 
30 40 50 60 70 
Elution time (mm) 
Fig. 4.5. fffecf of axidetion of /C/-'25/-EGF by hydrogen peroxide 
(-) НЛС profile of the nonaxidaed ICI-,25I-EGF We also added 30 μΙ of a 30% H202 solubon to 
aft. ox. 2 5 μς of 12Sl-EGF ml ml of assay buffer After 30 mm incubation at room temperature, Sxltf 
cpm of the oxidized 12SI-EGF were sub/ected to HPLC (-) Insert LE plots of the nonoxidaed (n) and 
the Н2Ог oxidized (x) 125l EGF 
4.3.3 Ligand equivalence analysis (LEA) of different HPLC column fracbons 
To investigate the binding behavior of 12SI-EGF entities eluting with different retention 
times on HPLC, Chloramine T- and Enzymobeads-,25l-EGF were chromatographed 
preparatively. HPLC column fractions (1 ml) were collected and counted for 
radioactivity. Four peaks (Fig. 4 6) were analyzed separately Each peak was 
rechromatographed on HPLC (see inserts of Fig. 4 7 and 4 8) and analyzed by LEA, 
as described in Materials and Methods As the sloping lines in Fig 4 7 show, all four 
12SI-EGF fractions obtained after chromatography of Chloramine T-12SI-EGF had lower 
affinity for the placental EGF receptor than unlabeled EGF. 
The binding behavior of the pooled Enzymobeads-,2Sl-EGF preparations was also 
investigated by LEA. Three fracbons (E2, E3 and E4) obtained after HPLC contained 
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12SI-EGF that was equivalent to the native EGF in receptor binding, as can be 
concluded from the horizontal LE plots (Fig 4 8b-d), therefore, these fractions could 
be used for accurate determinations of specific radioactivity In contrast, LEA of the 
E1 tracer resulted in a nonhonzontal plot, indicating nonequivalence (Fig 4 8a) This 
E1 tracer could have been generated by lodmation of already oxidized EGF entities 
present in the unlabeled EGF preparation (Fig 4 4a, dashed line) The overall 
nonchromatographed ,25I-EGF preparation (EO) showed ligand equivalence, from 
which it appears that no interference is encountered from the presence of the small 
amount of the nonequivalent E1 tracer Another mild radioiodinaüon procedure such 
as ICI, also yielded a tracer with overall ligand equivalence (Fig 4 5, insert) Oxidation 
of this ICI- l-EGF preparation by hydrogen peroxide introduced nonequivalence in 
binding behavior between labeled and unlabeled EGF (Fig. 4.5, insert) 
cpm χ 10* 
12 
4 -
12 
8 
4 
El 
- / ^ 
e 
,AJ 
ЕЭ 
v 
\ 
b 
30 40 SO 60 
Elution time (mki) 70 
Fig. 4.9. Preparative Isolation HPLC elutionprofiles of Chlommlne T-1isl-EGF (a) and Enzymobeads-125!-
EGF (b) Column fractions «vere pooled as indicated by C1-C4 and E1-E4 
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Fig. 4.7. Ligand equivalence plots of four isolated Chloremine T-125I-EGF preparations obtained by 
preparative separation by HPLC. a, CI; b, C2; с, СЭ; d, C4. (see Fig. 4.6). 
The HPLC profiles of the distinct '^l-EGF preparations are shown in the Inserts. 
mmol/CI к 10 
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Fig. 4.8. LE plots of four isolated Enzymobeads-'^I-EGF preparations obtained by preparative 
separation by HPLC. a, El; b, E2; α £3; d, E4. (see Fig. 4.6) 
The HPLC profiles of the distinct ,2il-EGF preparations are shown in the inserts. 
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The specific radioactivities of the equivalent fractions E2, E3, and E4 varied widely, 
being 144, 1Θ77, and 3296 Ci/mmol respectively. Fully in agreement with this 
observation was the finding by HPLC analysis with fluorescence detection of "cold 
lodmated" EGF (lodmation with nonradioactive iodine) that nearly all fluorescence 
intensity was located in the E2 area (data not shown). 
4.3.4 Scatchard analysis 
Because the specific radioactivity of commercially supplied Chloramme T-12SI-EGF 
preparations is given by the manufacturer (established by other procedures), we could 
perform Scatchard analyses (Scatchard 1949) of saturation and competitive binding 
data to observe the effect of using labeled or unlabeled EGF as a variable in an EGFR 
assay As demonstrated in Fig. 4 9a, the apparent number of binding sites obtained 
from the competitive analysis was lower than the apparent number of binding sites 
obtained when we used increasing concentrations of 125I-EGF (24 fmol/ml and 49 
fmol/ml respectively). Moreover, the apparent dissociation constant (Kd) was 
considerably higher when we used the latter method (0 20 nM and 0 65 nM 
respectively). 
Bound/Free Bound/Free 
0 0 6 
20 40 eo 
Bound (fmol/ml) 
20 40 eo 
Bound (fmol/ml) 
Fig. 4.9. a, Scatchard plots obtained from binding studies, with increasing concentrations of 
1,2*/-f GF (o) and increasing concentrations of unlabeled EGF (x), b, Scatchard 
i 1І5, commercially obtained plots obtained from saturavon (o) and competition (x) binding expenments by using /CI-,ZS/-EGF 
2 5 μg HPM protein was equilibrated with EGF, 015-3 5 nM, final concentration in a total volume of 140 
μΙ of EGFR assay buffer Specific binding (Bs) was calculated as the difference between total binding 
and nonspecific binding, assessed by parallel incubations in the presence of 250-fold excess of 
unlabeled EGF BIF = specifically bound/free ratio 
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Table 4.1. Scatchard analysis (saturation and competitive binding data) for 
nonchromatographed Enzymobeads-1№l-EGF (EO) and the HPLC column fractions of 
Enzymobeads-^I-EGF (E2, E3, and E4). 
Saturation analysis Competition analysis 
N(pM) Kd(nM) N(pM) Kd(nM) 
EO 
E2 
E3 
E4 
927 
973 
1028 
898 
0.21 
0.11 
0.10 
0.15 
887 
1085 
1050 
9«? 
0.20 
0.13 
0.11 
0.18 
See legend to Fig. 4.9. N - number ot receptors; Kd = dissociation constant. 
Scatchard plots derived from saturation and competitive binding data obtained with 
12SI-EGF labeled by the ICI method did not show significant differences with respect 
to the apparent number of receptors (42 fmol/ml and 39 fmol/ml respectively) and 
apparent dissociation constants (0.27 nM and 0.24 nM respectively) (Fig. 4.9b). Similar 
to observations for ICI-12SI-EGF, Scatchard plots obtained from saturation and 
competitive binding data with ,25I-EGF labeled with Protag or Enzymobeads were not 
different (data not shown). 
Furthermore, saturation and competitive binding experiments using 
non-tfiromatographed Enzymobeads-,25l-EGF (E0) or the HPLC purified 125I-EGF 
preparations E2, E3 and E4 resulted in similar number of receptors (N) and apparent 
Kd by Scatchard analysis (Table 4.1). 
4.3.5 Maximal binding capacity, nonspecific binding, and blank HAP binding 
The maximal binding capacity of all 125I-EGF preparations. Including the different HPLC 
fractions, was investigated under the conditions as described in materials and 
methods by incubating an increasing number of receptors with a fixed concentration 
of labeled EGF. Irrespective of the ¡odination procedure used, the maximal binding 
capacity was >95%. The specific radioactivity, therefore, was not corrected for the 
binding capacity of the 125I-EGF preparations. 
For all EGF tracers prepared with the six different methods (n=35), the nonspecific 
binding ranged from 1 to 2% of the total counts added and the non-specific 
adsorption to HAP (blank HAP binding) ranged from 0.6 to 1.7%. 
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4 3 6 fffecf of storage conditions of l-EGF on tracer charactenstics 
During storage of 125I-EGF preparations the nonspecific binding and the blank HAP 
binding of the tracer in binding experiments increased in a time- and temperature-
dependent manner (Table 4 2) Irrespective of the lodmation method used for 
lodmation, at -20 °C and -80 °C, this increase was on average about 0 05% per day 
of storage, whereas at 4 °C, it was almost negligible Sephadex gelpermeation 
chromatography revealed that the increase in nonspecific/blank HAP binding did not 
parallel the release of 125l from the 125I-EGF, but did roughly parallel the appearance 
of a radioactive high molecular weight ('^l-HMW) component in the 125I-EGF 
preparation (Table 4 2 and Fig 410) 
The binding of the radioactive markers (see legend to Table 4 2) to HAP was 
compared to the amount of binding of the radioactivity in the column fracbons after 
gelpermeation chromatography 70% to 80% of 125I-BSA bound to the HAP The 1 2 5 l -
HMW component also bound for 70% to the HAP The binding of both 125I-EGF and 
125l to HAP was very low (below 1%) (Fig 410b) 
According to these data, storage of ^l-EGF at 4 "C seemed to be most convenient 
However, storage of 125I-EGF at 4 °C resulted in nonequivalent tracer preparations 
within two weeks as observed by LEA (data not shown) In contrast, storage at -20 °C 
did not change the affinity of the 125I-EGF preparation for at least up to two months 
Correct receptor binding data were obtained with these 125I-EGF preparations rf 
radioactive decay was taken into account only for the determination of the actual 
specific radioactivity 
Table 4.2. Charactenstics of an Enzymobeads 12t'l-EGF preparation dunng prolonged 
storage (42 days) at venous temperatures. 
NSB blank HAP Free 12SI 1Z5I-HMW 
(%/day)1 (%/day) (%/day) (%/day) 
+ 20 "C 
+ 4 0C 
- 20 "C 
- 80 0C 
nd2 
0018 
0 054 
nd 
0059 
0018 
0064 
0056 
085 
048 
0 31 
036 
0 012 
0020 
0064 
0036 
1 9 
per cent increase per day of storage, 'not determined 
Nonspecific binding and blank HAP were determined as described In materials and methods 12SI-HMW 
and free 12SI were determined by gelpermeation chromatography (Fig 4 10a) as percentage of the total 
radioactivity eluted from the column Approximately 5 χ 10? cpm of 12SI-EGF were loaded on top of a 
30 χ 1 cm Sephadex GIOIOSO column (5 cm of G10, 25 cm of G50) and eluted with PBB-buffer 
Fractions (10 ór) were collected and counted for radioactivity Carrier-free 12SI, 12SI-BSA (100 ¿ig of 
BSA, ICI method), and freshly prepared 125I-EGF were used as markers 
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Fig. 4,10 a, Sephadex gelpermeation chromatography protile oían Enzymobeads-1t5l-EGF, stored at -
20 °C tor 80 days; b, blank HAP binding Ы the radioactive moieties in the column fractions to 100 μΙ 
Ы HAP suspension. 
4.4 Discussion 
Binding studies of EGFR require an ial-EGF preparation of which the binding behavior 
towards the receptor is identical to that of unlabeled EGF (Kermode 1988). Moreover, 
an actual and accurate value for the specific radioactivity of the radioiodinated EGF 
is required (Munson 1983). In the present study, we compared six direct methods for 
radioiodination of mouse EGF. The binding behavior of the different ,25I-EGF 
preparations, as compared with that of unlabeled EGF, was Investigated by 
comparison of saturation (increasing concentrations of 125I-EGF) and competitive (fixed 
concentration of 12SI-EGF and increasing concentrations of unlabeled EGF) binding 
data. This comparison of saturation and competition binding data is generally 
confusingly designated as self-displacement analysis (Morris 1976, Calvo et el. 1983). 
We prefer the term Ligand Equivalence Analysis (LEA). With LEA, an accurate 
determination of the specific radioactivity can be performed when the apparent affinity 
of labeled and unlabeled ligand towards the receptor is identical. If not, the LE plot 
shows a line of which the slope differs from zero (Hollemans and Touber 1974, 
ί 
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Hollemans and Bertina 1975, Van Zoeten 1992). 
The binding behavior of EGF preparations labeled with Chloramine Τ to HPM 
containing EGFR was studied. Apparently, the affinity of this radioligand was less than 
the affinity of unlabeled EGF. This nonequivalence between labeled and unlabeled 
EGF precludes an accurate determination of the specific radioactivity by LEA. 
Moreover, the LE plot in Fig. 4.1c showed curvilinearity which might be the result of 
heterogeneity of binding sites (Hollemans and Touber 1974) or of ligand. 
There are other approaches besides LEA for determination of the specific radioactivity. 
In many studies the specific radioactivity of the radioligand is measured simply by 
determining the mass of the ligand and the corresponding radioactivity. The use of 
specfic radioactivity obtained in this way, in concert with nonequivalence in binding 
behavior between labeled and unlabeled ligand, has important consequences in 
binding studies. For a tracer with a lower affinity than unlabeled EGF, displacement 
analysis will result in an underestimated EGFR value, whereas for a tracer with a 
higher affinity, an overestimation of the receptor number will be obtained. In contrast, 
saturation analysis will result in correct values for the number of binding sites, but the 
apparent dissociation constant will be incorrect to an extent that depends on the 
affinity of the tracer compared with that of unlabeled EGF. 
lodogen and lodo-beads have been claimed to be mild ¡odination reagents, compared 
to Chloramine T, because of their insolubility in water (Fraker and Speck 1978, 
Salacinski eí al. 1980, Markwell 1982). Our results however, do not support this claim 
as far as ¡odination of EGF is concerned. The decrease in receptor-binding affinity of 
EGF labeled with Chloramine T, lodogen or lodo-beads is very likely due to the 
oxidation of readily oxidizable amino acid residues in the EGF molecule-binding region 
(e.g. methionine and amino acids with aromatic side chains). Indeed, methionine is 
readily oxidized by Chloramine Τ treatment (Stagg et al. 1970). The oxidative capacity 
is probably not due to the ¡odination reagent itself, but more likely to oxidative 
intermediates formed in these procedures. When dissolved in water, Chloramine T, the 
n-monochbro derivate of p-toluenesulfonamide, generates hypochlorous acid (HOCI), 
a soluble and strongly oxidative molecule, lodogen (1,3,4,6-tetrachloro-3a,6a-
diphenylglycoluril), a virtually insoluble complex with four Chloramine T-like groups 
(Fraker and Speck 1978, Salacinski 1980), and lodo-beads, Chloramine Τ molecules 
coupled onto polystyrene beads (Markwell 1982), also generate HOCI as oxidative 
intermediate in the ¡odination reaction. Comparable oxidation damage to EGF therefore 
likely occurs when either one of these methods is used. The oxidation of EGF by HOCI 
from Chloramine T, lodogen, and lodo-beads obviously has serious implications for 
the binding behavior of the labeled ligand. The mechanism of the remaining three 
methods studied involves other intermediates to generate a reactive iodine molecule. 
ICI acts via isotopie exchange (Contreras et al. 1983). In the conventional 
lactoperoxidase method, a relatively high amount of hydrogen peroxide, which could 
be harmful for the peptide, is added to Initiate the lactoperoxidase reaction (Carpenter 
et al. 1975). According to the manufacturer, Enzymobeads initiate the ¡odination 
reaction mildly by a very slow generation of hydrogen peroxide after conversion of ß-
D-glucose by glucose oxidase. Unfortunately, we do not know the mechanism of 
Protag-125 ¡odination, but it is likely to act differently from Chloramine Τ ¡odination. 
lodination of EGF with ICI, Protag-125, or Enzymobeads apparently does not affect the 
binding characteristics of EGF. This equivalence in binding behavior between labeled 
and unlabeled EGF suggests that none of these ¡odination methods results in 
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substantial damage to the protein, at least in relation to its interaction with EGFH. 
Perhaps the tyrosine residues favored for iodination in these methods are not in the 
region of the protein moiety involved in the receptor interaction. The unaltered binding 
behavior of these EGF preparations enables accurate measurements of the specific 
radioactivity. Moreover, a reliable estimation of EGF receptors by multiple-point 
Scatchard analysis can be established with respect to the apparent number of binding 
sites and apparent dissociation constants, both for saturation and competitive binding 
analyses. 
All six methods used in the present study for direct radioiodination of EGF, generated 
highly heterogeneous 125I-EGF preparations. These results are In agreement with 
studies by Matrisian ef a/, who showed that radioiodination of EGF by the Chloramine 
Τ method results in a heterogeneous 125I-EGF preparation (Matrisian et al. 1985). The 
heterogeneity may be the result of the presence of five tyrosine residues in the EGF 
molecule (Savage et al. 1972), which provides the possibility for various labeled EGF 
spedes to be formed during iodination. 
In the Chloramine T, lodogen and lodo-beads iodination reactions, nearly all of the 
iodinated products had shorter HPLC retention times than unlabeled EGF. Because 
oxidation of methionine-containing proteins decreased their retention time on reversed-
phase HPLC (Seidah ef al. 1980), it may be concluded from these observations that 
EGF is oxidized during these iodination reactions. One of the effects of oxidation of 
125I-EGF is the formation of covalent-like ligand-receptor complexes (Comens et al. 
1982), which could affect equilibrium binding measurements. However, another study 
indicated that the covalent-like binding properties are not affected by various methods 
for iodination of EGF. Furthermore, even unlabeled EGF formed this covalent-like 
ligand-receptor complex (Marti et al. 1989). Thus, it is doubtful whether the forms of 
l-EGF iodinated by different methods are distinguishable as far as their covalent-like 
binding properties are concerned. 
LEA of different 12SI-EGF moieties after HPLC purification of Chloramine T-125I-EGF 
revealed that none of these moieties showed ligand equivalence. Therefore, the quality 
of a '^l-EGF preparation with respect to its equivalence to unlabeled EGF in receptor-
biriJing characteristics cannot solely be determined by its purity and retention time on 
HPLC. HPLC purified Chloramine T-125I-EGF preparations should therefore also not be 
used in receptor competition assays, using a single amount of 125I-EGF and increasing 
concentrations of unlabeled EGF. On the other hand, the radioligands in the pooled 
HPLC fractions of Enzymobeads-12Sl-EGF all showed equivalence in binding behavior 
between labeled and unlabeled ligand, except for the E1 tracer (Fig. 4.8). The EGF 
protein in this fraction could have been present already in the unlabeled EGF 
preparation as a probably oxidized contaminant. However, this small amount of E1 
tracer did not introduce nonequivalence in binding behavior between the overall 
Enzymobeads-,al-EGF preparation and unlabeled EGF. It is therefore concluded that 
it is not essential to purify an Enzymobeads-labeled EGF preparation to homogeneity 
to obtain a 125I-EGF preparation with ligand equivalence. HPLC purification is also 
unnecessary when EGF is radioiodinated by using ICI or Protag-125, because these 
12SI-EGF preparations show ligand equivalence. 
The observation that the maximal binding capacity of all tracers is similar and is still 
>95%, is an indication that neither cysteine residues or other amino acid residues 
critical for receptor binding are affected by iodination and/or oxidation, and that the 
oxidation of amino acid residues does not prevent, but only alters the ligand receptor 
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interaction. It is clearly shown, in agreement with Kenmode (1988) that maximal 
bindability and equivalence in binding behavior between labeled and unlabeled llgand 
are two separate aspects of radioligand quality, which both have to be examined 
before the radioligand is used in receptor studies. Moreover, treatment of EGF in the 
presence of nonradioactive Nal with ICI (iodination) or with Chloramine Τ (iodination 
and oxidation) did not affect its biological activity significantly. This was established in 
a serum-free proliferation assay with normal rat kidney cells (Van Zoelen ef al. 1988). 
These results also indicate that amino acids critical for receptor binding are not 
affected by either iodination or oxidation. Similar observations were made by Matrisian 
et a/. (1985), who showed that EGF radioiodinated with Chloramine Τ retained its 
biological activity. 
Prolonged storage at -20 °C did not affect the receptor-binding properties of the 4 2 5 l -
EGF preparations. However, an 125I-HMW that included probably an iodinated form of 
BSA which increased nonspecific binding, and free 125l increased during storage of 
125I-EGF at -20 0C and -80 "C. Nevertheless, correct receptor binding data were 
obtained if the specific radioactivity was corrected for radioactive decay only. For 
routine use, it was decided to store 125I-EGF preparations at -20 °C and to prepare 
12SI-EGF freshly at least every four weeks. 
Our present findings show that Chloramine T, lodogen, or lodo-beads iodination 
affects the ligand-receptor interaction, resulting In a lesser receptor binding affinity 
than that of unlabeled EGF. As a consequence, such ligands can not be used for 
reliable measurements of EGF receptors. This holds particularly for those assays in 
which Scatchard analyses are performed by using a single amount of ,2SI-EGF and 
increasing concentrations of unlabeled EGF. HPLC purification of 12SI-EGF, prepared 
by harsh oxidative iodination methods, also does not result in an EGF tracer with 
better binding characteristics than the overall ,25I-EGF preparation. In contrast, 1 2 5 l -
EGF preparations with binding affinity towards EGFR identical to the affinity of the 
unlabeled growth factor could be prepared by using ICI, Protag-125, or Enzymobeads. 
Sufficiently high specific radioactivities could be obtained with these methods. 
Therefore, sensitive and more-reliable EGFR assays can be performed by using EGF 
radioiodinated by these reagents. Moreover, HPLC purification of 12SI-EGF prepared 
by these methods is considered superfluous, because the overall heterogeneous 1 2 5 l -
EGF preparation shows ligand equivalence. HPLC purification, however, can yield 
tracers of very high specific radioactivity tracers (>3000 Ci/mmol) and ligand 
equivalence through the use of these mild radioiodination methods. 
References are listed on pages 99-110. 
W. van Rotterdam (Department of Cell Biology, University of Nijmegen) Is 
acknowledged for the assessment of biological activity. 
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CHAPTER 5 
ASSAYS FOR EPIDERMAL GROWTH FACTOR RECEPTOR UGAND(S) IN 
MAMMARY TUMOR CYTOSOLS 
5.1 Introduction 
5.2 Matertals and methods 
5.3 Results 
5.4 Discussion 
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5.Í Introductíon 
As described in previous chapters, numerous studies have been reported regarding 
the epidermal growth factor receptor (EGFR) in human breast cancer. In contrast, the 
attention paid to the assessment of the ligand(s) for this receptor has been nearly 
negligible and is limited to a few studies (Maclas et el. 1989, Foekens et al. 1989b). 
Assessment of EGFR ligand(s) is possible by using an EGFR-containing preparation 
as the binding source (radioreceptor assay, RRA). However, apart from EGF 
(Carpenter and Cohen 1990), transforming growth factor alpha (TGFa, Todaro ef al. 
1980), vaccinia growth factor (VGF, Stroobant et al. 1985), amphiregulin (Shoyab ef 
al. 1985), and cripto (Ciardiello ef al. 1991) have been shown to bind and activate the 
EGF receptor. Therefore, an RRA determines an overall concentration of EGFR 
ligand(s). A human placental membrane (HPM) preparation was used as the binding 
source in the RRA and 125l-mouse EGF as the tracer. EGFR ligand(s) were assessed 
in cytosols derived from human breast tumors and mouse mammary tumors. In 
addition, a specific polyclonal antibody against mouse EGF (mEGF) was raised and 
enabled us to develop a sensitive and specific radioimmunoassay (RIA) for mEGF in 
mouse mammary tumor cytosols. The devebpment and performance of both the RRA 
and RIA procedures are described in this chapter. 
5.3 Materials and methods 
5.3.1 Materials 
Receptor grade mouse EGF (mEGF) was obtained from Bioproducts for Science, Inc. 
(Indianapolis, IN, U.S.A.). Human recombinant EGF (hEGF) was obtained from 
Bioproducts for Science or from Amersham International (Amersham, 
Buckinghamshire, U.K.). Human recombinant TGFa (hTGFa) was obtained from 
PeproTech Inc. (Rocky Hill, NJ, U.S.A.). Carrier-free Na125l was obtained from 
Amersham International. Iodine monochloride (ICI) was obtained from Merck 
(Darmstadt, Germany). Enzymobeads and hydroxylapatite (HAP; DMA grade Biogel 
HTTP) were obtained from Bio-Rad Labs. (Richmond, CA, U.S.A.). 0-D-Glucose was 
supplied by Sigma Chemical Co. (St. Louis, MO, U.S.A.). Bacitracin was obtained from 
Serva (Heidelberg, Germany). Bovine serum albumin (BSA) was purchased from 
Behringwerke AG (Marburg/Lahn, Germany). 
5.3.2 Tissue cytosols 
Tumor tissue was pulverized in the frozen state by means of a microdismembrator 
(Braun, Melsungen, Germany). The tissue powder was homogenized in five volumes 
of buffer A (10 mM КгНРСуКНгРО«, 1.5 mM KjEDTA, 10 mM monothioglycerol, 3 mM 
NaNj, and 10%, v/v, glycerol, pH 7.4). After centrifugation for 10 min at 800 χ g (4 "С), 
the supemate was further centrrfuged for 1 h at 100,000 χ g (4 °C). The supernate was 
referred to as cytosol and used for measurement of EGFR binding factors. 
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EGFR ligand(s)-free cytosols, which were used in the standard curves, were obtained 
from human uterus or breast tumors. Tissue was grinded with a Retsch ultra 
centrifugal mill (Type ZM1, Retsch, Haan, Germany) and homogenized in ice-cold 
phosphate buffer A without glycerol (5 ml per gram of tissue). The homogenate was 
centrifugea for 1 h at 45,000 χ g (4 °C). 5 ml-aliquots of the supemate were lyophilized 
and stored at 4 "C. Before use, a lyophilized cytosol specimen was reconstituted with 
5 ml of water and incubated with 800 mg of charcoal (Norit A, Fisher Scientific, U.S A ) 
to adsorb possibly interfering substances (EGF and related peptides). 
A mEGF-containing cytosol was obtained from mouse submaxillary glands. Glandular 
tissue (about 50 mg) was homogenized in 5 ml of buffer A using an Omni-1000 (Omni 
International, Waterbury, CT, USA) for 10 sec at 4 °C. The homogenate was 
centrifuged for 1 h at 100,000 χ g (4 °C). 
5.3.3 ДЯА procedure 
Approximately 15.000 cpm of 125l-mEGF (10 μΙ, 500 Ci/mmol) and 50 μΙ of tumor 
cytosol were equilibrated in duplicate incubations with 100 μΙ of HPM (containing 50 
fmol EGFR protein, prepared as described in chapter 2), in a final volume of 170 μΙ 
of assay buffer (20 mM phosphate, 150 mM NaCI, 50 μΜ bacitracin, 0.1% BSA, pH 
7.4) for 16-20 h at 20 °C. In the standard curve 12SI-EGF (10 μΙ) was incubated with 50 
μΙ of charcoal-treated cytosol, 10 μΙ of EGF standard, and 100 μΙ of HPM. The 
standard curve was prepared using a charcoal-treated human breast tumor or human 
uterus cytosol to correct for matrix effects. Separation of receptor-bound from free 
ligand was performed using the hydroxylapatite (HAP) procedure. Results were 
calculated using a standard curve-fitting RIA program. 
5.3.4. RIA procedure 
An antibody was raised against mEGF in rabbit(s). The mEGF was coupled to BSA 
by the glutaraldehyde method (Avrameas and Ternynck 1971). 0.5 ml of a solution of 
the immunogen was mixed with an equal volume of Freund's complete adjuvans. 
Booster injections were given monthly (3 times). 
The RIA procedure was performed as described for the RRA procedure, except that 
100 μΙ of a 1:40,000 dilution of the antiserum was used in stead of HPM. For 
separation of antibody-bound from free ,25i-EGF we again used the HAP procedure. 
5.3 Resulta 
5.3.1. RRA 
A binding competition assay (radioreceptor assay, RRA) involving the HAP procedure 
for separation of receptor-bound from free 125I-EGF was introduced using HPM as 
EGF binding source. 
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First, the appropriate dilution of the HPM preparation was determined. A membrane 
dilution curve was prepared in assay buffer and samples were incubated with a fixed 
amount of 125l-mEGF (15,000 cpm). At a 40-fold dilution of HPM, 40-50% of the 1 2 S I -
EGF added was bound (Fig. 5.la), and this preparation was used in the RRA. 
Bound/Total (%) B/Bo(%) 
м юо 
HPM dilution 
αϊ ι io юо 
Competitor (nM) 
Fig. 5.1 a, HPM dilution curve obtained with 15,000 cpm 1Z*I-EGF. 
'"I-EGF bound to diluted HPM preparations was determined by adsorption of the bound fraction to 
HAP (see chapter 2) and counting of the HAP pellet after two washing steps, b, Competition curves of 
hEGF (two different preparations), mEGF, and hTGFa using a 10-fold diluted HPM preparation. About 
15,000 cpm 12il-mEGF and increasing concentrations of competitor were incubated with 100 μΐ of the 
HPM preparation. (·), mEGF; (o), hEGF (Amersham Int.); (x), hEGF (Bioproducts); (a), hTGFa. 
It was assumed that the quantity of the growth factor preparations was correctly stated 
on the vials. Stock solutions were made by dissolving the entire vial contents in 0.05 
M phosphate buffer (pH 7.4). Competitive binding curves of hEGF (two different 
preparations), mEGF, and TGFa are shown in Fig. 5.1b. It is obvious that the 
competition of 12SI-EGF by hTGFa is less as compared to either hEGF (25% and 57%) 
or mEGF (33%). Apparently, hEGF obtained from different manufacturers exhibited 
different receptor binding properties. As long as there are no standard EGF and TGFa 
preparations, the differences observed in Fig. 5.1 may also have been resulted from 
differences in concentrations. These results imply that dissimilar assay results are 
introduced if different EGF preparations are used as standard in the RRA. We chose 
hEGF (Amersham) as standard if human tumor cytosols were assayed and mEGF if 
cytosols derived from mouse mammary tumors were analyzed for EGFR ligand(s). 
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Tabi· 5.1 Reproducibility of the RRA 
Within-assay 
variation 
Between-assay 
variation 
n=10 
n=10 
n=10 
n=5 
n=5 
n=5 
EGFR ligand(s) 
mean : ± S.D. 
(fmol/50 μΙ) 
8.1 
39.2 
184.3 
8.2 
36.3 
198.5 
±0.6 
±3.0 
± 11.2 
± 1.6 
±2.2 
±5.3 
C.V. 
(%) 
7.8 
7.7 
6.1 
19.6 
6.0 
2.7 
Three mouse mammary tumor cytosols were analyzed in 10 duplicate experiments to assess the within-
assay variation. The between-assay variation was examined by measuring EGFR ligand(s) in the three 
cyfoso/s in five separate experiments. 
The reproducibility of the RRA was investigated using three mouse mammary tumor 
cytosols with different levels of EGFR llgand(s). The results of this examination of the 
within- and between-assay variation are shown in Table 5.1. The within-assay variation 
was found to be about 7%. whereas the between-assay variation ranged from 2.7% 
to 19.6%. 
The sensitivity of the RRA was evaluated by an experiment in which a pool of human 
breast tumor cytosols was serially diluted with charcoal-treated cytosol, which by 
еь.. er determination was found to be devoid of EGFR ligand(s). The hEGF standard 
RRA curve obtained in this experiment is shown in Fig. 5.2a. The concentration of 
EGFR ligand(s) in the diluted cytosols were linearly related to the corresponding 
dilution factor, down to about 3 fmol of EGF-activity per assay tube (=3 fmol/50 μΙ of 
cytosol) (Fig. 5.2b). 
A recovery experiment was performed in which a human breast tumor cytosol pool 
was assayed for EGFR ligand(s) employing standard curves prepared in different 
matrices (buffer and charcoal-treated cytosols). From Table 5.2 it appears that the 
composition of the medium in which the standard curve is prepared is of great 
influence on the values obtained. Lower values of EGFR ligand(s) were obtained using 
the standard curve prepared In the charcoal-treated cytosols as compared to the 
values obtained using the standard curve prepared in buffer. Furthermore, the tumor 
cytosol was supplemented with fixed amounts of hEGF (20, 40, and 100 fmol) to 
examine whether the hEGF added could be recovered. Using the standard curve 
prepared in charcoal-treated cytosol of either human breast tumor or human uterus, 
the recovery of hEGF was quantitative (102% and 98% for charcoal-treated breast 
tumor cytosol and uterus cytosol respectively). Using the standard curve prepared in 
buffer the measured values exceeded the expected values (recovery 116%). 
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В/Во (Id) (mol/tube 
io wo 
mEGF (nM) 
0 4 Οβ OB 
1/dllution 
Flg. 5.2. β, Standard curve of hEGF (Amersham) obtained by incubation of about 15,000 cpm I-
mEGF and increasing concentrations of hEGF with 100 μΙ of the 40-fold diluted HPM preparation b, 
Levels of EGFR ligand(s) in a pool of human breast tumor cytoso/s senally diluted with charcoal-treated 
cytosol. 
Table 5.2 Recovery of hEGF added to cytosol 
Standard curve 
prepared in: 
Buffer Breast tumor 
cytosol 
Uterus 
cytosol 
Expected Found 
(fmd) (fmol) 
Expected Found 
(fmol) (fmol) 
Expected Found 
(fmol) (fmol) 
EGF added to human breast 
tumor cytosol (fmol) 
0 
20 
40 
100 
23.8 
43.8 47.1 
63.8 72.5 
123.8 132.8 
13.9 
33.9 33.7 
53.9 56.8 
113.9 113.7 
13.1 
33.1 32.0 
53.1 54.7 
113.1 111.3 
A human breast tumor cytosol pool was analyzed for EGFR llgand(s), in the absence or presence of 
added hEGF, using standard curves prepared in buffer or in charcoal-treated human breast tumor с q. 
human uterus cytosol. 
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5.3.2. RIA 
A specific radioimmunoassay (RIA) for mEGF was developed using a polyclonal rabbit 
anti-mEGF antibody which was obtained from rabbits by immunization with the 
receptor grade mEGF. The RIA also involved HAP to separate antibody-bound and 
free 125l-mEGF. The antiserum dilution curve is shown in Fig 5.3a. The antiserum 
working dilution used was 1:40,000, yielding a boundAotai ratio of about 40%. 
The specificity of the antiserum was assessed by measuring the binding ability of 
mEGF, hEGF (two different preparations) and hTGFo to the antibody. As far as these 
ligands are concerned, the RIA was highly specific for mEGF, since no cross-reactivity 
was observed with either hEGF or hTGFa (Fig. 5.3b). 
The reproducibility of the RIA for the assay of mEGF was investigated using a mouse 
submaxillary gland cytosol (Table 5.3). The within-assay variation was 3.2-5.9%, and 
the between-assay variation was 6.1-8.5%. 
Bound/Total (») B/Bo(%) 
100 
Log antiserum dilution Competitor (nM) 
Fig. 8.3 a. Antiserum dilution curve obtained with approximately 15,000 cpm 1-mEGF. 
Bound '"/-mEGF was determined by adsorption to HAP (see chapter 2) and counting of the HAP pellet 
alter two washing steps, b, Cross-reactivity of the anti-mouse EGF antiserum with mEGF, hEGF and 
hTGFa. About 15,000 cpm 125l-mEGF was incubated together with increasing concentrations Ы 
competitors with 100 μΙ of a 1:40,000 diluted antiserum. (·), mEGF; (o), hEGF (Amersham Int.); (x), 
hEGF (Bioproducts); (a), hTGFa. 
The sensitivity of the RIA was evaluated in an experiment in which EGF was measured 
in mouse submaxillary gland cytosol that was serially diluted with charcoal-treated 
cytosol. The mEGF standard curve obtained in this experiment is depicted in Fig. 5.4a. 
The concentrations of mEGF in the diluted cytosols were linearly related to the dilution 
factor (Fig. 5.4b) down to about 2 fmol of mEGF per assay tube (=2 fmol/50 μΙ of 
cytosol). This parallellism could also be observed in Table 5.3. 
81 
Table 5.3 Reproducibility of the RIA 
Withm-assay 
variation 
Between-assay 
variation 
n=10 
n=10 
n=10 
n=9 
n=9 
n=9 
mEGF 
mean ± S.D. 
(fmol/50 ді) 
93.7 ± 3 2 
45.2 ± 1.6 
24.0 ± 1.4 
96.1 ± 5.9 
46 8 ± 4.0 
23.6 ± 1.9 
C.V. 
(%) 
3.2 
3.6 
5.9 
6.1 
8.5 
8.1 
A mouse submaxillary gland cytosol and 12 and 14 dilutions were analyzed for mEGF content by RIA 
Into duplicate experiments for examination or the within-assay variation The wlthin-assay venation was 
examined by measuring mEGF the cytosol in 9 separate experiments 
B/Bo(%) Imol/tube 
1 ю юо 
hEQF (nM) 
04 00 06 
1/dilutlon 
Fig. 5.4. a. Standard RIA curve of mEGF obtained by incubabon of about 15,000 cpm 1isl-mEGF and 
increasing concentrations of mEGF with 100 μΙ of the 1 40,000 diluted antiserum b. Levels of mEGF 
In a mouse submaxillary gland cytosol serially diluted with charcoal-treated cytosol 
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5.5 Discussion 
It appears from the present chapter that EGFR ligand(s) can be reproducibly 
assessed in both human and mouse mammary tumor cytosols by a highly sensitive 
RRA. It is obvious that no specificity is obtained by this assay, because there are 
several growth factors that are able to compete with 1-mEGF for binding to the EGF 
receptor. Measurement of EGFR ligand(s) in human tissue cytosols require hEGF as 
a standard. It is important to realize that hEGF preparations from different 
manufacturers behave different in receptor binding studies. These differences in 
apparent affinity between the different hEGF preparations might be the result of amino 
add substitutions in the respective recombinant EGF preparations. (However, until now 
a standard preparation is lacking, which implies that the question can be raised 
whether the differences in behavior are based upon differences in affinity or merely 
result from falsely assumed concentrations. As a result, the level of EGFR ligand(s) 
obtained depends on the hEGF preparation used in the RRA. Furthermore, it is 
imperative to prepare the standard curve in a charcoal-treated cytosol (e.g. from 
human breast tumors or human uterus) to obtain proper parallellism. 
The binding characteristics of EGF and TGFa are generally believed to be similar 
(Todaro et al. 1980, Massague et al. 1983). However, in some studies TGFa exhibits 
a lesser affinity to bind to the EGF receptor than does EGF (Winkler et al. 1989, Kore 
et al. 1991). In the present study we also observed differences in the relative binding 
affinities of hTGFa and hEGF towards the human placental EGF receptor. This 
difference in affinity between EGF and TGFa and the potential presence of other EGF-
like peptides in breast tumor cytosols that interact with the EGF receptor, precludes 
determination of precise molar concentrations of the EGFR ligand(s) present in any 
tumor cytosol by RRA. Moreover, no information regarding the nature of the ligand(s) 
present can be provided. Therefore, the availability of specific antibodies and highly 
sensitive radioimmunoassays to measure the levels of the individual growth factors in 
human breast tumor cytosols is highly desirable. However, specific antibodies to all 
EGFH Hgand(s) are not available and the availability of breast tumor cytosol is limited. 
Thbi efore, it was considered worthwile to measure the overall levels of EGFR ligand(s) 
in human and mouse mammary tumor cytosols by RRA. 
Pilot studies were designed to examine the associations between EGFR ligand(s) and 
EGFR, and steroid hormone receptors in human breast cancer and in a mouse 
mammary tumor model. For the study on EGFR ligand(s) in human breast cancer the 
reader is referred to the doctoral thesis by P.G. Koenders: "Epidermal growth factor 
receptor and its ligand(s): associations with prognosis of patients with breast cancer", 
University of Nijmegen, 1992. The examination of EGFR ligand(s) in cytosols derived 
from mouse mammary tumors is described in the next chapter. In the mouse tumor 
cytosols it was also possible to assess specifically EGF levels with high sensitivity and 
reliability in the tumor cytosols using the highly specific RIA. 
References are listed on pages 99-110. 
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CHAPTER 6 
EPIDERMAL GROWTH FACTOR RECEPTOR AND ITS UGAND(S) IN MOUSE 
MAMMARY TUMORS DURING PROGRESSION FROM HORMONE DEPENDENCE 
TO HORMONE INDEPENDENCE 
6.1 introduction 
6.2 Mataríais and methods 
6.3 Results 
6.4 Discussion 
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6.Í Introduction 
It has long been recognized that human breast tumors which at first respond to 
hormonal therapy (e.g. with anti-estrogens) later develop resistance to this treatment. 
Progression to hormone resistance is accompanied by a loss in detectable ER and 
PgR in the tumors (Jensen ef al. 1982). A progression of hormone dependence (HD) 
to hormone independence (HI) is also observed in serial transplants of tumors that are 
induced in ovariectomized female GR strain mice by continuous administration of 
estrone and progesterone (Sluyser and Van Nie 1974, Sluyser et el. 1976). The 
induced tumors are initially HD, but during transplantation they become hormone 
responsive (HR) and finally HI. 
Factors that regulate growth and development of mammary tissue include EGF and 
related peptides (e.g. transforming growth factor-α, TGF-a) (Dickson and Lippman 
1987, Dickson 1990). EGF and EGF-like peptides are potent mitogens that elicit their 
effect by binding to a 170,000 Da transmembrane glycoprotein (EGFR), which 
possesses an intrinsic tyrosine kinase domain believed to be involved in the 
transduction of the mitogenic signal (Hock and Hollenberg 1980, Downward et al. 
1984, Yarden and Schlessinger 1985, Gill et al. 1988). Studies in human breast 
carcinomas established an inverse relationship between ER and EGFR and suggested 
EGFR to be associated with the resistance to endocrine treatment of advanced breast 
cancer (Sainsbury et al. 1987, reviewed by Klijn et al. 1992). In order to investigate this 
in more detail, we have now analyzed GR mouse mammary tumors which progress 
from HD to HI. Tumors obtained from four different lines of this mammary tumor model 
(HD, HR and HI transplants) were analyzed for EGFR and EGFR ligand(s) to examine 
if EGFR and/or its ligand(s) are related to or involved in the progression of breast 
tumors to hormone independence in this animal model. 
6.2 Materials and methods 
6.2.1 Materials 
Receptor grade mouse EGF (mEGF) was obtained from Bioproducts for Science 
(Indianapolis, IN, U.S.A.). 3H-labeled estradiol, 3H-org2058, and carrier free Na12Sl were 
obtained from Amersham International (Amersham, Bucks., U.K.). Estrone and 
progesterone were from N.V. Organon Co. (Oss, The Netherlands). Enzymobeads and 
hydroxylapatite (DNA grade Biogel HTP, HAP) were from Bio-Rad Laboratories 
(Richmond, CA, U.S.A.). B-D-Glucose was from Sigma Chemical Co. (St. Louis, MO, 
U.S.A.). Bacitracin was obtained from Serva (Heidelberg, Germany). Bovine serum 
albumin (BSA) was purchased from Behringwerke AG (Marburg, Germany). 
6.2.2 Tumor initiation and transplantation 
Mouse mammary tumors were obtained from Dr. Sluyser (The Netherlands Cancer 
Institute). The tumors had been induced in female mice from the GR strain by estrone 
and progesterone treatment. Established tumors were transplanted in the flanks of 
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castrated 0 2 0 χ GR F, mice as described elsewhere (Sluyser and Van Nie 1974). For 
testing of hormone dependence, tumor tissue was inoculated into 2 or more castrated 
female or male mice that received no hormone treatment. Two or more castrated 
animals, treated with estrone and progesterone as above, served as controls. The 
animals were checked regularly for 3 months. If within this period no tumor appeared 
in the animals that did not receive hormones, but tumors grew progressively in 1 or 
both of the treated animals, the tumor tested was considered HO. However, if the 
tumor grew in the nontreated animals as well, and the time of tumor appearance was 
equal to that in the treated group, the tumor was considered HI. Tumors that were 
transplantable into nontreated animals but appeared more than 1 week earlier In the 
hormone-treated animals were called HR. HD tumors were transplanted every 4 to 6 
weeks; HI tumors were transplanted every 2 to 4 weeks (Sluyser and Van Nie 1974). 
6.2.3 Tumor cytosols and membrane fractions 
400-600 mg of mouse mammary tumor tissue stored at -80 "C, was pulverized in the 
frozen state by means of a dismembrator (Braun, Melsungen, Germany). The tissue 
powder was homogenized in five volumes of assay buffer (0.01 M phosphate buffer 
pH 7.4, containing 0.01 M К
г
НР04/КНгР04, 0.0015 M dipotasslum EDTA, 0.003 M 
NaNj, 0.01 M monothloglycerol, and 10%, v/v, glycerol). After centrifugation for 10 min 
at 800 χ g (4 eC), the supernatant was further centrifuged for 1 h at 105,000 χ g (4 °C). 
The resulting supernatant was referred to as cytosol and was used for measurements 
of steroid hormone receptors, EGF and EGFR ligand(s). The 105,000 χ g pellet was 
rinsed with 1 ml of EGFR assay buffer (0.02 M phosphate buffer, pH 7.4, containing 
0.15 M NaCI and 50 μΜ bacitracin). Subsequently the pellet was resuspended In 2 ml 
of EGFR assay buffer. This fraction was referred to as membrane fraction and was 
used for the determination of EGFR concentration. 
6.2.-* Protein assays 
Cytosolic protein was measured using the Folin-Ciocalteus reagent (Lowry ef al. 1951 ). 
Membrane protein was assessed by the Coomassie brilliant blue assay method 
(Bradford 1976). In both protein assays human albumin was used as a standard. 
6.3.5 Receptor assays 
Steroid hormone receptors were measured by the dextran-coated charcoal (DCC) 
method as recommended by the EORTC (1980). In short, 50 μΙ aliquots of tumor 
cytosol were incubated with Increasing concentrations of 3H-estradiol or 3H-Org2058 
In a final volume of 60 μΙ of assay buffer for 16 h at 4 °C. Separation of receptor-
bound from free ligand was performed by the addition of 100 μΙ of DCC suspension 
and incubation for another 10 min at 4 °C. After centrifugation for 15 min at 800 χ g 
(4 °C), 100 μΙ of the supernate was counted for radioactivity in a scintillation counter. 
EGFR was measured using the HAP assay as described in chapter 2. EGF was 
iodinated using Enzymobeads, to a specific radioactivity of about 500 Ci/mmol. 
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6.3.6 EGF radioreceptomssay/radioimmunoassay 
For the assessment of EGFR ligand(s) by radioreceptor assay (RRA), 50 μΙ of mouse 
tumor cytosol and about 15000 counts/min of ,25l-mEGF were incubated with a human 
placental membrane preparation (HPM) containing about 500 fmoles of EGFR 
protein/ml, as described in the previous chapter. 
mEGF was measured in the tumor cytosols specifically using a rabbit anti-mouse EGF 
antibody (working dilution 1:40,000). A mouse submaxillary gland cytosol served as 
a positive control for mEGF in the radioimmunoassay (RIA). 
6.3.7 Statístics 
Associations between variables were assessed by the Spearman rank correlation test. 
Homogeneity between groups was tested nonparametrically by means of the Wilcoxon 
two-sample test (Kruskall-Wallis test for multiple groups). Test results were considered 
significant at the P<0.05 level. Calculations were performed by using SAS (Statistical 
Analyzing System) statistical software (SAS Institute Ine, Cary, NC, USA). 
6.4 Resulta 
6.4.1 Steroid hormone receptors 
ER and PgR levels in the HI tumor cytosols were significantly lower as compared to 
those in HD and HR tumors (P-0.004 and P=0.001 respectively, Fig. 6.1a and 6.1b). 
HI tumors contained only 30% of the ER concentration that was found in HD and HR 
tumors (Fig. 6.1a) and there was a complete lack of detectable PgR in HI tumors (Fig. 
6.1b). These results are similar to those observed earlier using the same mouse tumor 
model (Sluyser and Van Nie 1974, Moncharmont et a/. 1991). 
6.4.2 EGFR 
All 26 GR tumor samples contained measurable amounts of EGFR protein, total levels 
ranging from 8 to 614 fmol/mg of membrane protein (Kd range 0.5 to 2.5 nM). An 
inverse correlation between EGFR and ER (R,=-0.463, P=0.02) was observed, while 
there was no significant relationship between EGFR and PgR (R,=-0.298, P=0.14). 
EGFR levels differed significantly between the HD, HR, and HI subgroups (P=0.006). 
Mean EGFR levels in HI tumors were 2.5 to 3-fold higher than they were in HD tumors 
(Fig. 6.2a). 
6.4.3 EGFR ligand(s) 
All GR mammary tumor cytosols contained EGFR ligand(s) (range: 20 to 723 fmol/mg 
of cytosolic protein). The level of EGFR ligand(s) was found to be positively associated 
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with ER (R,=0.532, P=0.005). Also a positive association was found between EGFR 
ligand(s) and PgR, although not statistically significant (R,=0.249, P=0.22). Fig. 6.2b 
shows that the mean level of EGFR ligand(s) in HD tumors was about three-fold higher 
than in HI tumors (P=0.004). The level of EGFR ligand(s) was inversely correlated with 
EGFR (R,=-0.578, P=0.002) in the tumors. In contrast to the radioreceptor assay, 
when using the radioimmunoassay involving a rabbit anti-mouse EGF antibody, EGF 
levels in the tumor cytosols were negligible. 
ER (Imol/mgpr) PgR (fmol/mflpr) 
b 
HO HR HI HD HR HI 
Tumor state Timor state 
Fig. β. f Relation between the hormonal status ot serially transplanted mouse mammary tumors (HD, 
HR, HI) versus cytosolic ER (a) and PgR levels (b). Steroid receptor levels are represented as lmol/mg 
ot cytosolic protein ± SEM. 
6.5 Discussion 
The loss of hormone dependence of human breast cancer and the concomitant loss 
of steroid hormone receptors in the tumors are generally acknowledged. However, 
additional tumor differentiation markers are required for a better prediction of the 
patients' response to endocrine therapy. Studies reporting the assessment of EGFR 
in human primary breast tumor biopsies predominantly showed the higher EGFR 
levels in the ER negative subgroup of tumors, suggesting this biological parameter to 
provide such additional information (reviewed by Klijn efe/. 1992). 
In the present report we have measured EGFR and EGFR ligand(s) in the GR mouse 
mammary tumor model, in which the tumors gradually become HI during serial 
transplantation. Several HD, HR, and HI mouse mammary tumors were examined for 
EGFR and EGFR ligand(s), in addition to ER and PgR. The steroid hormone receptor 
levels decreased during progression to hormone independence. HI tumors still 
contained measurable amounts of ER, but no PgR. These results are similar to those 
obtained earlier using the same tumor model (Sluyser and Van Nie 1974, 
Moncharmont ef a/. 1991). 
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Hg. 6.2 Relation between tumor status versus mean plasma membrane EGFR concentration (fmol/mg 
at membrane protein ± SEM) (a), and cytosclic EGFR ligand(s) (fmol/mg of cytosolic protein ± SEM) 
(b) in the tumors. 
EGFR increased during progression to hormone independence. This observation and 
the inverse association between ER and EGFR are in agreement with studies on ER 
and EGFR in human breast cancer, in which a higher sensitivity of EGFR positive 
tumors to growth promoting EGFR ligand(s) has been suggested to result in the poor 
prognosis of patients with those tumors (Sainsbury et al. 1987). In the present study, 
an inverse correlation was observed between EGFR and EGFR ligand(s), measured 
by using the radioreceptor assay, and a positive relationship between ER and EGFR 
ligand(s). Using the radioimmunoassay we could not detect EGF in the cytosols. The 
EGFR ligand(s) measured in the radioreceptor assay may therefore represent TGF-a. 
Nevertheless, the positive association between the level of EGFR ligand(s) and ER in 
this mouse tumor model suggests that the synthesis of EGFR ligand(s) could be 
regulated by estrogens, which is consistent with the finding that estrogens control the 
synthesis of EGF-like peptides in ER-positive human breast cancer cell lines (Dickson 
et al. 1986, Mori et al. 1986, Dickson and Lippman 1987). 
Regarding the inverse relationship between EGFR and EGFR ligand(s), the receptor 
is known to become internalized upon ligand binding (downregulation) and the low 
levels of EGFR in the HD/HR tumors compared to HI tumors may be the result of 
downregulation of the receptor by its ligand(s) produced under ER control. In this 
view, during progression from HD to HI this downregulation is removed in the absence 
of ER induced EGFR ligand(s) resulting in elevated EGFR levels in the tumors. 
The mice bearing HI tumors did not receive estrogen. From previous studies, however, 
it is known that treatment of such mice with estrogen does not result in an increase 
in the tumor PgR levels, indicating the presence of detectable but nonfunctional ER 
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(Moncharmont 1991). Therefore, assuming the synthesis of EGFR ligand(s) to be 
under ER control, administration of estrogen in these mice tumors also would not have 
been resulted In the synthesis of EGFR ligand(s) by these tumors. Therefore, it seems 
unlikely that the high levels of EGFR in HI tumors result from the fact that the mice 
bearing these HI tumors did not receive estrogen. 
HI was associated with low levels of EGFR ligand(s). As a consequence, instinctively 
one would assume the lower levels of EGFR ligand(s) to be associated with bad 
prognosis. However, a study analyzing EGFR and its ligand(s) in human breast tumor 
biopsies performed in our laboratory, showed the higher levels of both EGFR and 
EGFR ligand(s) in human breast tumor cytosols to be associated with worse 
prognosis of patients (P.G. Koenders, thesis 1992). Our results show that the 
progression of tumors from HD to HI is associated with a decrease In ER and a 
concomitant increase in EGFR. Provided the positive relationship between ER and 
EGFR ligand(s), the increase in EGFR seems to be a secondary effect rather than a 
key event In the progression to hormone independence in this mouse mammary tumor 
model. 
The present study is, to our knowledge, the first one regarding EGFR and its ligand(s) 
in an in vivo mammary tumor model and showed homology with studies regarding 
EGFR in human breast cancer. Therefore, this mouse mammary tumor model offers 
attractive possibilities to further examine the involvement of the ЕСРД6Ро-Е6РН 
pathway and its interactions with the steroid hormone receptor pathway in the 
progression from hormone dependent to hormone independent breast cancer. 
References are listed on pages 99-110. 
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CHAPTER 7 
GENERAL DISCUSSION 
93 
tt has long been recognized that estradiol in the normal breast acts as a mitogen and 
together with progesterone and numerous other factors regulates growth, 
development, and differentiation of the mammary gland (Horwitz et al. 1985). К is 
beyond doubt that estrogens play also an important role in development and 
progression of human breast cancer. It may be recalled that if no estrogenic 
stimulation does occur, for example as a result of primary ovarian failure, the incidence 
of breast cancer is less than 1% ofthat in normal women (Lippman ef a/. 1986). There 
are strong indications that estrogens can function as carcinogens as well as regulators 
of tumor growth (Clark ef a/. 1989). 
The mechanisms by which estrogens induce cell proliferation remain largely 
unresolved. However, circumstantial evidence supports the concept that epidermal 
growth factor (EGF) and its structural and functional homologue, transforming growth 
factor alpha (TGFa), play an important role as mediators in the estrogen effects 
(Lippman and Dickson 1989). Both EGF and TGFa are natural products of mammary 
cells but have also been detected in malignant mammary tumor tissue (Perroteau ef 
al. 1986, Travers ef al. 1988). There are indications that EGF functions principally via 
an autocrine mode, whereas TGFa acts locally via a paracrine or autocrine mechanism 
(reviewed by Velu 1990). It has been established many years ago that estrogens act 
via a highly specific intracellular receptor, the estrogen receptor (ER) (Jensen et al. 
1982, Gorski ef al. 1986) and, more recently, that EGF acts via a transmembrane 
receptor, the EGF receptor (EGFR) (reviewed by Carpenter 1987). К is of great interest 
that EGFR also binds TGFa and with a similar affinity as it binds EGF (Todaro et al. 
1980, Massague efe/. 1983). 
From numerous studies it became clear that mammary tumor cells still contain 
functional ER and thereby may retain hormone responsiveness. In 60-80% of human 
breast tumor biopsies ER can be detected and the cells of these tumors theoretically 
could be responsive to endocrine treatments designed either to lower estrogen levels 
or to block its effects (anti-estrogen therapy) (McGuire ef al. 1975). Unfortunately, only 
50% of the ER positive tumors actually show a beneficial response. When the tumor 
is also positive for the progesterone receptor, PgR, this percentage is about 70% 
(Horwitz 1987). So, ER and PgR assays became important for predicting response to 
endocrine therapy as well as the clinical course of patients with early stage disease 
(Seibert and Lippman 1982). Gradually human breast tumor cells become hormone 
independent and the progression to this more autonomous state goes along with a 
loss of ER and PgR. 
Studies in recent years have claimed and denied that quantification of EGFR could 
additionally provide prognostic information with respect to disease free survival and 
overall survival (see for reviews: Klijn eta/. 1992, Koenders, doctoral thesis University 
of Nijmegen, 1992). A high EGFR content in human breast cancer biopsies has been 
reported to be associated with poor prognosis (Sainsbury et al. 1987). Furthermore, 
high EGFR levels have been found in association with low ER levels. However, the 
reported incidences of EGFR-positive cases varies between 15% and 91%, whereas 
the incidence of EGFR-negative ER-negative biopsies varies even between 6% and 
35% (P.G. Koenders, doctoral thesis University of Nijmegen, 1992). These huge 
variations could be due to differences in methodology. Assay conditions differ widely 
with respect to: the preparation of the membrane fraction, the radioiodination 
procedure for preparing 125I-EGF, the incubation conditions such as time and 
temperature, the ligand concentrations used in multiple point and single saturation 
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dose analysis, and finally the method of separation of receptor-bound and unbound 
ligand (Table ZI). At least 20 studies involving EGFR assays reported so far differ 
from each other in one or more of these assay elements. 
To restrict the variation in EGFR assay results between laboratories it was decided to 
establish an efficient analytical method which under rigid assay conditions gives 
reproducible results with high comparability between laboratories. In addition, since 
EGF receptor function depends in a dose-dependent manner on its ligand (s) (EGF, 
TGFa, and other related peptides), it was of interest to measure the overall level of 
EGFR ligand(s) in breast tumor cytosols. In the present thesis reproducible assays for 
EGFR and its ligand(s) were described (chapters 2 and 5 respectively). 
The methods used for quantitation of EGFR emptoy radkriodinated EGF which Is 
incubated with a membrane fraction of the mammary tumor. Radioiodination of a 
polypeptide can lead to oxidation of the ligand molecule and oxidation of ligands often 
has serious implications for the binding behavior towards the receptor (Bolton 1985). 
As a consequence, the affinity of radioligands for their receptor can become 
considerably less than the affinity of the unlabeled EGF. This important analytical issue, 
which is often disregarded (Kermode 1988), has been addressed thoroughly in 
chapter 4. It appeared that with three iodination methods, Chloramine T, lodogen, and 
lodo-beads. one obtains 125I-EGF which, as was shown by HPLC analysis, is oxidized 
to a large extent and is not equivalent to unlabeled EGF in receptor binding. 
Unfortunately, these harsh oxidative iodination methods have been generally used in 
preparing radioligands for EGFR studies. It follows from the present study that there 
are other iodination procedures, iodine monochloride (ICI), Protag-125, and 
Enzymobeads, which can be employed for preparing nonoxidized 125I-EGF. These mild 
iodination methods do not affect the binding characteristics of the ligand, while the 
specific radioactivities obtained are sufficiently high. Measurement of apparent 
dissociation constants and number of binding sites can be expected to be more 
reliable if there is equivalence in binding behavior between labeled and unlabeled 
ligand. 
In quantitative binding studies using a single dose of radioligand, the concentration 
of me radioligand used is of paramount importance. The level of saturation of the 
receptor not only depends on the concentration of the ligand used, but also on the 
affinity of the receptor for the ligand. If in a tumor only one class of binding sites is 
present, e.g. with a Kd of 0.3 nM, a single point assay using a tracer concentration of 
0.6 nM would saturate about 70% of the receptors. In another tumor with receptors 
with a Kd of 0.6 nM, the single point assay with the same tracer concentration would 
only result in a calculated receptor concentration of 50% of the receptors present. 
Increasing the amount of radioactive tracer is in this case only beneficial to a certain 
extent, because the relative difference between total binding and nonspecific binding 
decreases at increasing amounts of tracer. Since the Kd's observed in the analysis of 
different tumors differ widely, the use of a single point assay for routine EGFR analysis 
has little to commend it. The ligand concentrations used in different 'single point' 
studies varies between 0.1 nM and 10 nM. Results obtained in those studies therefore 
hardly can be compared with each other. 
A wide range of ligand binding affinities have been reported, most of which have been 
derived by Scatchard analysis of binding data. Receptor populations with apparent 
Kd's varying between 0.1 nM and 1 nM are generally regarded as having a high 
affinity for the ligand. It may be emphasized that higher EGFR levels and apparent 
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Kd's are obtained at higher ligand concentration ranges if curvilinear Scatchard plots 
are observed and a linear regression analysis is employed. Curvilinear Scatchard plots 
are no unequivocal evidence for the presence of multiple classes of binding sites. 
Affinity difference between labeled and unlabeled ligand is one of the various other 
factors that can lead to curvilinear Scatchard plots (for reviews: Taylor 1975, Carpenter 
1987, Kenmode 1989). There is only one research group assessing EGFR in human 
breast cancer which demonstrates that the Scatchard plots obtained with tumors are 
curvilinear rather than straight lines (Nicholson et al. 1988). Nicholson et el. concluded 
from these observations (n=6) that two different types of binding sites are present, 
one with a Kd of about 0.6 nM, the high affinity binding site, and the second with a Kd 
of 11 nM, the low affinity binding site. It deserves attention that from an increasing 
number of biochemical EGFR studies performed on a great diversity of cell lines and 
tissues, evidence emerges that indeed high affinity (0.1-1 nM) and low affinity (3-10 
nM) EGF binding sites exist. These studies include A431 cells (Lin et al. 1988), Hela 
cells (Fanger et al. 1984), human KB cells (King and Cuatrecasas 1982), as well as 
human thyroid glands (Kanamori ef al. 1989), HCG producing tumors (Miyachi et al. 
1990), human placentas (Hock and Hollenberg 1980, Chen et al. 1988), meningiomas 
(Weismann et al 1987), murine mammary epithelial cells (Taketani and Oka 1983), 
etcetera. Monoclonal antibodies directed to either high- or low-affinity receptors have 
been described, suggesting a conformational difference between the two receptor 
populations (Defize et al. 1988, Bellot et al. 1990). In our study, all tumors were 
analyzed by multiple point titration analysis. Albeit that a number of Scatchard plots 
were slightly curvilinear, the EGF binding data obtained with the breast tumor 
membranes could be fitted best according to a one binding site model. For routine 
EGFR analysis compromises had to be made and we used the most simple model for 
calculation of the binding data, yielding a relatively reliable estimate of the number of 
high affinity receptors (mean Kd about 0.5 nM) present in the membrane preparations. 
The apparent Kd ranged between 0.1 nM and 1.1 nM (95% of the EGFR positive 
tumors, n=341). It may be remarked that in the study of Nicholson et al. (Nicholson 
et al. 1988) the span of ligand concentrations used (0.15-10 nM) was definitely larger 
than the concentration range we used (0.1-2 nM). It might be that therefore in our 
study the bw affinity binding site was not disclosed. Even in human placental 
membranes (HPM), which contain high levels of EGFR, no bw affinity binding sites (Kd 
>3 nM) could be detected. In these particular experiments a more extended range of 
125I-EGF concentrations (0.02-7.7 nM) was used. Interestingly, however, it appeared 
that in HPM a small number of very high affinity binding sites were present (Kd 0.01 
nM). Our observation is in agreement with a number of investigations in which it has 
been reported that certain carcinoma cells contain EGF binding sites with an extremely 
high binding affinity (Kd »0.01 nM) (Kawamoto et al. 1983, Winkler et al. 1989, Wada 
et al. 1990). It has even been suggested that the stimulatory effect of EGF might be 
mediated by these small amounts of very high affinity EGF receptors: occupancy of 
a small fraction of EGF receptors resulted in maximal stimulation of cell growth 
(Shechter et al. 1978). This important point has to be investigated in future 
experiments. Such investigations are the more imperative because there are strong 
indications that in a number of membrane fractions of breast tumors these extremely 
high affinity binding sites also are present. Measurement of those particular receptors 
requires a significant improvement of the sensitivity of the receptor assay. It Is 
noteworthy to remark that HPLC purification of 125I-EGF can yield tracers with very 
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high specific radioactivity and show equivalence in binding behavior between labeled 
and unlabeled ligand. The use of these 42SI-EGF preparations will certainly improve the 
sensitivity of the assay and may be beneficial in unravelling this phenomenon. 
The ultimate EGFR assay developed included an improved procedure for the 
separation of receptor-bound from free ligand. A bound-free separation step 
introduces a disturbance of the equilibrium state, which is a drawback of all receptor 
binding studies. To achieve maximal recovery of receptor-bound ligand with a 
minimum of dissociation of the ligand-receptor complex, hydroxylapatite (HAP) was 
introduced in the receptor assay for the separation of receptor-bound from free , 2 S I -
EGF. HAP is able to bind EGFH-containing membranes, leaving the nonbound 1 2 5 l -
EGF in solution. The use of HAP permitted a rapid separation procedure. An 
evaluation of the procedure showed the use of HAP to be favorable over the use of 
centrifugation or filtration, separation procedures that have been generally used in 
studies on EGFR in breast cancer (chapter 3). 
Recently, Palette ef al. suggested that measurement of EGFR by the ligand binding 
assay only disclosed nonoccupied receptor sites (Palette et al. 1992). They claimed 
that local production of EGF-like factors results In a masking of binding sites. They 
propagated an acid treatment of the membrane preparation to dissociate the 
endogenously bound ligands before measuring the total, i.e. occupied and free, 
receptor sites. This interesting view was thoroughly tested in our laboratory and the 
results of these experiments are reported in chapter 3. hEGF and hTGFa were added 
to an HPM preparation and, after incubation, the membranes were collected by 
centrifugation. The number of binding sites measured in these membrane preparations 
was unaffected by this addition, neither was the apparent Kd. This result strongly 
indicates that the binding of these ligands to the receptor is completely reversible and 
this is in agreement with the competitive Inhibition model. Furthermore it was shown 
that as a result of an add treatment step, proteins In the tumor membrane preprations 
were eliminated without loss of receptor sites. So, expression of EGFR as a fraction 
of membrane protein content leads to higher values, which erroneously can be 
Interpreted as increased receptor levels per se. The same effect as observed with acid 
trea'jnent was achieved by a simple washing step at neutral pH. 
The EGFR assay developed was easily applicable to the pellet fraction remaining 
following standard preparation of cytosols for routine assay of steroid hormone 
receptors. The developed HAP assay has been adopted by the European 
Organization for Research and Treatment of Cancer (EORTC) Receptor Study Group 
as standard for the measurement of EGFR In human derived tissue biopsy samples. 
From a pilot quality control trial it appeared that with the assay developed still a 
relatively large between-laboratory variation is observed, as compared to the small 
variation observed in the within assay experiments. This implies that extended quality 
control Is highly desirable. 
The radioreceptor assay (RRA) described in chapter 5 measures the overall level of 
EGFR ligand(s), i.e. all factors that compete with 12SI-EGF for binding to the EGF 
receptor. Apart from EGF, these factors include TGFo (Todaro ef al. 1980), vaccinia 
growth factor (Stroobant et al. 1985), amphiregulin (Shoyab ef a/. 1989), and cripto 
(Ciardiello ef al. 1991). In other words, no absolute specificity is obtained using this 
assay. Keeping this in mind, the overall levels of EGFR llgand(s) were assessed in 
human and mouse mammary tumor cytosols by RRA. 
The levels of ER, PgR, EGFR, and EGFR llgand(s) were examined in a mouse 
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mammary tumor model. In this model progression of tumors to hormone 
independence is observed in serial transplants of tumors that are induced in 
ovariectomized female mice by continuous administration of estrone and progesterone 
(Sluyser and Van Nie 1974). The induced tumors are initially hormone dependent, but 
during transplantation they gradually become hormone independent. In the present 
collaborative study with Dr. Sluyser (Netherlands Cancer Institute) we observed, in 
concordance with their earlier studies (Sluyser et el. 1976), that hormone dependent 
(HD) tumors were positive for both ER and PgR, whereas hormone independent (HI) 
tumors contained only 30% of the ER concentration that was found in the HD tumors. 
PgR was undetectable in HI tumors. 
Interestingly. HI tumors contained 2.5 to 3-fold higher EGFR levels than HD tumors. 
It may be recalled that high levels of EGFR in human breast cancer has been reported 
to be associated with poor prognosis (Sainsbury ef el. 1987). Furthermore it was 
observed that the level of EGFR ligand(s) was three-fold higher in HD tumors than in 
HI tumors. With the specific radioimmunoassay (RIA) available for measuring mEGF, 
no EGF was detected in the tumor cytosols. This discrepancy between the RIA and 
the RRA results could be ascribed to the presence of the alternative ligand, TGFa, an 
interesting point which should be confirmed by a specific RIA for TGFa. The positive 
association observed between ER and EGFR ligand(s) is in view with an ER controlled 
production of the EGFR ligands (Dickson and Lippman 1987). 
The low EGFR levels in HD tumors relative to HI tumors may have resulted from 
downregulation of the receptor by endogenous growth factors. It may be hypothesized 
that during progression to hormone independence this downregulation is less 
pronounced because of the lower level of ER. In this view, the increase in EGFR upon 
reaching hormone independence may therefore be a secondary effect rather than a 
key event in the progression to hormone independence in this mouse mammary tumor 
model, but future experiments are required to confirm this supposition. 
It is considered as a very interesting and important point that the observations in the 
mouse mammary tumor model are in concert with the associations observed in human 
breast cancer - negative between ER and EGFR, negative between EGFR and EGFR 
ligand(s), positive between ER and EGFR ligand(s) -, as described in the doctoral 
thesis by P.G. Koenders ("Epidermal growth factor receptor and its ligand(s): 
associations with prognosis of patients with breast cancer", University of Nijmegen, 
1992). The concordance between the results obtained in this in vivo mouse mammary 
tumor model and those obtained in human breast cancer makes this tumor model 
attractive for further clarifying the involvement of the "EGP'-EGFR pathway and its 
interactions with the steroid receptor pathway in the progression from hormone 
dependent to hormone independent breast cancer. 
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Addendum 
Evaluation of llgand-blndlng parameters. 
Interaction of a ligand with a binding protein at equilibrium may, according to the law of Mass 
Action, be represented as follows: 
[F][N']/[B] = К (1) 
where: 
[F] = free ligand concentration 
[N'] = concentration of free, unoccupied binding sites 
[B] = concentration of protein-bound ligand = concentration of occupied 
binding sites 
К = equilibrium (dissociation) constant 
Defining [N] as the total concentration of binding sites and rearranging yields: 
[F][N-B] = K[B] (2) 
This expression can be rearranged either to: 
[B]/[F] = -[B]/K + [N]/K (3) 
bei.q the classical Scatchard [1] relation, or to: 
[B] = [F][N]/(K+[F]) (4) 
which can be generalised to the m ligands, η orders of binding sites model according to 
Feldmann [2]. For one ligand and two orders of binding sites one obtains: 
[Β] = [ΡΗΝ,ΜΚ, + [F]) + [FHNJ/fly + tF]}) (5) 
where now [B] represents the total concentration of bound ligand, summed over the two 
orders of binding sites. 
So, In the case of a single ligand that binds to a single order of protein binding sites, 
transformation and plotting of binding data according to Scatchard ([B]/[F] vs [B], eq.3 ) 
yields, under the following conditions, a straight line: 
1. Ligand and binding sites are In dynamic equilibrium 
2. Quantitative separation of bound from free ligand, I.e. the separation technique 
must not affect the equilibrium, and free-in-bound or bound-ln-free inclusion 
must not occur. 
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Under those ideal conditions, the slope of the line equals the affinity constant of the binding 
equilibrium, and the Intercept on the abcissa reflects the total concentration of binding sites 
Thus, the above model is based on these two parameters equilibrium constant and binding 
sites concentration As will be shown below, it is convenient to express the equilibrium 
constant in terms of the dissoaabon constant as the latter has the dimensions of 
concentration 
If the range of ligand concentrations employed in a binding experiment does not extend 
beyond a few percent of the dissociation constant, the bound/free ratio will be almost 
constant, resulting In a Scatchard curve that runs virtually parallel to the abcissa This is can 
be inferred from eq 4 by assuming that К Is so high that [F] becomes negligible Now the 
equilibrium can be characterised by a single parameter, I e the dimenslonless ratio of binding 
site concentration and dissociation constant [N]/K, which equals the constant bound/free 
ratio The binding sites are said to be "unsaturable", such in contrast with 'saturable" sites 
that ara characterised by two parameters [N] and K. It Is evident that "saturability* Is a relative 
notion, depending on the range of ligand concentrations To be more precise, actually it Is 
the range of free ligand concentrations that determines whether saturation is can be observed 
by the decrease of [B]/[F] with increasing ligand concentration or not 
In receptor analysis it is usually assumed that the sample contains a combination of one 
order of saturable (two parameters) sites and one order of unsaturable (one parameter) sites 
(eq 5) Also it is assumed that the latter bears no relationship to the receptor Itself ("non­
specific" binding), but may anse from contaminating tissue or plasma, or experimental 
artefacts mimicking low-affinity binding Such a combination of two orders of binding activity 
theoretically leads to a non-linear Scatchard plot, from which the three parameters cannot 
readily be evaluated as can be done with either one-order-of-sltes model Evidently, non-linear 
plots also will result with two orders of saturable binding sites (4-parameters model) or two 
saturable and one unsaturable order of sites (5-parameter model) 
A graphical approach to analysis of binding data according to 3- and 4-parameter models 
was given by Rosenthal [3] This method requires that at least a few data points extend into 
the free ligand concentration range where the contribution of the higher affinity sites to total 
binding has become negligible A more widespread approach, which is actually a computed 
version of the Rosenthal method for the 3-parameter model, is by first estimating the third 
parameter by means of assessing ligand binding at excessive total ligand concentration, 
assuming that the contribution of saturable binding has become negligible Subsequently the 
binding data at lower ligand concentration are corrected for the unsaturable binding, thus 
yielding data that ideally should correspond to a two-parameter model that may be further 
analysed by determining slope and intercept With this method one runs the risk of 
underestimating the contribution of "unsaturable" binding within the regular concentration 
range, so that no complete linearisation is obtained Such underestimation may result from 
partial saturation occunng at extreme ligand concentrations in spite of the very low affinity 
To avoid this possibility, recently a new linearisation method for analysis of data according 
to a three-parameter model has been developed, in which no separate estimate of the third 
parameter is required (Van Zoelen [4]) 
Curve fitting 
Fitting of linearised expenmental binding data to a straight line, either "by hand' or by 
conventional unweighted linear least squares regression analysis gives unbiased estimates 
of dissoaabon constant and binding site concentration exclusively in the absence, or virtual 
absence of experimental error Both approaches presuppose an independent variable that 
is unaffected by expenmental error and a dependent variable that is subject to a uniform, 
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normally distributed random error. These conditions, that also Implicitly hold for fitting by 
hand", are not fulfilled by any of the methods mentioned so far. In the Scatchard 
transformation, both the abdssa and ordinate variable are functions of the measured 
concentration of bound ligand that evidently Is affected by random measurement error. The 
resulting error In the dependent variable (bound/free ratio) evidently is neither uniform nor 
independent If the relation between the dependent variable and its variance is known, 
weighted linear regression analysis could be applied. However, this does not solve the 
problem of neither abdssa or ordinate being error-free. This latter problem only can be 
relieved to a certain extent by using one or more types of principal component analysis, of 
which orthogonal linear regression can be considered as a particular case, assuming that the 
measurement, or residual variances of both variables are equal and Independent from each 
other. These assumptions never can never be fulfilled In a Scatchard plot because the 
variables are different functions of the same measurement result. 
As it seems not to be feasible to obtain accurate, unbiased parameter estimates from 
linearised binding data, except in the virtual absence of measurement error, the logical 
alternative is to explore the possibilities of non-linear (weighted) regression analysis. The 
principal advantage of this approach Is that it can be performed in such a way, that it closely 
reflects the reality of the experiment in which measured bound ligand (dependent variable with 
error) is a (non-linear) function of the (independent) most nearly error-free total ligand concen-
tration. Moreover, binding models with more than two parameters are handled almost with the 
same ease as the simple two-parameter or one order of saturable binding sites model. The 
principle of non-linear regression analysis Is the same as for linear regression, in that it aimes 
at parameter estimates that yield a minimum value for the sum of squared deviations of the 
measured data points from the curve that is based on these parameter estimates. In 
weighted regression analysis, the deviations are expressed In terms of the expected standard 
deviation of the measurement signal at each point. The sum of squares of these deviations 
from the fitted curve Is approximately chi-square-distributed. With linear regression analysis, 
the chi-square minimum with its corresponding parameter values can be calculated right 
away, whereas non-linear models require an Iterative procedure according to a suitable 
algorithm (e.g. Marquardt [5]) yielding succesive parameter estimates such that the minimum 
chi-square value Is rapidly approached. If the expected variances of the measurement points 
cannot be evaluated experimentally, e.g. if no replicates are available, an assumption con-
cerning the relation between the magnitude of the measurement signal and its error has to 
be made. In ligand-binding analysis using radioactively labelled ligand with low count rates, 
a reasonable assumption is a direct proportionality between variance and signal height. 
Choice of the binding model. 
In regression analysis a mie of thumb is, that the number of parameters to be estimated from 
a particular set of data should not exceed half the number of available data points, so that 
the number of remaining degrees of freedom will not be less than the number of estimated 
parameters. Thus, when eight points are available, one has the choice between two, three 
and four parameters to be evaluated. The chi-square values obtained from the three different 
curve-fittings are suited as a measure of goodness of fit. The model that is most appropriate 
for the data gives the lowest chi-square value. Chi-square values can be compared by means 
of the F-tables. E.g. with eight data points the chi-square for a four parameter fit must be 4.53 
times as high as for a two-parameter fit in order to reach significance at the p<0.05 level. In 
the case there Is no significant difference between models one should adhere to the simpler 
one for description of the data. 
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Regression analysis also can be applied to data that have been corrected for "non-specific 
binding'. Thus, it is possible to impose a model that has one parameter in addition to the 
number that is allowed from the number of measurement points. E.g. nine data points 
normally only allows fitting of four parameters. By using the highest dose point for estimating 
a fith parameter (constant bound/free ratio of unsaturable or non-specific binding) and 
subsequently correcting the other points one can evaluate the data according to a five 
parameter model in which one parameter is estimated by direct measurement and the other 
four by curve-fitting. 
Selection of the measurement range. 
When the supply of test material Is limited, the number of data points has to be limited 
accordingly, and selecting the proper range of ligand concentrations becomes critical. 
It Is extremely difficult to predict by calculation which dose points will yield the most significant 
information. When the free ligand concentration ranges from 0.1 to 10 times the dissociation 
constant of the receptor binding sites, saturation (I.e. [B]/[N]) of these sites runs from 10 to 
90 % , as can be calulated from eq. 4. Without taking into account the Influence of the 
measurement error It Is Intuitively felt that even distribution (e.g. free ligand concentrations of 
0.11,0.25,0.43,0.67,1,1.5,2.33, 4 and 9 times the dissociation constant leads to saturation 
from 10 to 90% with regular 10% Intervals) within this range gives the most significant 
Information. 
When the expected dissociation constant may vary by one order of magnitude one could aim 
at a range that gives 10% saturation of the low estimate to 90% saturation for the high 
estimate, Implying from 1 % for the high to 99% for the low estimate. 
H.A. Ross, Division of Endocrinology, University of Nijmegen 
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Nederiandstallgo шатвп аШпд 
Regulatie van groei van cellen en weefsels Is een uitermate gecompliceerd proces 
waarin vele hormonen en zogenaamde groeifactoren een sturende rol spelen. Wil een 
hormoon of een groeifactor een effect hebben op een cellulair proces, dan dient de 
onderhavige cel receptoren te bezitten voor dat specifieke hormoon of die specifieke 
groeifactor. 
Kwalitatieve en kwantitatieve metingen van receptoren is van belang gebleken om 
inzicht te verkrijgen in de wijze waarop de groei van normale cellen en weefsels door 
hormonen en groeifactoren wordt gereguleerd. Zulke inzichten zullen ongetwijfeld een 
positieve betekenis hebben voor het opsporen van defecten in de groeiregulatie. Een 
defect in de groeiregulatie kan als gevolg hebben dat er kwaadaardige tumoren 
ontstaan waarvan de groei niet beteugeld is. 
Het is in de laatste jaren steeds duidelijker geworden dat de geslachtshormonen 
oestradiol (E) en progesteron (Pg), in samenspel met onder andere de epidermale 
groeifactor (EGF), de groei, ontwikkeling en differentiatie van de borstklier reguleren. 
Het lijdt geen twijfel dat oestradiol ook een belangrijke rol speelt in de ontwikkeling en 
progressie van borstkanker. De aanwezigheid van receptoren voor de 
geslachtshormonen E (ER) en Pg (PgR) in een borsttumor is een aanwijzing voor 
hormoon-gevoeligheid van de tumor en wordt als leidraad gebruikt bij het maken van 
de keuze voor de juiste therapie voor patiënten met borstkanker. Helaas kan op deze 
wijze niet bij alle patiënten de reaktie op hormonale therapie betrouwbaar worden 
voo; speld. Naast de analyse van de steroidhormoon-receptoren is analyse van 
oar vullende prognostische factoren essentieel. 
De wijze waarop oestrogenen celproliferatie kunnen induceren is slechts zeer ten dele 
bekend. Er zijn in de laatste jaren echter steeds meer aanwijzingen verkregen, dat 
EGF een mediêrende functie heeft bij oestradiol effecten. Als gevolg van het signaal 
dat oestradiol afgeeft aan de cel, wordt door bepaalde cellen van de borstklier EGF 
of EGF-achtige factoren (EGFR liganden) geproduceerd. Deze (¡ganden blijken in staat 
om de cellen die deze liganden produceren te stimuleren (autocriene regulering). 
Bovendien kunnen deze liganden als stimulatoren werken op naburige cellen 
(paracriene regulering). Receptoren voor oestradiol zijn in het celplasma gelocaliseerd, 
receptoren voor EGF bevinden zich in de celmembraan. De ontwikkeling en evaluatie 
van kwantitatieve analyses van deze celmembraan geassocieerde EGFR en van EGFR 
liganden zijn onderwerpen van studie geweest waarvan de resultaten in deze 
dissertatie zijn beschreven. 
Ondanks verschillende onderzoekingen is de betrokkenheid van EGFR bij het ontstaan 
en de progressie van borstkanker niet eenduidig gebleken. Het percentage EGFR-
positieve borsttumoren dat wordt gerapporteerd in de literatuur varieert zeer sterk (van 
15% tot 91%), evenals de hoeveelheden aanwezig EGFR (hoofdstuk 1). 
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Deze grote variatie aan EGFR waarden resulteert In zeer controversiële resultaten 
m.b.t. de prognostische waarde van EGFR bij borstkanker. Het ontbreken van een 
algemeen geaccepteerde, betrouwbare methode voor het meten van EGFR zou hier 
zeker debet aan kunnen zijn. De Europese Organisatie voor Onderzoek en 
Behandeling van Kanker (EORTC) heeft ons laboratorium aangespoord een methode 
te ontwikkelen voor het betrouwbaar meten van EGFR. De ontwikkeling, optimalisering, 
en evaluatie van deze nieuw geïntroduceerde methode zijn uitvoerig beschreven in de 
hoofdstukken 2 en 3. De huidige methode is Inmiddels door de EORTC geaccepteerd 
om als standaardmethode te fungeren voor de meting van EGFR in menselijke 
weefsels. 
Het principe van de ontwikkelde receptormeting berust op de binding van radioactief 
gemerkt EGF (125I-EGF), aan geïsoleerde membranen van een tumor, waarna 
receptor-gebonden 125I-EGF en niet gebonden 12SI-EGF worden gescheiden middels 
hydroxylapatite (HAP). Het radloaktief merken (joderen) van EGF kan tot gevolg 
hebben dat de interactie van de llgand met de receptor ongunstig wordt beïnvloedt. 
Echter, om een zo betrouwbaar mogelijke bepaling te garanderen dient het 125I-EGF 
dezelfde bindingseigenschappen te bezitten als het niet gejodeerde EGF. Dit 
belangrijke analytische aspect is intensief onderzocht In hoofdstuk 4. Uit de hier 
beschreven studie bleek dat gangbare joderingsmethodes (Chloramine T, lodogen, 
lodo-beads) leiden tot oxidatie van l-EGF. De interactie van deze geoxideerde 
producten met EGFR is niet Identiek aan de interactie van het normale EGF met de 
receptor. Het zijn juist deze geoxideerde llganden die over het algemeen gebruikt 
worden in studies naar de rol van EGFR bij borstkanker. Tevens is gebleken dat 
m.b.v. mildere joderingsmethodes (ICI, Protag-125, Enzymobeads) '^l-EGF preparaten 
kunnen worden verkregen die wel identieke bindingseigenschappen vertonen als die 
van het ongemerkte EGF. Het gebruik van deze niet geoxideerde 12SI-EGF preparaten 
in EGFR bindingsstudies leidt tot meer betrouwbare EGFR metingen, hetgeen voor de 
bestudering van de rol van EGFR bij borstkanker van belang is. 
Niet alleen EGF is in staat om aan EGFR te binden. Ook verwante Polypeptiden, 
waaronder de transformerende groeifactor alfa (TGFa) zijn in staat om aan EGFR te 
binden met als gevolg een groeistimulerend effect. In tegenstelling tot het overvloedige 
aantal studies naar de rol van EGFR in borstkanker, is er sporadisch onderzoek 
verricht naar de rol van EGFR ligand(en) bij deze aandoening. Gebruikmakend van 
een EGFR-bevattend humaan placenta preparaat en het principe van de HAP-assay 
kon een radioreceptor assay (RRA) worden ontwikkeld waarmee de combinatie van 
deze EGFR ligand(en) in het weefsel van borsttumoren kon worden bepaald. Verder 
werd m.b.v. een tegen muize-EGF opgewekt antilichaam een radioimmunoassay (RIA) 
ontwikkeld waarmee specifiek EGF kon worden bepaald in tumoren afkomstig van 
muizen. De RRA en de RIA zijn beschreven in hoofdstuk 5. 
De in dit proefschrift beschreven methoden werden toegepast zowel in een klinische 
als in een experimentele studie. De resultaten van de klinische studie bij patiënten met 
een mammacarcinoom zijn beschreven in het proefschrift van P.G. Koenders 
("Epidermal growth factor receptor and its llgand (s): associations with prognosis in 
patients with breast cancer, Universiteit Nijmegen, 1992), dat tegelijkertijd met het 
onderhavige proefschrift verschijnt. De resultaten van de experimentele studie, waarbij 
muize-mammatumoren werden geanalyseerd, zijn beschreven in hoofdstuk 6 van dit 
proefschrift. Het betreft hier hormoon-afhankelijke (HA) mammatumoren die door 
seriële transplantaties hormoon-onafhankelijk (HO) zijn geworden. De HA-tumoren 
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bleken positief voor ER en PgR, terwijl de HO-tumoren slechts 30% van de 
oorspronkelijke ER concentratie bevatten en PgR-negatief waren geworden, hetgeen 
de progressie naar HO status van de tumoren illustreert. De concentratie EGFR-
ligand(en) in de HA-tumoren, gemeten met de RRA, was drie maal zo hoog als in de 
HO-tumoren, wat erop zou kunnen wijzen dat ook in dit proefdiermodel de synthese 
van EGF en/of TGFa gereguleerd wordt door ER. Met de specifieke RIA kon echter 
in geen van de tumoren EGF worden aangetoond. Dit wijst erop dat TGFa de ligand 
is die aanwezig in deze tumoren. Een specifieke bepaling voor TGFa zal dit in 
toekomstige experimenten moeten uitwijzen. 
interessant was de waarneming dat de onderzochte HO-tumoren 2,5 tot 3 maal zoveel 
EGFR bevatten dan de HA-tumoren. In dit verband dient vermeld te worden dat bij 
menselijke borsttumoren hoge EGFR waarden geassocieerd zijn met een slechte 
prognose van de patiënt. Een zeer belangrijk punt in deze is het feit dat de associaties 
tussen de verschillende receptoren en factoren die werden gevonden in dit muize-
tumormodel overeenkomen met de associaties die gevonden werden in de klinische 
studie bij patiënten met borstkanker, zoals beschreven in het bovengenoemde 
proefschrift van P.G. Koenders. Deze analogie en het feit dat kennelijk zowel bij de 
mens als bij de muis uiteindelijk hormoon-onafhankelijkheid optreedt, maken dit muize-
tumormodel zeer de moeite waard om de progressie van hormoon-afhankelijkheid 
naar hormoon-onafhankelijkheid, en de eventuele betrokkenheid van EGFR en zijn 
liganden daarbij, nader te bestuderen. Dergelijk onderzoek is van belang om in de 
toekomst borstkanker beter te kunnen behandelen. 
117 
Curriculum vltae 
De schrijver van dit proefschrift werd op β augustus 1965 te Harbnnkhoek in de 
gemeente Tubbergen geboren. Na het behalen van zijn HAVO-diploma aan het Pius-X-
College te Almelo in 1982, volgde hij het Hoger Laboratorium Onderwijs, 
afstudeerrichting klinische chemie, aan de HTS/SLP te Hengelo. Het diploma werd in 
1986 behaald en datzelfde jaar begon hij met de studie scheikunde met hoofdvak 
biochemie aan de Rijksuniversiteit te Groningen. In augustus 1989 werd het doctoraal 
examen "met genoegen" behaald. Vanaf 1 september 1989 is hij als assistent in 
opleiding tot onderzoeker werkzaam op de afdeling Experimentele en Chemische 
Endocrinologie (hoofd: prof.dr. Th.J. Benraad) van het Academisch Ziekenhuis St. 
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